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Study objectives  
 
Chlamydophila psittaci (formerly Chlamydia psittaci) is found in birds and can be 
transmitted to humans by inhalation or direct contact causing psittacosis or parrot fever. 
The disease name dates back to 1893 when transmission of Cp. psittaci from parrots (Latin; 
psittacus or parrot) to humans, causing flu-like symptoms, was observed in Paris 
(Morange, 1895). In the mean time Cp. psittaci infections have been found in at least 475 
bird species (Kaleta and Taday, 2003; Chahota et al., 2006).  
Chapter I gives and overview on the history, taxonomy, and infection biology of 
chlamydial infections. Moreover, different aspects of avian chlamydiosis such as 
epidemiology, clinical disease, diagnosis, treatment, public health significance and 
prevention and control measurements are reviewed.  
Cp. psittaci includes 9 known outer membrane gene A (ompA) genotypes designated 
A to F, E/B, M56, and WC (Everett et al., 1999a; Geens et al., 2005a). The 7 first 
genotypes are known to naturally infect birds. These genotypes are distinct from those 
associated with chlamydiosis in mammals. Some avian genotypes appear to occur more 
often in a specific order of birds. Genotype A for instance, is endemic among psittacine 
birds. Genotype B is endemic in pigeons. Water fowl most frequently seem to be infected 
with genotype C strains while genotype D strains are often associated with turkeys. 
However, genotype E, also known as Cal-10, MP, or MN was first isolated during an 
outbreak of pneumonia in humans during the early 1930s. Later on, genotype E isolates 
were obtained from a variety of bird species including ducks, pigeons, ostriches, and rheas. 
Genotype F is represented by the psittacine isolates VS225, Prk Daruma, 84/2334 and 
10433-MA, but has also been isolated on a Belgian turkey farm (Van Loock et al., 2005a). 
The mammalian M56 and WC genotypes were isolated during an outbreak in muskrats 
and hares and during an outbreak of enteritis in cattle, respectively. All genotypes should 
be considered to be readily transmissible to humans. In the present study, we focused on 
the avian Cp. psittaci genotypes A to F and E/B causing psittacosis in man. Psittacosis is a 
notifiable disease in most European countries, the U.S, Australia and Japan (Smith et al., 
1973; Williams et al., 1998; Longbottom and Coulter, 2003; Telfer et al., 2005; Matsui et 
al., 2007) 
Over the years, human psittacosis has occurred worldwide and reported cases were 
mostly related to contact with psittacine birds or poultry, especially turkeys and ducks 
(reviewed in Vanrompay et al., 1995a; Andersen, 2004). In Belgium, only three psittacosis 
  
cases were reported to the Wetenschappelijk Instituut Volksgezondheid (WIV) last year 
(http://www.iph.fgov.be/). Reported cases probably represent only the tip of the iceberg as 
diagnosis of this obligate intracellular, biosafety level (BSL) 3, Gram-negative organism 
has been extremely difficult due to the lack of sensitive and specific diagnostic tests and 
the believe that psittacosis was only a rare disease. The latter, was probably due to the fact 
that only severe infections, involving pneumonia with or without cardiac and/or 
neurological complications are noticed by medical doctors. Less severe infections, 
characterized by flu-like symptoms and asymptomatic infections are probably unnoticed.  
At present, Cp. psittaci diagnostic research has made enormous progress with the 
development of highly specific and sensitive molecular diagnostic techniques such as a Cp. 
psittaci- specific nested PCR enzyme immunoassay (PCR/EIA), (Van Loock et al., 2005b), 
a Cp. psittaci- specific real-time PCR (Geens et al., 2005b) as well as an ompA-based 
genotype-specific real-time PCR and a recombinant antibody ELISA (Verminnen et al., 
2006) allowing both detection and tracing of the pathogen. So far, these techniques have 
only been used to detect Cp. psittaci infections in birds. The first objective of the present 
study was the implementation of these diagnostic techniques in Cp. psittaci molecular 
epidemiology in man and to get insight in the real prevalence of Cp. psittaci infections in 
Belgium. In Chapter II, we therefore studied the prevalence of psittacosis in a large 
representative and healthy Flemish population (945 men or women; 35-55 year) using a 
nested PCR/EIA and a recombinant antibody ELISA. Pharyngeal swabs and serum were 
taken and supplementary questions concerning contact frequency with different bird 
species, as well as the presence of respiratory signs were included in the anamnesis. Most 
human Cp. psittaci infections could be traced back to psittacine birds and infections were 
clearly related to contact frequency. Psittacine birds are popularly kept as pet and 
considerable numbers of people are involved in breeding and selling these birds.  
In chapter III, we studied the prevalence of Cp. psittaci ompA genotypes in a human 
risk population, which we defined in Chapter II, namely psittacine pet bird breeders. 
Nested PCR/EIA as well as an ompA genotype-specific real-time PCR were used to detect 
and genotype Cp. psittaci in samples of both birds and their owners. In chapter III, we 
additionally document three psittacosis cases related to contact with African Grey parrots 
(Psittacus erithacus), hereby demonstrating the occupational risk for veterinarians.   
Thus, Cp. psittaci infected psittacine birds are a major source of infection for humans. 
Any attempts to prevent chlamydial infections in Psittacidae would diminish the risk for 
human health. Therefore, the third objective of the study was to develop a Cp. psittaci 
 DNA vaccine for psittacine birds as former research has demonstrated the ability of 
plasmid DNA to significantly reduce clinical signs, macroscopic lesions and bacterial 
excretion in experimentally infected turkeys (Vanrompay et al., 1999b; Vanrompay et al., 
2001a; Van Loock et al., 2004; Verminnen et al., 2005).  
In Chapter IV, we therefore evaluate the ability of plasmid DNA (pcDNA1) encoding 
the major outer membrane protein (MOMP) of a Cp. psittaci genotype A strain, the most 
prevalent genotype among psittacine birds, to produce protective immunity in budgerigars 
(Melopsittacus undulatus), experimentally infected with the homologous Cp. psittaci 
genotype A strain.  
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Chlamydophila psittaci infections in birds and its  zoonotic 
consequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from: 
 
 
Taher Harkinezhad, Tom Geens and Daisy Vanrompay. 2008. Chlamydophila psittaci 
infections: a review with emphasis on zoonotic consequences. Veterinary Microbiology. 
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1. History 
In 1879, psittacosis or parrot fever was documented for the first time when Ritter 
(1880) described an epidemic of unusual pneumonia in seven Swiss humans associated 
with exposure to tropical pet birds. The disease name “psittacosis” however, dates back to 
1893, when transmission of an infectious agent from parrots to humans, causing flu-like 
symptoms, was observed (Morange, 1895).  
In 1907, Halberstaedter and von Prowazek were the first to make drawings of 
Chlamydia-infected conjunctival cells of trachoma (C. trachomatis) patients, holding the 
observed vacuoles for mantled protozoa and conclusively naming them Chlamydozoa 
(after the Greek word for mantle: chlamys) (Halberstaedter and von Prowazek, 1907). The 
following years, similar infective agents causing inclusion conjunctivitis of the newborn or 
infection of the adult genital tract were described. The inability to grow these, in fact C. 
trachomatis organisms, on artificial media made scientists assume that they were viruses. 
The relationship with the psittacosis agent detected by Ritter (1880) was not yet made.  
During winter of 1929-1930, a pandemic of human psittacosis occurred in the United 
States and Europe. The disease was attributed to the importation of Green Amazon parrots 
from Argentina. Shortly after, 174 cases of human psittacosis were reported from the 
Faroe Islands in the period from 1930 to 1938. The human dead rate was 20% and was 
especially high (80%) in pregnant women (Rasmussen-Ejde, 1938). Humans contracted 
the infection while capturing juvenile fulmars (Fulmarus glacialis) and preparing them for 
cooking. Herrmann et al., (2006), presented phylogenetic data on the outer membrane 
protein A (ompA) gene supporting the speculation that fulmars in the Faroes acquired 
psittacosis from infected and dead parrots thrown overboard during shipment from 
Argentina to Europe in 1930.  
The psittacosis agent was finally identified in humans by (Bedson et al., 1930) and 
was classified together with the simultaneously identified, causative agent of 
lymphogranuloma venereum (LGV), as viruses of the psittacosis-LGV group. Bedson et 
al., (1930) defined the unique biphasic developmental cycle of ‘these viruses’ and the 
following years, the organisms became referred to as Bedsoniae. Hereafter, Thygeson 
described the resemblance between the developmental cycle of the trachoma and 
psittacosis agent, and suggested that lymphogranuloma venereum (LGV) strains and 
mouse pneumonitis strain also belonged to the same unique group of viruses (Thygeson, 
  Chapter I   8 
1963). The next years, the “viruses” were propaged in chorio-allantoic chick embryo 
membranes, monkey brains and mice. In 1965, with the development of electron 
microscopy, scientists could actually see that the chlamydial agent was not a virus, but a 
bacterium. Page (1966) proposed to gather all organisms of the psittacosis-LGV-trachoma 
group in one genus Chlamydia. For some time Chlamydia were then considered among the 
Rickettsiae, but later on they have been differentiated from Rickettsiae because they lack 
an electron transport system, have no cytochromes and apparently could not synthesise 
ATP and GTP in the same way as Rickettsiae. Finally, Chlamydiae were classified as 
Gram-negative intracellular bacteria because they divided by binary fission, had cell walls 
comparable in structure to those of Gram-negative bacteria, possessed DNA containing 
nucleoids without membranes between the nucleoid and the cytoplasm and had ribosomes 
with antibiotic susceptibilities characteristic for prokaryotic ribosomes. Shortly afterwards, 
the genus Chlamydia was placed in the order Chlamydiales, family Chlamydiaceae. In the 
late sixties, two species were identified within the genus Chlamydia: Chlamydia 
trachomatis (Capponi and Haider, 1969) and Chlamydia psittaci (Tamura et al., 1971), to 
which the species Chlamydia pneumoniae (Grayston et al., 1989) and Chlamydia pecorum 
(Fukushi and Hirai, 1992) were added in the nineties.  
2. Taxonomy 
2.1. A controversial new taxonomy 
Until 1999, taxonomic classification of Chlamydia was based on limited phenotypic, 
morphologic and genetic criteria. This old classification did not take into account recent 
analysis of the ribosomal operon or recently identified obligate intracellular organisms 
with a Chlamydia-like developmental cycle or replication. Neither did it provide a 
systematic rational for identifying new strains. In 1999, Everett et al. (1999a) presented 
data on phylogenetic analyses of the 16S and 23S rRNA genes with corroborating genetic 
and phenotypic information, showing that the order Chlamydiales contained at least four 
distinct groups at the family level, and that two distinct lineages, Chlamydia and 
Chlamydophila, branch into nine separate clusters within the Chlamydiaceae family (Fig 
1.1).  
Cp. psittaci infections in birds and its zoonotic consequences  9
 
 
Fig. 1.1. The new taxonomic classification introduced in 1999 versus the old one. Three new 
families were added to the order Chlamydiales and the new genus Chlamydophila was introduced 
in the family Chlamydiaceae. The new genus comprises the old Cp. psittaci strains specifically 
infecting birds, as well as three new species, each having a specific mammalian host (Adapted 
from Bush and Everett,  2001) 
 
 
 
There has been a lot of controversy concerning this taxonomy (Schachter et al., 2001) 
and the debate is still ongoing. The main criticisms were that there was (i) insufficient 
reason to divide the Chlamydiaceae into 2 new genera and that this was counterintuitive, 
(ii) it had taken a long time to get clinicians used to Chlamydia and that it would confuse 
them, (iii) there is too much emphasis on limited nucleotide sequence data and insufficient 
consideration of basic biological characteristics, and (iv) the evidence for some species 
and families, notably the Waddliaceae and the Simkaniaceae, rests on limited data derived 
from a single isolate. Some objected to the genus name Chlamydophila, which literally 
means "like Chlamydia". Some groups keep using the old classification, especially in 
human medicine (Longbottom and Coulter, 2003), while others use the new species names 
within the Chlamydiaceae but proceed with the old genus name Chlamydia for all nine 
species (Subtil et al., 2004). A third group chooses to use the new taxonomy 
(http://www.chlamydiae.com), which in the meantime has been adopted in the second 
edition of Bergey’s Manual of Systematic Bacteriology, then considering the chlamydiae 
 Cp. abortus 
 Cp. psittaci 
 Cp. Felis 
 Cp. caviae 
 Cp. pecorum 
 Cp. pneumoniae 
 C. trachomatis 
 C. suis 
 C. muridarum 
 N. hartmanellae 
 P. acanthamoeba 
 W. chondrophila 
 S. negevensis 
Parachlamydiaceae 
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as a novel (eu)bacterial phylum: Chlamydiae phylum B-XVI (Garrity and Holt, 2001). 
Throughout the present study, the official Chlamydophila genus designation will be used, 
and in abbreviations, Cp. will be used for the reader’s comfort. When members of the 
Chlamydiales order are referred to, the widely trivial name “chlamydiae” will be used. 
 
2.2. Nine chlamydial species and their social and/or economical 
importance 
Chlamydia trachomatis comprises two biovars (trachoma and LGV) and multiple 
serovars (A to K, L1, L2 and L3). Serotyping is based on the presence of serovar-specific 
epitopes on the major outer membrane protein (MOMP). Serovars A, B and C cause 
trachoma, worldwide the major cause of preventable infectious blindness. Serovars D–K 
are sexually transmitted and cause both ocular and genital infections (urethritis, acute 
epidymitis and proctitis in men; cervicitis, salpingitis, tubal infertility, ectopic pregnancy 
and pelvic inflammatory disease in women). Other serovars (L1-L3) are responsible for 
the development of lymphogranuloma venereum (LGV). About 17% of the neonates of C. 
trachomatis-infected mothers develop conjunctivitis and 20% develop pneumonia. C. 
trachomatis may also trigger reactive arthritis. Some of the strains have an 
extrachromosomal plasmid and most strains are sensitive to sulfadiazine and tetracyclines. 
C. trachomatis infections have an enormous impact on human health. C. trachomatis is the 
most common cause of sexually transmitted infections throughout the world. Six hundred 
million people are estimated to be infected (Gerbase et al., 1998). Additionally, there are 
between five and six million cases of infectious blindness in man due to a chlamydial 
infection (Thylefors et al., 1995). Genital infections are asymptomatic in most females 
(>75%) and can result in scarring and fibrosis of urogenital tissues, resulting in chronic 
pelvic pain, ectopic pregnancy, and pelvic inflammatory disease, which can lead to 
infertility. Acute C. trachomatis infections can be treated effectively with antibiotics, 
although once infection and pathology are established, treatment may not prevent 
complications. Therefore, treating only symptomatic patients will never control the spread 
of infection. Asymptomatic individuals can be identified through screening programs, but 
this approach is likely to be too costly for developing countries. A vaccination program 
would be much cheaper and have a greater impact on controlling C. trachomatis infections 
worldwide. The reference strain for the trachoma biovar is C/PK-2 while the reference 
strains for the LGV biovar is L2/434/BU (ATCC VR-902B). 
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Chlamydia suis has only been isolated from swine, where it causes conjunctivitis, 
enteritis, pneumonia, pericarditis, perinatal mortality and reproductive disorders, although 
the infection can also be asymptomatic (Rogers and Andersen, 1996; 1999; 2000). Limited 
epidemiological evidence suggests that C. suis infections in pigs are both common and 
wide spread, but under-diagnosed, although there appears to be a high prevalence of mixed 
infections with Cp. abortus (Hoelzle et al., 2000), making it difficult to attribute clinical 
pathology to C. suis alone. The 16S rRNA genes that have been sequenced to date differ 
by < 1.1%. The ompA sequence diversity is larger than for other chlamydial species. As 
for C. trachomatis, glycogen has been detected in C. suis inclusions. Chlamydia suis 
strains carry a plasmid called pCS and some of the strains are resistant to sulfadiazine and 
tetracyclines. The type strain for C. suis is S45 (ATCC VR-1474).  
Chlamydia muridarum strains MoPn and SFPD have been isolated from mice and 
hamsters, respectively. MoPn can cause pneumonia in mice, whereas SFPD was obtained 
from a hamster, concurrent with a causative agent of proliferative ileitis. The 16S rRNA 
genes that have been sequenced to date differ by 0.13% and their 16S-23S intergenic 
spacers and 23S domain I segments are identical. Analysis of the ompA gene can also 
identify this species. The species is sulfadiazine sensitive and glycogen production is 
difficult to detect in MoPn. The type strain for C. muridarum MoPn (ATCC VR-123) 
carries a pMoPn plasmid.  
Chlamydophila pneumoniae has been isolated from humans worldwide. In addition, a 
number of isolates obtained from koalas and a horse have genetic and antigenic 
characteristics very similar to the human isolates. Cp. pneumoniae has three known 
biovars, TWAR, Koala and Equine and the coherence of this taxon has been demonstrated 
by DNA sequence analysis of rRNA, ompA, kdtA (KDO-transferase) and the 60 kDa 
cysteine-rich gene. The TWAR biovar contains strains that are primarily pathogens of the 
human respiratory tract where they predominantly cause acute or chronic bronchitis and 
pneumonia and in some cases otitis media, obstructive pulmonary disease and pulmonary 
exacerbation of cystic fibrosis. The TWAR biovar is responsible for one tenth of the 
pneumonia cases in industrialized countries (Grayston, 1999). The name TWAR was 
formed by merging the first two letters of isolates TW-183 and AR-39 (Grayston et al., 
1989). TWAR has also been associated with Alzheimer’s, atherosclerosis, asthma, 
erythema nodosum, reactive airway disease, Reiter’s syndrome and sarcoidosis (Kuo et al., 
1995; Jackson et al., 1997; Ellis, 1997; Braun et al., 1997; Balin et al., 1998). TWAR 
strains are genetically almost indistinguishable. The Koala biovar has only been found in 
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the marsupial Phascolarctos cinereus and it was present in all five Australian free-ranging 
koala populations that have been tested, including a colony that was suffering from 
respiratory disease. Isolates are commonly obtained from ocular and urogenital sites, 
where they do not appear to be highly pathogenic. The reference strain for the Koala 
biovar is LPCon. The Equine biovar currently includes only one strain (N16), isolated 
from the respiratory tract of a horse (Wills et al., 1990). Inoculation of horses with N16 
leads to asymptomatic infections. The equine strain was the only Cp. pneumoniae strain 
carrying a plasmid (pCpnE1). The type strain for Cp. pneumoniae is TW-183 (ATCC VR-
2282).  
Chlamydophila pecorum strains characterized so far have been limited to mammals, 
but not to a specific host family. They are serologically and pathologically diverse. The 
organism has been isolated from ruminants, a marsupial and swine. In koalas, Cp. 
pecorum causes reproductive disease, infertility and urinary tract disease. It has been a 
major treat to the Australian koala population. In other animals Cp. pecorum causes 
abortion, conjunctivitis, encephalomyelitis, enteritis, pneumonia and polyarthritis 
(Kaltenboeck et al., 1993; Salinas et al., 1996). The Cp. pecorum strains have a high 
degree of ribosomal sequence conservation. Chlamydophila pecorum 16S rRNA genes 
that have been sequenced differ by < 0.6%. Analysis of the domain I signature sequence in 
the 23S rRNA gene or of other genes like the ompA gene and the 16S rRNA gene 
sequence can help to identify this species. Two strains, E58 (ATCC VR-628) and Koala II, 
have been shown to have extrachromosomal plasmids.  
Chlamydophila felis is endemic among house cats worldwide. It causes primarily 
conjunctivitis and rhinitis (Gaillard et al., 1984; TerWee et al., 1998). Cp. felis strains are 
characterized by a high degree of rRNA and ompA conservation and have a distinctive 
serotype (Andersen, 1991a; Sayada et al., 1994; Pudjiatmoko et al., 1997). Strain FP Pring 
and FP Cello have an extrachromosomal plasmid while the FP Baker strain does not. 
Zoonotic infection of humans has been reported (Schachter et al., 1969; Yan et al., 2000; 
Hartley et al., 2001). The type strain for Cp. felis is FP Baker (ATCC VR-120). 
Chlamydophila caviae comprises five known isolates, all isolated from guinea pigs. 
The natural infection site is the mucosal epithelium of the conjunctiva where a non-
invasive infection is established. However, it is possible to infect the genital tract of guinea 
pigs eliciting a disease that is very similar to human genital infection. Cp. caviae is highly 
specific for guinea pigs, as attempts to infect other animals failed, with the exception of 
one experiment infecting gerbils. Analysis of the domain I signature sequence in the 23S 
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rRNA gene or other genes sequences including ompA and 16S rRNA can assist in 
identifying this species (Everett and Andersen, 1999). The type strain for Cp. caviae is the 
guinea pig inclusion conjunctivitis (GPIC) strain (ATCC VR-813) containing the 
extrachromosomal plasmid pCpGP1. 
Chlamydophila abortus strains are endemic among ruminants and efficiently colonize 
the placenta (Rodolakis and Souriau, 1989). They have a distinctive serotype and nearly 
100% conservation of ribosomal and ompA sequences. Typical isolates include strains 
B577, EBA, OSP, S26/3 and A22 (Storz et al., 1960; Denamur et al., 1991; Andersen, 
1991a). Extrachromosomal plasmids were never found in Cp. abortus strains. 
Chlamydophila abortus is the most common infectious cause of abortion in sheep, where 
the disease is known as ovine enzootic abortion (OEA) or enzootic abortion of ewes (EAE) 
in countries of Northern, Central and Western Europe. In the UK alone, the disease, which 
accounts for around 50% of all diagnosed abortions, is estimated to cost £20 (€30) million 
per annum to agricultural industry. Enzootic abortion in goats is similar in severity to that 
occurring in sheep, although the spread and economical impact across Europe is less clear 
because of the lack of epidemiological data. The disease can also affect cattle, swine and 
horses but this is thought to occur to a much lesser extent (Longbottom, 2004). Sporadic 
zoonotic abortion due to Cp. abortus has been confirmed by analysis of isolates from 
women who work with sheep (Herring et al., 1987; Jorgensen, 1997; Longbottom and 
Coulter, 2003) and goats (Pospischil et al., 2002). 
Chlamydophila psittaci produces avian respiratory infections and is a serious threat to 
industrial poultry production. Additionally, it causes epizootic outbreaks in mammals and 
respiratory psittacosis in humans. The infection is often systemic and can be inapparent, 
severe, acute or chronic with intermittent shedding. Cp. psittaci was first classified in to 
serovars using monoclonal antibodies to the major outer membrane protein (MOMP) 
(Andersen, 1991b; Vanrompay et al., 1997).  Seven of the nine known serovars (A to F 
and E/B) solely occur in birds. The other two -M56 and WC- were isolated from mammals. 
All serovars should be considered to be readily transmissible to humans. Cp. psittaci 16S 
rRNA genes differ by < 0.8%. Several strains have an extrachromosomal plasmid and 
many strains are susceptible to bacteriophage Chp1 (Storey et al., 1989a; 1989b). Analysis 
of the MOMP encoding outer membrane protein A (ompA) gene, can also identify this 
species. Recently, (Geens et al., 2005b) developed genotype-specific real-time PCR for 
typing avian Cp. psittaci strains. The type strain for Cp. psittaci is 6BC (ATCC VR-125).  
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3. Infection biology 
3.1. Morphology 
Morphologically distinct forms of Chlamydophila are termed elementary body (EB), 
reticulate body (RB), and intermediate body (IB). The EB is a small, electron dense, 
spherical body, about 0.2-0.3 µm in diameter (Costerton et al., 1976; Carter et al., 1991; 
Miyashita et al., 1993) (Fig 1.2). The EB is the infectious form of the organism, which 
attaches to the target cell and gains entry. The EBs are characterized by a highly electron-
dense nucleoid, located at the periphery of the EB and clearly separated from an electron-
dense cytoplasm. The chromatin is maintained condense by the histon H1-like protein, 
Hc1. Following entry into the host cell, the EB expands in size to form the RB (Fig 1.2), 
which is the intracellular metabolically active form. Differentiation of EBs into RBs is 
accompanied by chromatin dispersal as chlamydiae become transcriptionally active. The 
RB is larger, measuring approximately 0.5-2.0 µm in diameter. The inner and outer 
bacterial membranes of RBs are relatively closely opposed. The RB divides by binary 
fission and thereafter matures into new EBs. During this maturation, morphologically 
intermediate forms (IB), measuring about 0.3-1.0 µm in diameter, can be observed inside 
the host cell. The IB has a central electron-dense core with radially arranged individual 
nucleoid fibers surrounding the core. Cytoplasmic granules are tightly packed at the 
periphery of the IB and are separated from the core by a translucent zone. At the end of the 
replication cycle, less and highly condensed EBs can be observed (Litwin et al., 1961; Eb 
et al., 1976; Costerton et al., 1976; Louis et al., 1980; Soloff et al., 1982; Matsumoto, 
1982a; Matsumoto, 1988; Vanrompay et al., 1996; Rockey and Matsumoto, 2000). 
Immature, less condensed EBs have few fibrous elements transmigrating the granular 
cytoplasm towards the condensed electron-dense nucleoid. The latter lies adjacent to the 
inner bacterial membrane. Mature, more condensed EBs posses a homogeneous ovoid, 
elongated or irregular electron-dense nucleoid separated from cytoplasmic elements by a 
very distinct electron-transparent space.  
Electron microscopy and freeze-fracture structures clearly indicate the existence of 
curious surface projections on both EBs and RBs (Fig 1.2) (Matsumoto et al., 1976; 
Matsumoto, 1982b). These projections extend from the chlamydial surface into the 
inclusion membrane. Matsumoto et al., (1999) also observed images of arrayed-rosettes in 
negatively  stained  EB  preparations.  It  is  tempting to speculate that these dome-like and  
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Fig. 1.2. Electron micrographs of Cp. psittaci and C. trachomatis EB and RB. 
a)  Transmission electron microscopic picture of an elementary body of Cp. psittaci Cal 10. The 
sample has been treated with ruthenium red to enhance the electron opacity of the surface 
projections (arrows). The most obvious feature is the eccentric, electron dense (black) DNA core 
(n), which is tightly compacted onto chlamydial histone protein. Histones are basic, DNA-binding 
proteins commonly found in higher plant or animal cells, but unusual in bacteria. Note that the EB 
cytoplasm (c) has a granular appearance due to the presence of 70S ribosomes. Surrounding the 
cytoplasm is a lipid cytoplasmic membrane and a rigid outer envelope (both ~8 nm) containing a 
regularly packed hexagonal structure of 16.7 nm. This structure, together with extensive -S-S- 
bridging of the sulphur amino-acid rich outer envelope proteins, probably accounts for much of the 
outer envelope strength. (bar 0.15 µm). Adapted from Matsumoto (1988). 
 b)  Rotational symmetry of a Cp. psittaci Cal 10 EB. Cp. psittaci rosette made up of 9 subunits 
(bar 30 nm). Adapted from Matsumoto (1979).  
c) Negatively stained envelope fragment of a Cp. psittaci Cal 10 EB. Note the dark centred rosettes 
(arrows). (bar 0.1 µm). Adapted from Matsumoto (1979). 
 d) Deep freeze-etching replica of C. trachomatis D-12N EBs within a McCoy cell inclusion at 44 
hours PI. Note the projections radiating from the surface of each EB. (bar 0.1 µm). Adapted from 
Matsumoto (http:// /docs/biology_biol_EB.asp)www.chlamydiae.com .  
e) Transmission electron microscopic picture of a reticulate body of Cp. psittaci Cal 10 showing 
the connection between reticulate bodies and the inclusion membrane of isolated 
inclusions (bar 0.1µm). Adapted from Matsumoto (1988). 
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needle-like surface projections correspond to Type III Secretion pores used to deliver 
virulence proteins into the host cell (Bavoil and Hsia, 1998). 
 
 
3.2. Developmental cycle 
Cp. psittaci is an obligate intracellular bacterium replicating within a non-acidified 
vacuole, termed an inclusion. Within the inclusion, Cp. psittaci undergoes a unique 
biphasic developmental cycle alternating between the elementary body or EB, which 
guarantees extracellular survival and infection of host cells and the reticulate body or RB, 
which is responsible for intracellular replication and generation of infectious progenitor 
bacteria. 
Infection is initiated by the attachment and subsequent parasite-mediated endocytosis 
of the infectious EB. EBs are sometimes seen in association with clathrin-coated pits. In 
vitro, EBs rely on the actin cytoskeleton to facilitate their entry into host cells. Once 
internalized, EBs are redistributed from the periphery of the cell and aggregate at the 
Golgi region of the cell that corresponds to the Microtubule Organizing Centre (MTOC). 
Internalized EBs occupy small vesicles or inclusions, which avoid fusion with lysosomes 
and fusion with any other endocytic organelles. Thus, the nascent inclusion is derived 
from host plasma membrane proteins and lipids. Within the first several hours after 
internalization, EBs begin to differentiate into RBs, which is characterized by a loss in 
infectivity, nucleoid decondensation and enlargement of the organism. By 8 hours post 
infection, RBs start to replicate by binary fission and RBs are in close association with the 
inclusion membrane (Fig. 1.3). Numerous mitochondria surround the inclusion 
(Vanrompay et al., 1996). Host kinesin possibly plays a role in mitochondrial recruitment 
to the inclusion. Cp. psittaci may not be as capable as other chlamydial species at 
generating its own ATP, and therefore, a close association of the inclusion with 
mitochondria might provide an alternative mechanism to obtain ATP from the host.  
 Unlike bacteria that replicate in the host cell cytosol and have free access to 
cytosolic nutrients, Cp. psittaci must import host nutrients across the inclusion membrane. 
Chlamydial organisms indeed require amino acids and nucleotides from host pools, but the 
mechanisms that facilitate delivery of these molecules into the inclusion have not been 
clearly defined. Because the inclusion is disconnected from the endosomal/lysosomal 
pathway, delivery of nutrients by fusion of endocytic vesicles is unlikely. Furthermore, 
although exocytic vesicles containing sphingomyelin are known to fuse with the inclusion,  
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Fig. 1.3. Chlamydial development cycle. Numbers refer to hours post infection (Geens, 2005) 
 
 
 
and may be a source of nutrients and lipids, the luminal contents of these vesicles have not 
been identified.Recent data demonstrate that the inclusion membrane is freely permeable 
to small molecules with a molecular weight of 100-520 Da (Hackstadt et al., 1999; 
Grieshaber et al., 2002). After delivery into the lumen by passive diffusion, specific 
membrane transporters located in the bacterial membrane would facilitate uptake into the 
  Chapter I   18 
organisms themselves. In addition, specific membrane transporters would still be needed 
to transport molecules larger than 520 Da across the inclusion membrane. However, no 
such membrane transporters have been localized to the inclusion membrane as of yet.  
As the developmental cycle progresses, the inclusion enlarges to accommodate the 
increasing numbers of bacteria. The growing inclusion intercepts biosynthetic membrane 
trafficking pathways and acquires the ability to fuse with a subset of Golgi-derived 
vesicles, thereby increasing its membrane surface (Hackstadt, 1999). When more and more 
RBs are actively replicating the next 20 hours (each RB can be responsible of a progeny of 
up to 1000 new RBs), the inner side of the inclusion membrane becomes overcrowded, 
leading to RB ‘detachment’ from the inclusion membrane. Detachment of RBs could be 
the signal to convert into intermediate bodies and new infectious EBs. At the end of the 
cycle, approximately 50 hours post infection, the host cell and its inclusion(s) either lyse 
or the EBs and some non-differentiated RBs are liberated via reverse endocytosis.  
In some cases, the developmental cycle can be altered towards persistence. Persistent 
chlamydiae fail to complete development from RBs into infectious EBs but retain 
metabolic activity. Persistent RBs are oval shaped to strongly enlarged, morphologically 
aberrant and form small inclusions. They accumulate chromosomes because DNA 
replication continues, but do not divide. Persistent growth forms have been associated with 
chronic infections. These cryptic persistent forms can rapidly retransform to normal RBs 
and infectious EBs. How chlamydiae modulate between normal and persistent growth is 
not yet understood (Belland et al., 2003; Hogan et al., 2004; Gieffers et al., 2004). 
 
 
4. Avian chlamydiosis 
4.1. Strain Classification 
The family Chlamydiaceae was recently reclassified into two genera and nine species.  
The new genera Chlamydia and Chlamydophila correlate with the former species 
Chlamydia trachomatis and Chlamydia psittaci.  The genus Chlamydia includes C. 
trachomatis (human), C. suis (swine), and C. muridarum (mouse, hamster). The genus 
Chlamydophila includes Cp. psittaci (avian), Cp. felis (cats), Cp. abortus (sheep, goats, 
cattle), Cp. caviae (guinea pigs), and the former species Cp. pneumoniae (human) and Cp. 
pecorum (ruminants). All known avian strains belong to the species Chlamydophila 
psittaci, which includes six avian serovars (serovars A through F), and two mammalian 
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isolates (WC and M56) (Andersen, 1991b; Vanrompay et al., 1993; Vanrompay et al., 
1997). WC and M56 are isolates from epizootics in cattle and muskrats, respectively. The 
avian serovars are relatively host-specific. Serovars A and B are usually associated with 
psittacine birds and pigeons, respectively. The natural hosts of the other serovars are more 
uncertain.  Serovar C has primarily been isolated from ducks and geese, and serovar D 
mainly from turkeys. Serovar F was isolate from a psittacine bird and from turkeys. The 
host range of serovar E is the most diverse of the strains: it is isolated from about 20% of 
pigeons, from many cases of fatal chlamydiosis in ratites, from outbreaks in ducks and 
turkeys, and occasionally from humans. All serovars should be considered to be readily 
transmissible to humans.  
Cp. psittaci 16S rRNA genes differ by < 0.8%. Several strains have an 
extrachromosomal plasmid and many strains are susceptible to bacteriophage Chp1 
(Storey et al., 1989a; 1989b). At present, analysis of the MOMP encoding outer membrane 
protein A (ompA) gene is more often used to characterize avian Cp. psittaci strains in to 
genotypes A to F and E/B (Geens et al., 2005b). So far, genotype E/B has mainly been 
isolated from ducks. 
 
4.2. Epidemiology 
Psittacosis outbreaks of 1929-1930 and 1930-1938 were attributed to psittacine birds. 
However, in the next years it became clear that Cp. psittaci infections were not limited to 
psittacine birds, but could also affect other bird species. In 1939, the bacterium was 
isolated from two South African racing pigeons and soon, additional pigeon isolates were 
obtained, this time from Californian racing pigeons. At that time, Psittacosis in two New 
York citizens could be attributed to contact with infected feral pigeons. In 1942, 
serological evidence showed ducks and turkeys to be frequently infected and within the 
next 3 years, human infections due to contact with infected ducks were reported in 
California and New York. In the early 1950s, Cp. psittaci could be isolated from turkeys 
and from humans in contact with infected turkeys, during severe respiratory outbreaks in 
the US turkey industry (Meyer, 1967). The incidence of severe Cp. psittaci epidemics in 
US poultry declined during the 1960s. However, avian chlamydiosis remained a 
continuing threat to both birds and humans. During the 1980s, chlamydiosis was reported 
again in US turkeys (Grimes and Wyrick, 1991) and in the 1990s also in the European 
turkeys (Vanrompay et al., 1993a; Ryll et al., 1994; Hafez and Sting, 1997). Nowadays, 
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Cp. psittaci is nearly endemic in the Belgian turkey industry (Van Loock et al., 2005a; 
Verminnen et al., 2006), and there is evidence to believe that it is also endemic in other 
European countries (Van Loock et al., 2005a; Sting et al., 2006). However, devastating, 
explosive outbreaks like in ‘ancient days’ are rare and respiratory signs without or with 
low mortality characterize outbreaks nowadays. More recently, an increase in the number 
of chlamydiosis outbreaks in ducks and in people in contact with infected ducks has been 
reported (Laroucau, 2007, personal communication; Laroucau et al., 2008; Andersen and 
Vanrompay, 2008). In the past, human infections associated with outbreaks in ducks have 
already been described (Arzey and Arzey, 1990; Arzey et al., 1990; Martinov and Popov, 
1992; Hinton et al., 1993; Goupil et al., 1998; Lederer and Muller, 1999; Bennedsen and 
Filskov, 2000).  
The list of avian species in which Cp. psittaci infections occur increased rapidly. 
Today, Cp. psittaci has been demonstrated in about 465 bird species comprising 30 
different bird orders (Kaleta and Taday, 2003). The highest infection rates are found in 
Psittacine birds (Psittacidae) and pigeons (Columbiformes). The prevalence in psittacine 
birds ranges between 16 and 81%  and a mortality rate of 50% or even higher is not 
unusual (Raso et al., 2002; Dovc et al., 2005)l. Psittacidae are predominant chlamydial 
reservoirs, especially under captive conditions, and nowadays these birds are extremely 
popular pets (Chahota et al., 2006; Vanrompay et al., 2007).  
Data on the seropositivity of racing pigeons range from 35.9 to 60%. Thirty-eight 
studies on the seroprevalence of Cp. psittaci in feral pigeons conducted from 1966 to 
2005, revealed a seropositivity ranging from 12.5 to 95.6% (Laroucau et al., 2005; Tanaka 
et al., 2005; Haag-Wackernagel, 2005; Mitevski et al., 2005; Prukner-Radovcic et al., 
2005). More recent studies, performed in feral pigeons in Italy, Bosnia and Herzegovina, 
and Macedonia revealed a seropositivity of 48.5%, 26.5% and 19.2%, respectively (Ilieski 
et al., 2006; Residbegovic et al., 2007; Ceglie et al., 2007). Free-living pigeons are 
distributed in urban and rural area over the world and are in close contact with humans in 
most outdoor public places. 
Birds mostly living on sea shores and other waters, like gees, ducks, gulls and 
penguins are more frequently infected than hens, pheasants and quails (Kaleta and Taday, 
2003). Common reservoirs of Cp. psittaci include wild and feral birds such as sea gulls, 
ducks, herons, egrets, pigeons, blackbirds, grackles, house sparrows, and killdeer, all of 
which freely intermingle with domestic birds. Highly virulent strains of Cp. psittaci can be 
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carried by and excreted in large numbers by sea gulls and egrets without any apparent 
effect on these hosts. 
 
4.3. Transmission between birds 
Cp. psittaci transmission primarily occurs from one infected bird to another 
susceptible bird in close proximity. Cp. psittaci is excreted in the faeces and nasal 
discharges. Faecal shedding occurs intermittently and can be activated by stress caused by 
nutritional deficiencies, prolonged transport, overcrowding, chilling, breeding, egglaying, 
treatment or handling. Bacterial excretion periods during natural infection vary according 
to strain virulence, infection dose and host immune status. However, shedding may occur 
for several months. Transmission of chlamydiae is mainly by inhalation of contaminated 
material and sometimes by ingestion. Large numbers of Cp. psittaci can be found in 
respiratory tract exudate and fecal material of infected birds. The importance of the 
respiratory exudate has become more apparent. In turkeys, the lateral nasal glands become 
infected early and remains infected for more than 60 days. Choanal/oropharyngeal swabs 
are more consistent for isolation of the agent than faecal swabs, especially during early 
stages of infection. Direct aerosol transmission through aerosolization of respiratory 
exudate must be considered as the primary method of transmission. 
Avian species, including domestic poultry sharing aquatic or moist soil habitats with 
wild infected aquatic birds may become infection via contaminated water. Granivorous 
birds like pigeons, doves, pheasants and house sparrows may become infected by dust 
inhalation in faecal contaminated barnyards and grain storage sites. The consumption of 
infected carcasses may transmit Cp. psittaci to host species that are predators or 
scavengers of other birds.  
Transmission of Cp. psittaci in the nest is possible. In many species, such as 
Columbiformes, cormorants, egrets, and herons, transmission from parent to young may 
occur through feeding, by regurgitation, while contamination of the nesting site with 
infective exudates or faeces may be important in other species such as snow geese, gulls 
and shorebirds. Cp. psittaci can be transmitted from bird to bird by blood-sucking 
ectoparasites such as lice, mites and flies or, less commonly, through bites or wounds 
(Longbottom and Coulter, 2003). Transmission of Cp. psittaci by arthropod vectors would 
be facilitated in the nest environment.  
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Vertical transmission has been demonstrated in turkeys, chickens, ducks, parakeets, 
seagulls and snow geese, although the occurrence appears to be fairly low (Wittenbrink et 
al., 1993). However, it could serve as a method of introducing chlamydia into a poultry 
flock. 
Cp. psittaci can be introduced into susceptible pet birds and poultry through the wild 
bird population. Contaminated feed or equipment can also be a source of infection, and 
feed should therefore be protected from wild birds. Careful cleaning of equipment is 
extremely important as Cp. psittaci can survive in faeces and bedding for up to thirty days. 
Cleaning and disinfection with most detergents and disinfectants will inactivate Cp. 
psittaci, as this Gram-negative bacterium has a high lipid content. 
 
4.4.  Clinical disease 
Depending on the chlamydial strain and the avian host, chlamydiae cause pericarditis, 
air sacculitis, pneumonia, lateral nasal adenitis, peritonitis, hepatitis, and splenitis.  
Generalized infections result in fever, anorexia, lethargy, diarrhea, and occasionally shock 
and death. Chlamydiosis is a very common chronic infection of psittacine birds. Infections 
cause conjunctivitis, enteritis, air sacculitis, pneumonitis, and hepatosplenomegaly. 
Droppings are often green to yellow-green. Many of the birds become chronically infected 
but show no clinical signs until stressed. These birds often shed chlamydiae intermittently 
and serve as a source of infection for humans and other birds.   
 Chlamydiosis is also a common chronic infection of pigeons. Clinical signs include 
conjunctivitis, blepharitis, and rhinitis (Andersen, 1996). Survivors can become 
asymptomatic carriers 
 Infected turkeys show vasculitis, pericarditis, pneumonitis, air sacculitis, and 
hepatosplenomegaly, and lateral nasal adenitis at necropsy. Mortality rates of 5–40% may 
occur unless early antibiotic treatment is instituted (Grimes et al., 1970; Andersen, 1996). 
Experimentally, virulent turkey strains cause little, if any, disease in chickens, pigeons, 
and sparrows; however, cockatiels and parakeets succumb rapidly to infection by these 
agents. Turkey outbreaks with low mortality and little or no human involvement usually 
are caused by the ”pigeon serovar”. The mortality rate is usually less than 5%. 
 Chlamydiosis in ducks is rare in the United States (Andersen 1996), but is a serious 
economic and occupational health problem in Europe (Andersen, 1996). Trembling, 
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conjunctivitis, rhinitis, and diarrhea are observed in infected ducks. Mortality ranges up to 
30%. 
 
4.5. Diagnosis 
The methods used to diagnose Cp. psittaci infections are 1) direct visualization of the 
agent in clinical specimens by staining techniques, 2) isolation of the agent from clinical 
specimens followed by identification of the isolated agent, 3) detection of specific 
chlamydial antigens or genes in clinical specimens, and 4) serological tests in which 
antibodies are measured, preferably by demonstrating rising titers in paired acute and 
convalescent sera. Different diagnostic methods used for detection of a Cp. psittaci 
infection and their advantages and disadvantages are listed in Table 1.1.   
 
4.5.1. Sample collection and storage of specimens 
The laboratory diagnosis of avian chlamydiosis usually includes the isolation and 
identification of the organism from the host. Because Cp. psittaci requires living cells to 
multiply, isolation requires inoculation of either laboratory animals or cell cultures. 
Specimens should be collected aseptically, as contaminant bacteria may interfere with 
isolation of the chlamydiae. 
Proper handling of clinical samples is necessary to prevent loss of infectivity. If 
specimens are used to inoculate animals or cell cultures immediately, most diluents will be 
adequate; however, if the specimen is to be shipped or stored, a special diluent should be 
used.  A diluent consisting of sucrose–phosphate–glutamate (SPG) was developed for 
rickettsiae and has proven satisfactory for transport of chlamydial field samples 
(Bovarnick and Snyder, 1950; Spencer and Johnson, 1983). The recommended medium 
for chlamydiae consists of SPG buffer (sucrose, 74.6 g/liter; KH2PO4, 0.512 g/liter; 
K2HPO4, 1.237 g/liter; and L-glutamic acid, 0.721 g/liter), which can be sterilized by 
autoclaving.  To this is added fetal calf serum (10%), vancomycin and streptomycin (100 
mg/ml), and nystatin and gentamicin (50 mg/ml).  The antibiotics reduce the effect of 
contamination even when samples are shipped at ambient temperatures. This medium also 
serves as a laboratory diluent and a medium for freezing of chlamydiae. 
For isolation and identification of Cp. psittaci from acute and subclinical cases of 
chlamydiosis, the following samples should be collected: pharyngeal/choanal slit swabs 
(Andersen, 1996),  lung   tissue,   thickened   exudate-coated   air  sacs  and  free  exudates,  
 Table 1.1. Different diagnostic methods used for detection of a Cp. psittaci infection and their advantages and disadvantages.   
Diagnostic methods advantages disadvantages 
Cytological staining  - easy  
- cheap  
- quick  
- no sophisticated equipment needed  
- dead and live bacteria can be demonstrated
- non-specific 
- less sensitive  
- non-automated  
- interpretation by experienced person  
Immunocytochemie  - more sensitive and specific than cytology  
- easy  
- quick  
- dead and live bacteria can be demonstrated
- cross-reaction with other bacteria (when MAb is against LPS)  
- interpretation by experienced person  
- more expensive  
- fluorescence microscope required 
- non-automated 
Immunohistochemistry - automation possible 
- detection in the morphological context  
- more labor intensive than immunocychemistry 
- histology laboratory required 
- MAb detecting Cp.psittaci-specific antigen in formalin-
fixed samples needed 
- more time consuming than immunocytochemistry 
- more expensive 
Antigen-ELISA  - quick
- multiple samples can be tested at once 
- quantification 
- easy 
- dead and live bacteria can be demonstrated
- commercial kits often insensitive  
- non-specific if the target is LPS or Hsp60 
- ELISA reader needed 
Culture  - propagation for further investigations 
- more specific than direct antigen detection 
- direct evidence of live bacteria 
- quantification of live bacteria 
 
- transport and storage of samples is critical 
- BSL3 laboratory  
- time consuming 
- expensive 
- labor intensive 
- trained personnel required 
- not all strains can be cultured 
Table 1.1. Different diagnostic methods used for detection of a Cp. psittaci infection and their advantages and disadvantages (continued). 
Diagnostic methods advantages disadvantages 
Molecular diagnosis  
(PCR, Micro array) 
- highly sensitive 
- highly specific 
- quick 
- automation possible 
- multiple samples can be tested at once 
- possibility of direct typing on clinical 
samples 
- can be quantitative 
- can detect live and dead bacteria 
- expensive 
- specialized equipment needed 
- trained personnel needed 
 
Serology: antibody ELISA - easy 
- quick 
- multiple samples can be tested at once 
- quantification is possible 
- automation possible 
- valuable for epidemiological research 
 
- convalescent sera (retrospective diagnosis) 
- not a proof  that the  organism is still present 
- tests detecting antibodies against LPS, hsp60 or whole 
organisms are non-specific 
- less sensitive than molecular diagnosis 
- ELISA reader needed 
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thickened pericardial tissues and exudates, sections of enlarged spleen and liver, intestinal 
mucosa at sites of hyperemia, colon contents, and conjunctival and nasal discharges. In the 
live bird, pharyngeal/choanal slit swabs, fecal samples, and cloacal swabs are the preferred 
specimens (Andersen, 1996). All three specimens should be collected, as no one sample 
will provide an isolation in all cases. Other specimens that can be collected, depending on 
the disease signs present, include whole blood, conjunctival scrapings or exudates, and 
peritoneal exudates. When companion birds are being tested for subclinical infection 
before placement in facilities, repeated sampling is necessary. 
The same tissues can be collected for PCR and other molecular tests. If the DNA 
extraction will not be done immediately, it may be beneficial to collect the specimen in a 
DNA stabilization buffer (DeGraves et al., 2003). 
The stability of chlamydiae during storage depends upon the material in which it is 
contained. Chlamydiae in tissue specimens or yolk-sac suspension can be preserved 
indefinitely by storage at  -70° C (Andersen and Vanrompay, 2003; Andersen, 2004). Note 
that chlamydiae harvested from cell culture require special media during freezing. A 
satisfactory method for freezing them is to replace the cell culture medium with SPG 
buffer before freezing, as the organism is highly susceptible to the presence of sodium ions 
in the medium (Spencer and Johnson, 1983). The transport medium described earlier will 
provide adequate stability during freezing. At 4° C, the organism can survive with gradual 
loss of infectivity for 30 days or longer when in heavily infected tissues or in SPG 
transport medium (Spencer and Johnson, 1983). 
 
4.5.2. Microscopic examination of specimens 
4.5.2.1. Cytological Staining  
Chlamydiae can be detected in smears of exudates and feces and in impression smears 
of liver and spleen by a variety of techniques. Giemsa, Stamp and Giménez stains are 
commonly used. The modified Giménez technique (Vanrompay et al., 1992), using carbol 
fuchsin and malachite green, is routinely used by several laboratories for detection of 
chlamydial inclusions in smears. The organisms appear as red to purple stained bacteria 
(Fig 1.4). These stainings can be helpful but are far less sensitive and specific than 
immunochemical stainings or molecular detection methods since other Gram-negative 
bacteria like for instance E. coli may also stain red due to their affinity for carbol fuchsin.  
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Fig 1.4. Giménez staining of an impression smear of the spleen from an infected and diseased 
pigeon. Note Cp. psittaci (red) inside a macrophage. (x 1000).  
 
 
4.5.2.2. Immunohistochemical staining 
Immunohistochemistry is another method for detection of chlamydiae in cytologic 
and histologic preparations (Moore and Petrak, 1985; Tappe et al., 1989). The use of 
immunohistochemical staining on formalin-fixed sections is gaining in popularity because 
a number of laboratories are using automatic staining equipment. The technique also 
allows laboratories to take routine samples for histopathology and then retrospectively 
examine them for chlamydiae, if necessary. The technique is more sensitive than 
histochemical staining, but experience is required to interpret findings. Cross-reactions 
with some bacteria, fungi, and epithelial intercellular material dictate that morphology 
must be considered in making a positive diagnosis.  
Chlamydial antigen is most often found in macrophages in areas of inflammation. 
Antigen can be found in the lateral nasal gland up to 50 days post infection. Inflamed air 
sacs and pericardium also consistently contain antigen. However, care must be taken to 
avoid misinterpreting hemosiderin as antigen. Antigen-positive tissue and hematoxylin-
and-eosin-stained sections are used as controls. 
For immunohistochemical staining of paraffin sections, a family-specific monoclonal 
detecting all chlamydia and chlamydophila or a polyclonal antibody is used as the primary 
antibody. The antibodies should be produced to formalin-inactivated chlamydiae and 
selected for reaction with formalin-inactivated chlamydiae. They are mostly detecting the 
family-specific epitope on the lipopolysaccharide of Chlamydiales. The specific procedure 
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used for staining the paraffin sections will depend on the equipment available, as most 
techniques will give satisfactory results. 
 
4.5.3. Enzyme-linked immunosorbent assays to detect chlamydial 
antigens   
A number of manufacturers are producing enzyme-linked immunosorbent assay 
(ELISA) kits for detection of Chlamydia trachomatis in humans. These test kits will detect 
Cp. psittaci as they react to the lipopolysaccharide (LPS) or family (Chlamydiales) antigen. 
The advantages of ELISA are that it is rapid, does not require a high level of expertise, and 
is safe for the technician because the sample can be inactivated. A number of the test kits 
have been evaluated for use in avian samples (Vanrompay et al., 1994), although none of 
the kits are licensed for use in veterinary medicine. One of the problems of some of these 
tests is that the chlamydiae LPSs share some epitopes with the LPSs in other gram-
negative bacteria, which can lead to a high number of false positives. This problem has 
been reduced or eliminated in the more recently developed kits by the use of monoclonal 
antibodies. However, these kits still lack sensitivity: a few hundred organisms are needed 
for a positive reaction. The general rule with these tests is that a diagnosis of chlamydiosis 
can be made when a strong positive reaction is seen along with clinical signs of 
chlamydiosis. Because of the number of false positives, a positive test without signs 
cannot be considered significant. 
 
4.5.4. Isolation of the organism 
4.5.4.1. Preparation of inoculum 
Tissue specimens, fecal samples, and swabs are routinely used as samples for the 
isolation of chlamydiae. The processing of the samples is similar for inoculation of cell 
cultures, embryonated eggs, or laboratory animals. Diluents such as beef heart infusion 
broth, phosphate-buffered saline (PBS; pH 7.2), and cell culture media often are used to 
prepare a 20%–40% suspension of the homogenized sample. These diluents, with 
antibiotics, are satisfactory when the samples are to be inoculated within 24 h and will not 
be frozen. For routine use, a number of laboratories are using SPG buffers, such as the 
transport medium described earlier or Bovarnick's buffer (1950; Spencer and Johnson, 
1983). These buffers have the added advantage of stabilizing the agent during refrigeration 
or freezing of the samples. 
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Before the inoculation of animals or cell cultures, contaminated samples must be 
treated by one of three basic methods: treatment with antibiotics (Bevan and Bracewell, 
1986), treatment with antibiotics plus low-speed centrifugation (Andersen and Vanrompay, 
2003), or treatment with antibiotics plus filtration (Bevan and Bracewell, 1986). A number 
of antibiotics that do not inhibit chlamydiae are available. A standard procedure is to 
homogenize the sample in diluent containing streptomycin, vancomycin, and kanamycin. 
Amphotericin B will control yeast and fungal growth. Other antibiotic solutions are often 
used, but penicillin, tetracycline, and chlooramphenicol should be avoided, as they will 
inhibit the growth of chlamydiae. 
If the sample is lightly contaminated, adequate treatment for inoculation into chicken 
embryos, guinea pigs, mice, or cell culture consists of homogenization of the sample in an 
antibiotic solution. The sample is often left in the antibiotic solution for 24 h before the 
inoculation of cell cultures or animals. If the sample is heavily contaminated, such as a 
fecal sample, it should be homogenized in antibiotics and centrifuged at 1000–2000 × g 
for 30 min. The surface layer and the bottom layer should be discarded; the supernatant 
fluid is collected and recentrifuged, and the final supernatant fluid is inoculated into the 
experimental host or cell culture. If contamination persists, the sample may also be passed 
through a filter of 0.45–0.8 µm pore size. 
 
4.5.4.2. Cell cultures and SPF embryonated chicken eggs 
Cell cultures are the most common and convenient method for the isolation of Cp. 
psittaci.  The most commonly used cell lines are BGM, McCoy, HeLa, Vero, and L-929, 
although a number of other cell cultures can be used.  A study showed BGM to be the 
most sensitive, with Vero and L-929 listed as satisfactory (Vanrompay et al., 1992). 
Standard cell culture medium is used, containing 5%–10% fetal calf serum and antibiotics 
like vancomycin, streptomycin and amphotericin B as they do not inhibit the growth of 
chlamydiae.  
The laboratory equipment and supplies available will determine the type of vessel 
used to grow the cell culture monolayer for incubation with the homogenated samples. The 
equipment, however, must be suitable for the following procedures: identification by 
direct fluorescent antibody (FA) or another appropriate technique of staining of the 
infected monolayer; centrifugation of the inoculum into the monolayer to enhance 
infectivity; possible blind passage at 3 or 6 days post inoculation to increase sensitivity of 
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isolation; examination of the sample two to three times during a passage; and protection of 
humans against possible infection. Small flat-bottomed vials (1-dram shell vials) or bottles, 
with 12-mm diameter glass coverslips, will meet these requirements and are often used 
(Bevan et al., 1978; Bevan and Bracewell, 1986) because the cell culture monolayer can 
be grown directly on the coverslip. Several vials are inoculated with each sample to permit 
fixing and staining at various times and to permit repassaging of negative samples after 6 
days of inoculation.  
Chlamydiae can be isolated from cells that are replicating normally. Most 
diagnosticians, however, prefer to use non-replicating cells for two reasons: to provide 
increased nutrients for the replication of chlamydiae, and because non-replicating cells can 
be maintained for longer periods for observation. Host-cell replication can be suppressed 
either by irradiation or by cytotoxic chemicals; the use of chemicals is becoming more 
common. Cytotoxic chemicals include 5-iodo-2-deoxyiodine, cytocholasin B, 
cycloheximide, and emetine hydrochloride (Paul, 1982). Cycloheximide (0.5-2.0 mg/ml) is 
most commonly used.  
Chlamydiae are known to have a low infection rate in cell cultures, and methods to 
enhance the infection rate are often used. A common method to increase attachment of the 
chlamydiae to the cells is to centrifuge (500-1500 x g) the inoculum onto the monolayer 
for 30–90 min.  Adsorption is enhanced by temperatures near 37 °C. Incubation is usually 
at 37–39 °C. Cultures must be examined at regular intervals by an appropriate staining 
method for the identification of chlamydiae. Staining is usually done at days 3 and days 6. 
Cultures that are negative at day 6 are harvested and repassed. Disruption of the 
monolayer by freeze-thawing should be avoided, as it can destroy the chlamydiae. 
A number of laboratories still use chicken embryos for primary isolation of 
chlamydiae. The standard procedure is to inject up to 0.3 ml of inoculum into the yolk sacs 
of 6-day-old embryos (Andersen and Vanrompay, 2003). Replication of the chlamydiae 
usually will cause the death of the embryo within 5–12 days after inoculation. If no deaths 
occur, two additional blind passages are usually made before calling the sample negative. 
Chlamydial infection typically causes vascular congestion of the yolk-sac membranes, 
which are harvested and homogenized as a 20% yolk-sac suspension. This suspension can 
be frozen to preserve the strain or inoculated into other eggs or into cell culture 
monolayers. Identification of Cp. psittaci is usually performed by staining of yolk-sac 
impression smears by either cytological or immunohostochemical stainings. 
 
Cp. psittaci infections in birds and its zoonotic consequences  31
4.5.4.3. Staining cell monolayers or yolk-sac impression smears 
The preferred method for fixing of the monolayer is to remove the medium, wash 
once with PBS, and fix with acetone for 2–10 min. If the cell culture vessel is plastic, the 
monolayer can be fixed with a mixture of 50% acetone and 50% methyl alcohol or with 
100% methyl alcohol. The preferred method for staining is the direct FA method (Bevan 
and Bracewell, 1986; Andersen and Vanrompay, 2003; Andersen, 2004) (Fig. 1.5.A), but a 
number of other methods can be used. With the FA method, the fluorescein-conjugated 
anti-chlamydia serum is applied to the glass slide and incubated for minimum 30 min at 
37° C. The slides are then washed with PBS and aqua dest, air-dried, and mounted. The 
chlamydial inclusions will fluoresce a light green color under ultraviolet microscopy. 
Commercially prepared conjugates using monoclonal antibodies are available. Conjugates 
also can be prepared from polyclonal sera from rabbits, guinea pigs, sheep, or goats. The 
main problem is obtaining a specific, high-titre antiserum. The fluorescein conjugate is 
prepared using standard techniques (Bevan and Bracewell, 1986; Andersen and 
Vanrompay, 2003; Andersen, 2004). 
Other techniques to demonstrate chlamydial inclusions are the indirect 
immunofluorescent technique, the immunoperoxidase technique (Moore and Petrak, 1985), 
and direct staining techniques, such as Giemsa, or Macchiavello's stains. The 
immunoperoxidase, Macchiavello, and Giminez (Fig. 1.5.B) staining techniques allow the 
use of standard light microscopes. 
 
 
 
B A A 
Fig. 1.5. A. Direct immunofluorescence staining of Cp. psittaci replicating in BGM cells. Note the 
green chlamydia inclusions inside the cells. (bar 20 µm). B. Modified Giménez staining of Cp. 
psittaci replicating in BGM cells. Note the red inclusions inside the cells (bar 20 µm).  
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4.5.5. Polymerase chain reaction  
The possibilities of diagnostic detection of Chlamydophila psittaci are considerably 
improved with the introduction of molecular methods, particularly the polymerase chain 
reaction (PCR), which permits direct identification from clinical specimens and 
accelerates diagnosis from several days to a single working day. Tests published in the 
literature utilize two different genomic target regions for amplification, namely the 
ribosomal RNA gene region (Messmer et al., 1997; Everett et al., 1999c; Madico et al., 
2000) and the gene encoding the MOMP antigen designated omp1 or ompA (Hewinson et 
al., 1991; Kaltenboeck et al., 1997b; Yoshida et al., 1998). 
The sensitivity of the PCR largely depends on the amount and quality of the extracted 
DNA. Optimal extraction of nucleic acids from a wide range of clinical samples is one of 
the most under appreciated, but nevertheless challenging and important steps. Proper 
extraction must efficiently release nucleic acids from samples, remove PCR inhibitors, 
avert the degradation of nucleic acids, and ensure adequate concentration of the nucleic 
acids after extraction. This is relatively easy achievable for viral and mammalian 
amplification targets, but much more difficult and inconsistent for nucleic acid targets of 
bacteria, as these pathogens frequently possess highly resistant outer membranes, and 
specific methods for disruption of these membranes are necessary for quantitative 
recovery of nucleic acids from these organisms. In some cases, concentration of target 
organisms by physical means increases the assays’ sensitivity, but it is important to 
ascertain the enrichment effect (DeGraves et al., 2003). Such methods include 
immunomagnetic, centrifugal, or filter concentration (Lindqvist et al., 1997; Al-Soud et al., 
1998; Radstrom et al., 2003). Several in-house-made and commercial DNA extraction 
methods have been described (Wilson et al., 1996; Sachse and Hotzel, 2003; Harkinezhad 
et al., 2007).  Alternatively, commercial DNA extraction kits can be used for the extraction 
of chlamydial DNA. In our hands the QIAamp® DNA Mini Kit (Qiagen) performed the 
best for pharyngeal swabs while the High Pure PCR Template Preparation Kit (Roche) 
performed best for cloacal swabs and faeces. The use of commercial kits can be 
recommended especially when dealing with PCR inhibitors. They contain a special buffer 
reagent for lyses of the bacterial and eukaryotic host cells mostly based on a guanidine-
detergent lysing solution first described by Chomczynski and Sacchi (1987). Simultaneous 
disruption of cells and inactivation of nucleases is achieved by lysis in strong denaturing 
reagents, for instance 4M guanidinium isothiocyanate (GIT) or 4M guanidinium 
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hydrochloride. Guanidinium isothiocyanate (GIT) is 2.5 times more effective on a molar 
basis than guanidine HCl. Both anion and cation act as denaturants in the GIT buffer but 
only the guanidine cation in GIT-HCl buffer. An optimal RNase digestion is intended to 
remove cellular RNA. The lysate is then centrifuged through a mini-column, where the 
released DNA is effectively bound to a solid phase: modified silica, hydroxyl apatite, or a 
special filter membrane. After washing, the DNA can be eluted with an elution buffer or 
water. DNA prepared in this manner is usually of high purity and free of PCR inhibitors.  
Tissue sample homogenization in cell culture medium, PBS, or TBS and/or freeze-
thaw cycles of samples lead to rapid loss of chlamydial target DNA. Specimens that 
contain low target numbers before freezing often become negative after cryostorage. The 
preservation of DNA from degradation is critically important. De Graves et al., (2003) 
advise to collect all specimens for PCR analysis in a DNA stabilization reagent. Such 
reagents are commercially available; for instance the RNA/DNA Stabilization Reagent for 
Blood/Bone Marrow® from Roche Applied Science. This stabilization reagent is based on 
the denaturation of proteins in a concentrated solution of guanidinium isothiocyanate and a 
reducing agent, as introduced by Chirgwin et al., (1979) for the inactivation of 
ribonuclease during RNA isolations. However, it also works perfectly well to stabilize 
DNA as demonstrated by De Graves et al., (2003) extracting chlamydial DNA from 10% 
(w/v) tissue suspensions of lungs from mice and by Harkinezhad et al., (2007), 
unpublished results) extracting chlamydial DNA from avian pharyngeal and cloacal swabs 
stored in this reagent as well as faeces.  
The choice of a PCR test depends on the skill of the personnel in the laboratory and 
the equipment available. Nested procedures are more sensitive than traditional PCR and in 
most cases are also more sensitive than real-time PCR. Recently, two highly sensitive 
nested PCR assays have been developed to detect Chlamydophila psittaci in avian samples 
(Sachse and Hotzel, 2003; Van Loock et al., 2005b). The nested PCR of Sachse and 
Hotzel (2003) is based on a first amplification generating a genus-specific ompA product 
(576-597 bp) followed by a second amplification using one species-specific and one 
genus-specific primer generating a Chlamydophila psittaci-specific amplicon (389-404 bp). 
PCR results are visualized by agarose gel electrophoresis using ethidium bromide 
containing gels. The sensitivity of the nested PCR-EIA was established at 1 to 0.1 
infection forming unit (IFU). Van Loock et al. (2005b) developed a nested PCR-enzyme 
immuno assay (PCR-EIA) (Fig. 1.6). The fluorescein–biotin labelled PCR products were 
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immobilized on streptavidin-coated microtiter plates and detected with anti-fluorescein 
peroxidase conjugate and a colorimetric substrate, although detection by use of a 
fluorimeter is also possible by using this method. The sensitivity of the nested PCR-EIA 
was established at 0.1 infection-forming units (IFU). Specificity was 100%. An internal 
inhibition control was included to rule out the presence of inhibitors of DNA amplification. 
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Fig. 1.6. Location of the outer and inner primers in the ompA gene. Numbering according to ompA 
sequences in Genbank. 
 
 
A number of real-time PCR tests have been developed. The real-time PCR systems 
have the advantage that their sensitivity approaches that of the nested PCR systems, and 
they require no additional pipetting or handling of the PCR product following the initial 
set-up of the PCR mix. This reduces both the time needed for the test and the incidence of 
contamination. Recently a SYBR Green-based real-time PCR was developed targeting the 
rDNA ribosomal spacer of Chlamydophila psittaci (Geens et al., 2005b). The test could 
detect 10rDNA copies/µL DNA extract and could detect all known ompA Chlamydophila 
psittaci genotypes (Geens et al., 2005a).  
 
4.5.6. DNA microarray-based detection  
Micro-arrays can be coupled with PCR where they serve as a set of parallel dot-blots 
to enhance product detection and identification of bacterial isolates. Recently, Sachse et al. 
(2005) developed a DNA microarray-based detection and identification method for 
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Chlamydia and Chlamydophila spp. The test was developed using the ArrayTube platform 
(CLONDIAG®chip technologies). Unique species-specific hybridization patterns were 
obtained for all nine species of the family Chlamydiaceae on both microarray types. The 
present assay proved suitable for unambiguous species identification of chlamydial cell 
cultures and showed a potential for direct detection of these bacteria from clinical tissue. 
Recently, Clondiag has also developed an ompA-based Cp. psittaci genotyping microarray 
(D. Vanrompay, personal communication). 
 
4.5.7. Serology 
Despite the introduction of very sensitive and specific tests like PCR, the idea of 
serological diagnosis still lingers in the minds of several veterinary clinicians. However, 
serology alone is not particularly useful in diagnosing a current chlamydial infection in 
birds because of the high prevalence of this infection in birds and the long-term, up to 
several months, persistence of anti-chlamydial antibodies. In most bird species, there is a 
high background rate of anti-chlamydial antibodies, and until we have more information 
on the disease pattern in certain bird species in relation to direct identification of the 
bacteria and serology, we are unable to comment on the real significance of antibody titers 
obtained. Thus, to determine if a single bird is infected, serology should always be used in 
conjunction with antigen or gene detection or paired sera should be examined. However, 
obligatory examination of paired sera removes serology from immediate clinical relevance. 
A positive test is evidence that the bird was infected by the bacterium but does not 
necessarily indicate an active infection. False negative results can occur in birds with acute 
infections that are sampled before sero-conversion. Treatment with antibiotics may also 
delay and/or diminish the antibody response. The main serological methods that are being 
used for detecting chlamydial antibodies are: 1) various methods of elementary body 
agglutination (EBA), 2) the complement fixation test (CF), 3) an indirect (micro) 
immunofluorescence (MIF) test and 4) several commercial ELISAs. The EBA detects 
primarily IgM antibodies and thus can detect early infections (Grimes et al., 1994; Grimes 
and Arizmendi, 1996; Grimes, 1996). Titers > 1:10 in budgerigars, cockatiels and 
lovebirds; and titers > 1:20 in larger birds are frequently seen in cases of recent infection. 
A negative result does not guarantee that a bird is free of infection as the sensitivity of the 
test is rather low. The direct complement fixation (DCF) test detects avian IgG but not 
IgM. An advantage is that there is a readily available microprocedure. Disadvantages are: 
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1) test antigens commercially unavailable, 2) the test can not be used for testing sera from 
avian species whose immunoglobulins do not fix complement, such as small psittacine 
birds, 3) it is only relatively sensitive, 4) it cannot be used to differentiate between IgG and 
IgM antibodies, making it necessary to test paired sera, and 5) the technique is fairly 
laborious when there is a large number of samples to be tested. The modified DCF test is 
more sensitive but has the same disadvantages as the DCF test (Grimes et al., 1993; 
Grimes et al., 1994; Tully, Jr. et al., 1996; Andersen, 2004). The indirect IF test detects all 
immunoglobulin isotypes and is, as is the MIF test, widely used to detect C. trachomatis, 
Cp. pneumoniae and Cp. psittaci antibodies in human sera using selected strains of these 
bacteria (Salinas et al., 1993b; Wong et al., 1994; Fernandez et al., 2004). The MIF test 
appears to be more sensitive than the complement fixation tests. Some years ago a large 
number of commercially available ELISAs were evaluated for demonstrating Cp.psittaci 
antibodies in birds. All of these ELISAs were highly sensitive but showed low specificity, 
as they were mainly based on the use of whole chlamydial organisms, LPS, or chlamydial 
outer membrane fractions of LPS and lipoglycoprotein nature (Sting and Hafez, 1992; 
Benheim et al., 1993; Fudge, 1993; Ley et al., 1993; Tully, Jr. et al., 1996). When using 
these sources and antigen, false-positives due to the presence of antibodies cross-reactive 
to the chlamydial LPS or hsp60 cannot be ruled out. More recently, peptide-based ELISA 
systems, or ELISAs using recombinant LPS, have become commercially available for the 
specific detection of C. trachomatis, Cp.pneumoniae and Cp.abortus antibodies (Medac, 
Savyon, Labsystems), (Kaltenboeck et al., 1997a; Morre et al., 2002; Hoymans et al., 2003; 
Tiran et al., 2004). These tests performed as well as the MIF assay, but are less time-
consuming, less expensive, and easier to perform. In the future this principle might also be 
useful in the serodiagnosis of Cp. psittaci infections. At present, an ELISA using 
recombinant MOMP of Cp. psittaci has already been described (Vanrompay et al., 2001a; 
Verminnen et al., 2005) for testing avian sera. The test is not species-specific as the 
recombinant MOMP, produced by transiently tranfected COS7 cells (Vanrompay et al., 
1998), comprises all four variable domains as well as conserved domains and thus detects 
antibodies against all members of the genus Chlamydophila and Chlamydia (Vanrompay 
et al., 2004). However, this is not a problem when testing avian sera as birds can only 
become infected by Cp.psittaci. Unfortunately, Cp. psittaci-specific ELISAs are not yet 
available.  
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5. Public health significance 
Cp. psittaci can infect humans and should be handled carefully under conditions of 
bio-containment. Humans most often become infected by inhaling the organism when the 
urine, respiratory secretions or dried faeces of infected birds is dispersed in the air as very 
fine droplets or dust particles. Other sources of exposure include mouth-to-beak contact, a 
bite from an infected bird or handling the plumage and tissues of infected birds. Therefore, 
post-mortem examinations of infected birds and handling of cultures should be done in 
laminar flow hoods or with proper protective equipment. Human infection can result from 
transient exposures. The disease is of public health significance because of the popularity 
of psittacine birds as pets and the increased placement of these birds in child-care facilities 
and in homes for the aged. Risk of psittacosis is not only limited to direct contact with 
birds but also associated with rural environment and activities like mowing or trimming 
lawns without a grass catcher and with gardening, which suggests that these outdoor 
activities may expose individuals to the infectious agent (Telfer et al., 2005; Fenga et al., 
2007). Person-to-person transmission of psittacosis is possible but it is believed to be rare 
(Hughes et al., 1997; Ito et al., 2002). 
The incubation period is usually 5–14 days; however, longer incubation periods are 
known. Human infections vary from inapparent to severe systemic disease with interstitial 
pneumonia and occasionally encephalitis. The disease is rarely fatal in properly treated 
patients; therefore, awareness of the danger and early diagnosis are important. Infected 
humans typically develop headache, chills, malaise and myalgia, with or without signs of 
respiratory involvement. Pulmonary involvement is common; auscultatory findings, 
however, may appear to be normal or to underestimate the extent of involvement. Several 
severe psittacosis (pneumonia) cases were recently documented (Chorazy et al., 2006; 
Strambu et al., 2006; Haas et al., 2006; Pandeli and Ernest, 2006) and recently Cp. psittaci 
has been associated with ocular lymphoma although this still is a matter of debate as 
conflicting results have been found (Ferreri et al., 2004; Chanudet et al., 2006; Rosado et 
al., 2006; Zhang et al., 2007). However, ‘severe’ psittacosis cases are probably only the tip 
of the iceberg. What lies underneath are less severe, clinically unnoticed infections, which 
are misdiagnosed due to symptoms similar to those of other respiratory pathogens, or even 
asymptomatic infections (Harkinezhad et al., 2007; Vanrompay et al., 2007). The impact 
of these types of Cp. psittaci infections on human health is difficult to determine. We can 
try to extrapolate our knowledge on avian infections to human psittacosis. As in birds, 
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carrier status might occur, as well as pathogenic interactions with other respiratory 
pathogens (Van Loock et al., 2006b). 
Diagnosis can indeed be difficult and is usually established through testing paired sera 
or only one serum sample by use of the micro-immunofluorescence (MIF) test which is 
more sensitive and specific than the previously (and sometimes still) used complement 
fixation (CF) test. However, the MIF test shows cross-reactivity with other chlamydial 
species. Highly sensitive nucleic acid amplification assays can be used to specifically 
detect Cp. psittaci. Culture is also possible, but technically rather difficult requiring 
laboratory biosafety level 3. Like in birds, tetracyclines are the drugs of choice for treating 
human psittacosis. Doxycycline or tetracycline is usually administered unless 
contraindicated like for pregnant women and children < 9 years, where erythromycin can 
be used. The length of treatment will vary with the drug, but should be continued for at 
least 14 days for tetracycline.  
Psittacosis is a notifiable disease in Australia and the U.S. and in most European 
countries like Belgium, France, Germany, Italy, Switserland, An overview of reported 
psittacosis cases in several countries is presented in Table 1.2. 
 
I   
 Table 1.2. Human cases of psittacosis (available data on the internet)      
Country/Territory 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
per million 
of  habitants 
Austria               1 1 2 3 0 3 6 0.36
Argentina              
              
               
            
   2        
                
                
               
              
               
               
              
              
               
              
38 1 0.5
Australia 86 35 55 81 99 137 213 200 239 164 171 62 5.54
Belgium 0 0 8 12 13 10 23 39 12 7 2 3 0.95
Bosnia and 
Herzegovina
ile 
162
 
  0 0 0 - 
Ch - 
Croatia 7 4 0 5 8 3 5 4 1.10
Czech Republic 3 5 6 0 3 0 0
Denmark 0 31 8 13 14 8 22 7 11 2.18
Finland 2 1 2 0 0 0 0 -
F.Y.R. of Macedonia 0 14 0 0 5 0 0 -
Germany 134 124 155 109 86 53 40 42 15 33 26 12 0.51
Hungary 0 0 0 1 5 1 6 85 7 140 29 28 0.60
Japan 23 18 35 54 44 40 34 0.27
Poland 2 2 0 2 0 5 2 2 0.05
   
Table 1.2. Human cases of psittacosis (available data on the internet) (continued) 
Country/Territory 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
per million 
of habitants 
Slovakia               2 0 1 3 10 0 0 1 0 0.18
Spain              
               
               
              
               
              
              
5 4 0 1  0.06
Sweden 25 66 30 29 24 12 13 12 7 5 2 9 1.3
The Netherlands 0 28 25 36 24 17 27 33 49 59 27 1.7
U.K./Great Britain 353 322 293 207 204 106 68 100 62 59 1.75
U.K./N. Ireland 52 37 0 0 44 16 15 13 8.61
Ukraine 161  2 3 2 0 0 0 0 0 _
U.S.A. 45 38 54 15 13 19 13 11 0.05
 
 
 
Cp.psittaci infeections in birds and its zoonotic consequences  41
7. Prevention, control recommendations and legislation  
7.1. Desinfection 
Chlamydiae are highly susceptible to chemicals that affect their lipid content or the 
integrity of their cell walls. Cleaning of equipment and cages of infected birds is important 
because Cp. psittaci can survive for up to 30 days in faeces and bed materials. Disinfection 
with most common detergents and disinfectants will inactivate Cp. psittaci.  The following 
disinfectants can be used to inactivate the organism: 1 in 1000 dilution of quaternary 
ammonium compounds, 70% isopropyl alcohol, 1% Lysol, 1 in 100 dilution of household 
bleach or chlorophenols (Longbottom and Coulter, 2003; Smith et al., 2005). 
 
7.2. Chlamydiaceae vaccine development over the years 
Protective immunity to Chlamydiaceae is believed to be effected primarily through 
the action of CD4+ T helper type 1 (Th1) lymphocytes, CD8+ T lymphocytes, 
mononuclear phagocytes, and cytokines secreted by these cells. In addition, the role of 
local antibodies in mucosal secretions is not to be underestimated. 
Initial attempts to develop an effective vaccine for controlling both animal and human 
chlamydial infections began with the use of inactivated or live whole organism 
preparations in the 1950s. In general, such preparations offered a reasonable level of 
protection, although they have been more successful in protecting animal infections than 
human infections.  
Initial vaccine studies investigated the efficacy of formalin-inactivated whole 
organisms derived from Cp. abortus infected ovine placental material, but the large 
amounts of material required for this proved impractical. Subsequent studies with 
embryonated egg grown material resulted in the commercialization of a single Cp. abortus 
strain (A22), yolk sac derived, formaldehyde-inactivated, Falba-adjuvanted vaccine in 
1958 by the Wellcome Foundation Ltd. This vaccine was effective at controlling ovine 
enzootic abortion (OEA) for approximately 20 years until disease started to reappear in 
vaccinated sheep flocks in the late 1970s. Initially, it was thought that field isolates 
differing from the vaccine strain or emergence of more virulent wild type strains was the 
cause of the vaccine breakdown. However, the subsequent inclusion of a second Cp. 
abortus strain (S26/3), isolated from a vaccinated ewe in 1979, into the vaccine did not 
improve the protective efficacy, and the vaccine was eventually withdrawn in 1992. The 
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failure of the vaccine was most likely due to production problems, since these strains 
continue to provide good levels of protection in experimental challenge model systems. 
During the 1960s unsuccessful attempts were made to develop inactivated and live 
vaccines against trachoma using both human and non-human primates (Grayston et al., 
1963; Woolridge et al., 1967; Dhir et al., 1967; Collier and Blyth, 1967; Wang et al., 
1967). These vaccines reduced disease in some individuals but they enhanced disease in 
others resulting from stimulation of an enhanced delayed-type hypersensitivity (DTH) 
response. Therefore, the use of whole organisms for developing human chlamydial 
vaccines was essentially abandoned. 
In the early 1980s an attenuated strain of Cp. abortus was developed as a live vaccine 
at the Institut National de la Recherche Agronomique, Nouzilly, France (Rodolakis and 
Souriau, 1983; Rodolakis and Bernard, 1984). This live vaccine (Enzovax, Intervet UK 
Ltd.; Cevac Chlamydophila, Cevac Animal Health) is one of the 5 commercially available 
vaccines in Europe and the USA, the other four being inactivated whole organism based 
vaccines including: 1) Mydiavac (Novartis Animal Health UK Ltd.), 2) Ovax Clamidia 
(Fatro), 3) Enzabort EAE-Vibrio and 4) Chlamydia psittaci Bacterin (Colorado Serum). 
The live attenuated vaccine was produced by chemical mutagenesis, and consists of a 
temperature sensitive mutant strain that can grow at 35°C but not at 39.5 °C, the body 
temperature of sheep. These commercial live-attenuated and inactivated vaccines offer 
good protection against OEA and significantly reduce the shedding of infective organisms, 
a factor important in limiting the spread of infection to other animals. However, concerns 
remain over the safety of using live-attenuated vaccines, particularly since Cp. abortus can 
cause abortion and serious disease in pregnant women. There may also be a risk of the 
attenuated strain reverting to virulence, thus having the potential to cause disease and 
abortion in the vaccinated animal. Furthermore, the vaccine cannot be administered during 
pregnancy or to animals being treated with antibiotics limiting its use. In contrast, the 
inactivated vaccines can be administered to pregnant ewes, although care must be taken in 
handling and administering these vaccines as they are adjuvanted with mineral oils, which 
have the potential to cause tissue necrosis if accidentally self-injected. The only other 
animal chlamydial vaccines, which are commercially available are for Cp. felis infection 
in cats. There are 7 commercial vaccines available for cats. Five of them are live 
attenuated and two are inactivated vaccines. Felocell CVR-C Ch (Pfizer Animal Health) 
and Nobivac Forcat (Intervet) contain the attenuated Cp.felis strain Baker. The three others 
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Throughout the 1980s renewed efforts were made to develop a vaccine to protect 
from C. trachomatis infection. However, it was thought that chlamydial components, 
particularly heat shock protein 60 (hsp60), which was possibly responsible for the 
inflammatory damage caused by whole organism vaccines (Brunham and Peeling, 1994), 
should be avoided in a vaccine. Following the identification of the major outer membrane 
protein (MOMP) as the structurally and immunologically dominant protein (Caldwell et 
al., 1981), vaccine research largely focused on this protein. A certain level of protection 
has been achieved with COMC preparations, in which MOMP constitutes 90% or more of 
the protein content, using the guinea pig (Batteiger et al., 1993) and mouse (Pal et al., 
1997) models for C. trachomatis genital tract infection, and in a mouse toxicity test for Cp. 
felis infection (Sandbulte et al., 1996). 
  
 
 
 
 
More recently, mice have been shown to be protected from an upper genital tract 
challenge with C. muridarum following vaccination with a purified and refolded MOMP 
preparation (Pal et al., 2001). This study supports the view that conformational MOMP 
epitopes are important in protection and strengthen the argument for pursuing MOMP as a 
vaccine candidate. 
are; Purevax RCCh (Merial), Purevax RCPCh (Merial) and Purevax RCPCh FeLV (Merial) 
and contain the attenuated Cp.felis strain 905. The two inactivated vaccines, Fevaxyn 
iCHPChlam and Fevaxyn Pentofel, (Fort Dodge Animal Health), are inactivated 
preparations comprising the Cp. felis Cello strain. Information on commercially available 
vaccines is shown in Table 1.3. Although vaccination is successful in reducing acute 
disease, it does not, however, prevent shedding of the organism and therefore chlamydial 
spreading in the population nor does it prevent re-infection (Wills et al., 1987). A small 
percentage of vaccinated cats may also develop post-vaccinal reactions such as fever, 
vomiting, anorexia and/or depression and lethargy. Vaccination of pregnant cats is also not 
advised. 
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 Table 1.3. Commercially available chlamydial vaccines. 
Vaccine name  Disease  Marketing 
authorization holder  
Animal Description 
Felocell CVR-C Ch Feline viral rhinotracheitis (FVR), 
feline calicivirus (FCV), feline 
panleukopenia (FPL), feline 
chlamydiosis 
Pfizer Animal Health, 
USA 
Cat Attenuated:  feline calicivirus (strain F9), feline 
herpes virus type 1 (strain G2620A), feline 
panleucopenia virus (strain MW-1) and  Cp. 
felis (strain Baker) 
Fevaxyn Pentofel Feline panleucopenia, feline 
chlamydiosis,  leukaemia and 
respiratory diseases caused by 
feline rhinotracheitis virus, feline 
calicivirus  
Fort Dodge Animal 
Health, U.S.A 
Cat Inactivated: panleucopenia virus (CU4 strain), 
feline Calicivirus (255 strain), Feline 
Rhinotracheitis Virus (605 strain), Cp. felis 
(Cello strain),Feline Leukaemia Virus (61E 
strain) 
Nobivac  Forcat Feline panleucopenia, feline 
chlamydiosis and respiratory 
diseases caused by feline 
herpesvirus, feline calicivirus 
Intervet, the Nederlands Cat Attenuated :  feline herpesvirus type 1(strain 
G2620A), feline calicivirus (strain F9), Cp. 
felis (strain Baker) and feline panleucopenia 
virus (strain MW-1) 
Purevax RCCh Feline viral rhinotracheitis, feline 
chlamydiosis and respiratory 
diseases caused by feline 
calicivirus,  
Merial, France Cat Attenuated: feline rhinotracheitis herpesvirus 
(strain FVH F2), feline calicivirosis antigens 
(FCV 431 and FCV G1 strains) and Cp. felis 
(strain 905) 
Purevax RCPCh Feline viral rhinotracheitis, feline 
panleukopenia , feline chlamydiosis 
and respiratory diseases caused by 
feline calicivirus  
Merial, France Cat Attenuated: feline rhinotracheitis herpesvirus 
(FVH F2 strain), feline calicivirosis antigens 
(FCV 431 and FCV G1 strains), Cp. felis 
(strain 905) and feline panleucopenia virus 
(PLI IV)  
Fevaxyn i-CHP 
Clam 
Feline panleukopenia, feline 
chlamydiosis 
Fort Dodge Animal 
Health U.S.A.  
Cat Inactivated Cp. felis Cello strain (Cello, 1967) 
     
Table 1.3. Commercially available chlamydial vaccines (continued). 
Vaccine name  Disease  Marketing 
authorization holder  
Animal Description 
Purevax RCPCh 
FeLV 
Feline viral rhinotracheitis, feline 
panleukopenia (FPL), feline 
chlamydiosis,  leukaemia and 
respiratory diseases caused by 
feline calicivirus 
Merial, France Cat Attenuated:  feline rhinotracheitis herpesvirus 
(FVH F2 strain), feline calicivirosis antigens 
(FCV 431 and FCV G1 strains), Cp. felis 
(strain 905), feline panleucopenia virus (PLI 
IV) and FeLV recombinant canarypox virus 
(vCP97) 
Chlamydia psittaci 
Bacterin 
Enzootic abortion of ewes Colorado Serum, USA Sheep inactivated cultures of Cp. psittaci emulsified 
with a mineral oil adjuvant. 
Enzabort EAE-
Vibrio 
Campylobacter and chlamydia Colorado Serum, USA Sheep killed vaccine 
Ovax Clamidia Chlamydial abortion Fatro, Italy Sheep egg-grown, formalin-inactivated, whole-
organism 
Ovilis®Enzovax Chlamydial abortion Intervet, the Nederlands Sheep an avirulent, temperature-sensitive, live 
chlamydia vaccine 
Enzovax Enzootic abortion of ewes Intervet UK Sheep Attenuated vaccine 
Mydiavac Enzootic abortion of ewes Novartis Animal health, 
UK Ltd. 
Sheep   Inactivated whole-organism
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Although vaccination with purified COMCs and refolded, purified MOMP 
preparations have been reasonably successful, the problems associated with the bulk 
growth of chlamydial organisms that is required for their preparation, make these options 
commercially non-viable. For these reasons, attention turned to the development of the 
cheaper and more cost-effective alternative of recombinant protein vaccines, particularly 
those based on MOMP. However, this approach proved difficult because the expression of 
full-length recombinant MOMP in E. coli was generally toxic. Sheep protection studies 
with Cp. abortus recombinant MOMP, expressed as insoluble inclusion bodies in a 
bacterial overexpression system, offered some protection against infection, although 
results were inconsistent (Herring et al., 1998). Another approach has been to express Cp. 
abortus MOMP, or fragments of MOMP, as overcoat protein on the surface of a plant 
virus (Herring et al., 1998). This method, although initially promising in mouse studies, 
ultimately proved unsuccessful and trials did not progress to sheep. Other studies with 
MOMP peptides (Allen et al., 1991; Knight et al., 1995) and oligopeptide vaccines (Su et 
al., 1995) containing antigenically common T-helper and neutralising B-cell epitopes have 
been variable. The disappointing results achieved with recombinant MOMP vaccination 
could be due to a lack of native protein structure and conformationally intact protective 
epitopes. Glycosylation of additional antigens may also be required to augment protection. 
Attempts to express or refold recombinant MOMP to a native confirmation have largely 
been unsuccessful, and are unlikely to yield large enough quantities of native recombinant 
MOMP to make them a viable option for use in commercial vaccines. 
In recent years, attention has turned to DNA vaccination as a way of inducing a 
protective response against chlamydial infections (Zhang et al., 1999; Vanrompay et al., 
1999b; Dong-Ji et al., 2000). One of the main advantages of this technology compared to 
the more conventional methods of vaccination is that the vaccine antigen is produced de 
novo by the host cell. The antigen is then processed in the same way as internalised viruses 
and intracellular bacterial pathogens, thus mimicking natural infection and resulting in 
humoral and cell mediated immune responses. However, in terms of human chlamydial 
infections, this method has generally been more successful at eliciting a protective 
response in the murine respiratory model (Zhang et al., 1997; Dong-Ji et al., 2000) than in 
the genital tract (Pal et al., 1999). Similarly, for animal infections, DNA vaccination has 
been more successful at inducing protective immune responses in turkeys infected with Cp. 
psittaci (Vanrompay et al., 1998; Vanrompay et al., 1999a; Vanrompay et al., 1999b; 
Vanrompay et al., 2001b), than in sheep (Longbottom, 2003) or mouse models (Hechard et 
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al., 2003a; Hechard et al., 2003b) infected with Cp. abortus. A Cp. psittaci DNA vaccine 
can be used in the presence of maternal antibodies (Van Loock et al., 2004). Thus, further 
research is needed to enhance the immunogenicity of DNA vaccines and to lower the 
production price of these vaccines.  
There are currently no vaccines available against avian chlamydiosis although 
research on MOMP-based DNA vaccination in SPF turkeys was very promising 
(Vanrompay et al., 1999a; Vanrompay et al., 1999b). DNA vaccination significantly 
diminished clinical signs, lesions and chlamydial excretion though gave no full protection. 
But this is maybe impossible. So far, we have to rely on risk reduction strategies and 
treatment. Worldwide, psittacosis prevention and control recommendations and legislation 
are focusing on a reduction in human morbidity.  
 
7.3. Legislation 
Until recently, EU legislation for the importation of birds other than poultry from 
third countries was encompassed in Commission Decision 2000/666/EC (CEC, 2000) and 
2005/760/EG, which were primarily concerned with restricting the introduction of 
Newcastle disease or avian influenza. Essentially these decisions required: 1) the bird must 
come from a flock in the country of origin where they have been kept for at least 21 days 
prior to export, 2) the birds are transported in cages or crates that contain only one species 
of bird or one species per compartment if compartimentalised and, 3) the birds are moved 
to designated licensed quarantine premises where they are held for 30 days and subjected 
to at least two veterinary inspections, usually beginning and end, before release. There was 
only one mention on Cp. psittaci: “if during quarantine it is suspected or confirmed that 
psittaciformes are infected with Cp. psittaci, all birds of the consignment must be treated 
by a method approved by the competent authority and the quarantine must be prolonged 
for at least two months following the last recorded case”. Thus, these requirements did not 
apply to any other bird species nor were there any rules that applied to the management of 
psittacosis within the EU. Therefore, decisions 2000/666/EC and 2005/760/EC were 
repealed and a new commission regulation, EC no 318/2007 applies from 1 July 2007 after 
being published in the Official Journal of the EU.  This regulation lays down the animal 
health conditions for imports of certain birds from third countries and parts thereof into the 
EU. Thus it is not applicable to: a) poultry, b) racing pigeons, c) birds imported from 
Andorra, Liechtenstein, Monaco, Norway, San Marino, Switzerland and the Vatican City, 
  Chapter I  48 
and not to, d) third countries which can use an animal health certificate referred to in 
annex I of the regulation. The regulation also lays down the quarantine conditions. For 
instance: 1) approved quarantine facilities and centres, 2) direct transport of birds to 
quarantine stations, 3) attestation by the importers or their agents, 4) quarantine for at least 
30 days, 5) examination, sampling and testing to be carried out by an official veterinarian, 
6) actions in case of disease suspicion which are in case of chlamydiosis treatment of all 
birds and prolonged quarantine for at least two months following the date of the last 
recorded case.  Importantly the regulation only allows imports of birds from approved 
breeding establishments, thus for birds other than poultry, only birds bred in captivity 
carrying an individual identification number and accompanied by an animal health 
certificate are allowed. 
In the US, State regulatory agencies may impose quarantine on intrastate movement 
of diseased poultry flocks and may require antibiotic treatment of the flock prior to 
slaughter. Because regulations may vary from state to state, the appropriate public health 
and/or animal health agencies should be consulted as necessary. According to USDA 
regulations, movement of poultry, carcasses, or offal from any premise is prohibited where 
the existence of chlamydiosis has been proved by isolation of a chlamydial agent. The 
Animal and Plant Health Inspection Service of the USDA and the U.S. Department of 
Health and Human Services forbid interstate movement of birds from infected flocks, but 
there is no restriction on movement of eggs from such flocks. 
In 2006, the US National Association of State Public Health Veterinarians (NASPHV; 
wwwnasphv.org) published a compendium of measures to control Cp. psittaci infections 
among humans and pet birds, including prevention and control recommendations such as: 
1) protect persons at risk, 2) maintain accurate records of all bird-related transactions for at 
least one year to aid in identifying sources of infected birds and potentially exposed 
persons, 3) avoid purchasing or selling birds that have signs consistent with avian 
chlamydiosis, 4) isolate newly acquired, ill, or exposed birds, 5) test birds before they are 
to be boarded or sold on consignment, 6) screen groups of birds with frequent public 
contact routinely for anti-chlamydial antibodies, 7) practice preventive husbandry, 8) 
control the spread of the infection and finally 9) used disinfection measures.  
Large-scale commercial import of psittacine birds ended in the US in 1993 with the 
implementation of the Wild Bird Conservation Act and the Veterinary Services of the 
Animal and Plant Health Inspection Service of the USDA regulates the legal importation 
of pet birds set forth in the Code of Federal Regulations, (Title 9, Chapter 1). The 
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Department of the Interior (DOI) monitors and regulates wildlife shipments at U.S. ports 
of entry and conducts investigations on smuggling and interstate trafficking of endangered 
and protected species including birds, which is extremely important as these birds are a 
potential source of new Cp. psittaci infections in domestic birds.  
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Abstract 
Chlamydophila psittaci infections in man still present an epidemiological and 
diagnostic challenge. Psittacosis cases are underestimated. We therefore investigated the 
occurrence of Cp. psittaci infections in a representative Flemish population of 540 
individuals. Participants, 264 males and 276 females, at the age of 36 to 57 years (median 
46) were sampled pharyngeally and at the same moment a blood sample was obtained. 
Each individual completed a questionnaire allowing insight into professional and 
nonprofessional activities, smoking habits, medical history and contact frequency with 
different bird species and other animals. Pharyngeal swabs were analyzed using a Cp. 
psittaci-specific nested PCR/enzyme immunoassay (EIA), and a Cp. pneumoniae- specific 
nested PCR. Sera were tested for IgG/IgM by a recombinant Cp. psittaci MOMP-based 
ELISA, by MIF and by the Serion Chlamydia IgG/IgA ELISA. Results confirmed our 
suspicion on the underestimation of psittacosis in Belgium. Psittaciformes and racing 
pigeons were the main infection source. Non-exposition related risk factors for PCR or 
ELISA positivity were gender (women being more frequently infected) and excessive 
alcohol intake defined as an averaged intake of > 2 units daily for women and >3 units 
daily for men. We analyzed the effect of seropositivity and/or PCR positivity on 
inflammation (white blood cell count, high-sensitive CRP, fibrinogen). After adjustment 
for known confounders, we found no clear significant pattern suggesting an increased 
inflammatory burden. 
 
1. Introduction 
Members of the family Chlamydiaceae are obligate intracellular Gram-negative 
bacteria. The family comprises two genera, Chlamydia and Chlamydophila. Chlamydia 
has three species including C. trachomatis (humans), C. suis (swine) and C. muridarum 
(mice, hamsters).The genus Chlamydophila includes the species Cp. psitttaci (birds), Cp.- 
abortus (sheep, goats, cattle) Cp. caviae (guinea pigs), Cp. felis (cats), Cp. pecorum (sheep, 
cattle, swine) and Cp. pneumoniae (humans, koala’s, horses) (Everett et al., 1999a). All 
animal infecting species are considered potentially infectious to humans although 
particularly Chlamydophila psittaci and Cp. abortus, are known to be transmissible from 
animals to humans, causing significant zoonotic infections.  
The most important animal chlamydiosis of zoonotic character is psittacosis, a 
systemic disease in birds of acute, protracted, chronic or subclinical manifestation. 
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Although the causative agent Cp. psittaci is known to be very wide-spread in many avian 
species, not all carrier birds actually show symptoms of disease. However, they may 
transmit the infection to humans, the symptoms being mainly non-specific and influenza-
like, but severe pneumonia, endocarditis and encephalitis are not uncommon. In Germany, 
the annual average of notified human cases of psittacosis is approximately 100 with 
several deaths (Sachse and Grossmann, 2002). A study in the United States revealed that, 
while the average prevalence may be at a few percent, up to 30% of households having 
purchased pet birds from infected flocks were affected by clinical psittacosis or were 
serologically positive (Moroney et al., 1998). The general situation in Europe, and thus 
also in Belgium is believed to be no different although human psittacosis cases are only 
sporadically reported, with 7, 2 and 3 cases in 2005, 2006 and 2007, respectively 
(www.iph.fgov.be). Cp. psittaci causes a symptomatic or asymptomatic course of infection 
depending on the virulence of the strain, the infective dose and the immune status of the 
host. An asymptomatic infection will be unnoticed, as people do not seek medical 
attention. On the other hand, in case of a symptomatic infection, flu-like symptoms occur 
which are often treated with antibiotics to prevent ‘secondary bacterial’ infections. Thus, 
in most symptomatic cases, diagnostic tests for Cp. psittaci are not performed. Therefore, 
the number of Cp. psittaci infections in humans is most likely underestimated.  
Infections of workers in abattoirs in connection with the slaughtering of ducks, 
turkeys or geese, as well as cases among bird breeders are regularly reported in several 
European countries (Bracewell and Bevan, 1982; Newman et al., 1992; Bennedsen and 
Filskov, 2000; Harkinezhad et al., 2007; Vanrompay et al., 2007; Laroucau et al., 2008). 
Feral pigeons are quite commonly found infected in many urban habitats, which also  
raises serious questions as to the hazards to human health (Haag-Wackernagel, 2005; 
Laroucau et al., 2005; Mitevski et al., 2005). But, we better not forget the group of persons 
facing an elevated risk of infection because of frequent contacts with domestic and 
companion birds at work or in their spare time. As a consequence of the increasing habit 
of keeping parrots, parakeets, budgerigars, etc. as pet birds many more persons are at risk. 
However, the occurrence of Cp. psittaci infections in a generally healthy human 
population in contact with domestic and companion birds is not documented. The aim of 
the present study was to investigate the actual number of Cp. psittaci infections in such a 
human population, using recently developed molecular diagnostic techniques. We also 
tried to retain information on the relation between zoonotic risk, bird contact frequency 
and on the bird species most often involved in Cp. psittaci transmission to humans.  
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2. Material and methods 
2.1. Study population and samples  
 Data are from a population survey (n=2524) of apparently healthy community-
dwelling subjects, aged 35-55 years at study initiation, from the communities of Erpe-
Mere and Nieuwerkerken. Subjects were recruited by random sampling of the population 
database of subjects within the age and geographic constraints. From the first 987 
consecutive subjects entering the study (October 2002 until July 2003), pharyngeal 
specimens were taken using rayon-tipped, aluminium-shafted swabs (Copan, USA). 
Swabs were provided with DNA stabilization buffer (Roche) and stored at –80°C until 
tested by PCR. Additionally, blood was collected, and sera were stored at –80°C until 
serologically tested.  
Each participant completed a questionnaire (reviewed by his/her primary care 
physician and a study nurse at study entry), designed to assess information on professional 
and non-professional activities, smoking habits, general health, personal medical history, 
use of medication, and contact with companion and/or domestic animals. In case of 
contact with birds, participants defined the bird species and contact frequency. The 
questionnaire was used to assign participants to groups having: 1) daily, 2) weekly, 3) 
sporadic or 4) no contact with birds. Swabs of 420 male (264) or female (276) participants 
having contact with companion/domesticated birds and of 120 of 567 randomly chosen 
participants having no contact with birds were examined. Persons were of 35 to 57 years.  
The ethical committee of Ghent University approved the study and a written informed 
consent was obtained from each participant prior to participating in the study. 
 
2.2. Polymerase chain reactions  
Pharyngeal DNA as well as positive control DNA (genomic DNA of Cp. psittaci 
strain 89/1051 and of Cp. pneumoniae strain TW183) was prepared as previosly decribed 
(Van loock et al., 2005b). Pharyngeal swabs were tested by a nested PCR enzyme 
immunoassay (PCR/EIA) which specifically targets the Cp. psittaci ompA gene (Van 
Loock et al., 2005b). The nested PCR/EIA was performed using external and internal 
primer pairs generating a biotin-fluorescein dual labeled ompA product of 451 bp, detected 
by spectrophotometry in streptavidin-coated ELISA plates.  Subsequently, Cp. psittaci 
PCR/EIA positive specimens were also examined for the presence of Cp. pneumoniae, by 
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a Cp. pneumoniae- specific 16S-rRNA nested PCR (Messmer et al., 1997) using genus-
specific external primers and species-specific internal primers generating PCR products of 
436 and 127 bp, respectively. Results were visualized by agarose gel electrophoresis.  
 
2.3. Serology   
Sera of individuals positive by Cp. psittaci nested PCR/EIA and negative by Cp. 
pneumoniae nested PCR were examined for antibodies using: 1) a micro-
immunofluorescence (MIF) test (Focus Diagnostics Inc.), detecting IgG and IgA against 
whole elementary bodies of Cp. psittaci genotype A strains 6BC and DD34 of which the 
lipopolysaccharide (LPS) had been removed, 2) the ELISA classic Chlamydia IgG/IgA 
(Virion/Serion), detecting antibodies against detergent extracted elementary bodies of the 
Cp. psittaci genotype D Borg strain, and 3) an ELISA detecting IgG and IgM against 
recombinant MOMP (rMOMP) of the genotype A Cp. psittaci strain 89/1051 (Verminnen 
et al., 2006). Sera, negative in both nested PCR’s were also examined.  
Tests were performed and interpreted as advised by the manufacturers diluting sera 
1/20 and 1/100 in the Serion ELISA for IgG and IgA detection, respectively. In the MIF 
test, 1/10 diluted sera were used. The recombinant ELISA was performed on two-fold 
serum dilutions (starting at 1/100) of kaolin pre-treated sera (Novak et al., 1993). 
Recombinant MOMP was produced in pcDNA1::MOMP A transfected COS7 cells 
(Vanrompay et al., 1998). IgG and IgM titers were determined using rMOMP coated 
ELISA plates and 1:500 dilutions of horseradish peroxidase-labelled anti-human IgG 
(H+L) and anti-µ-chain specific antibodies (Nordic Immunological Laboratories, Tilburg, 
The Netherlands). Results were positive if the absorbance exceeded the cut off value of the 
mean of three negative control sera plus two times the standard deviation. Positive control 
sera originated from 3 humans infected while visiting a turkey farm experiencing a Cp. 
psittaci genotype A infection (Verminnen et al., 2008a).  
 
2.4. Biochemical analyses 
All subjects were fasting, refrained from smoking for at least 6 hours, and were 
screened for active infection/inflammation. Those with recent or active 
infection/inflammation were asked to return for blood sampling after their symptoms had 
subsided for at least 10 days. Serum parameters were measured using commercial reagents 
on a Modular P system (Roche Diagnostics, Mannheim, Germany) in an ISO 9002 
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certified reference laboratory.15 Hs-CRP concentrations were measured by a high-
sensitive, particle-enhanced immunoturbidimetric method on an Integra 400 analyzer 
(Roche Diagnostics, Mannheim, Germany). Latex particles coated with mouse monoclonal 
anti-CRP antibodies were used. Precipitation was determined at 552 nm. The method was 
standardized with regard to the CRM 470 (RPPHS 91/0619) reference preparation of the 
IFCC.15 Coefficient of variation of all tests was <3.0%. Excessive alcohol intake was 
defined as an averaged intake of > 2 units daily for women and >3 units daily for men. 
 
2.4. Statistics  
Potential zoonotic risk factors were analyzed by SPSS 15.0.1.1. 
 
3. Results  
3.1. Contact frequency with different bird species  
Based on the questionnaire, completed by all 540 participants, 254 (47%), 58 (10.7%), 
108 (20%) and 120 (22.2%) had daily, weekly, sporadically or no contact with birds. In 
the daily-contact group (n = 254), most people had contact with canaries (65.3%), 
followed by Psittaciformes (46.4%) (Table 1). In the weekly-contact group (n=58) most 
people had contact with racing pigeons (63.7%) followed by canaries (60.3%). In the 
sporadic contact group (n = 108) most people had contact with Psittaciformes (29.63%) 
followed by canaries (28.7%).  
Sixty one, 58.6 and 83.3% of the participants having daily, weekly or sporadically 
contact with birds, actually had contact with more than one bird species. Participants in 
contact with only one bird species are presented in Table 2. 
 
3.2. Polymerase chain reactions 
Sixty-nine of 540 (12.7%) pharyngeal swabs (44 and 25 of female and male 
participants, respectively) contained C. psittaci DNA. Positives included 57 of 254 
(22.4%), 11 of 58 (19%), 0 of 108 (0%) and 1 of 120 (0.8%) persons having daily, weekly, 
sporadic, or no contact with domestic or companion birds, respectively. Thus, 471 of 540 
(87.3%) examined individuals were negative. Of those, 197 (41.8%), 47 (10%), 108 
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(22.9%) and 119 (28.5%) had daily, weekly, sporadic, or no contact with birds, 
respectively. None of 69 C. psittaci positive swabs contained C. pneumoniae DNA.  
 
 
Table 2.1 Contact frequency with different bird species 
Birds  Daily  
n=254 
Weekly 
n=58 
Sporadic 
n=108 
Total 
n=420 
Canaries  166 (65.3%) 35 (60.3%) 31 (28.7%) 232 (55.2%) 
Psittaciformes 118 (46.4%) 24 (41.3%) 32 (29.63%) 174 (41.4%) 
Pigeons 58 (22.8%) 37 (63.7%) 24 (22.2%) 119 (28.3%) 
Ducks  53 (20.8%) 14 (24%) 21 (19.4%) 90 (21.4%) 
Geese  48 (19%) 21 (36.2%) 21 (19.4%) 88 (21%) 
Turkeys  24 (9.4%) 7 (12%) 15 (13.8%) 46 (11%) 
 
 
 
3.3. Serology 
 All 69 Cp. psittaci PCR positives and 96 Cp. psittaci and Cp. pneumoniae PCR 
negatives, were examined by the rMOMP ELISA, the MIF test and the Serion Chlamydia 
ELISA.  
Twenty-eight on 69 (40.6%) sera (21 and 7 of female and male participants, 
respectively) reacted positive in the rMOMP ELISA. Positive sera originated from 24 and 
4 people having daily or weekly contact with domestic or companion birds, respectively. 
Serum from the single PCR positive person out of the ‘no-contact group’ was negative in 
the rMOMP ELISA. IgG antibody titers ranged from 1/100 to 1/400, while IgM antibody 
titers were 1/100. Three of 28 (10.7%) sero-positives had only IgM, 11 individuals had 
IgM and IgG, and 14 had only IgG.  
Only 3 of 69 (4.3%) sera of Cp. psittaci PCR positives reacted positive in the MIF 
test, revealing IgG titers of 16, 64 and 16, respectively and IgA titres of 16, <16 and 32, 
respectively. The rMOMP ELISA revealed IgG titers of 1/100, 1/100 and 1/200 in those 3 
sera, respectively. Interestingly, positive control sera were negative in the MIF test. 
Surprisingly, all 69 Cp. psittaci PCR positives were negative in the Serion ELISA while 
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positive control sera contained IgG, but no IgA.  
Ninety-six Cp. psittaci and Cp. pneumoniae PCR negatives were assigned to 4 groups 
having: 1) daily, 2) weekly, 3) sporadic or 4) no contact with birds. Interestingly, 11 of 43 
(25.6%), 3 of 8 (37.5%), 1 of 4 (25%) and 3 of 41 (7.3%), thus 18 sera (18.7%) of 
individuals having daily, weekly, sporadic or no contact with birds, respectively, reacted 
positive in the rMOMP ELISA. Of those 18 positive sera, 9 and 9 were from female and 
male participants, respectively. The IgG titers ranged from 1/100 to 1/400 while the IgM 
titers were 1/100. Six of 18 (33.3%) had IgG and IgM, while 1 (5.5%) and 11 (61%) only 
had IgM or IgG antibodies, respectively. Sera of 96 PCR negatives were negative in the 
MIF test and in the Serion ELISA.  
Zoonotic risk related to daily or weekly contact with one single bird species is 
presented in Table 2.3 and 2.4, respectively. Sporadic contact with one bird species gave 
no positives. 
 
3.4. Statistics  
Individuals in contact with Psittaciformes, especially parakeets and persons in contact 
with racing pigeons were significantly more frequently infected with Cp. psittaci (Table 
2.2). Daily contact with especially racing pigeons and parakeets (Table 2.3) is significantly 
more dangerous than contact with canaries. Interestingly, weekly contact with 
Psittaciformes (parakeets + parrots) (Table 2.4) resulted in a significant higher infection 
rate than weekly contact with pigeons or canaries.  
Thirteen (19%) of 69 PCR positives were smokers. However, smoking appeared to 
have no significant effect on acquiring psittacosis. The odd ratio for the PCR positives of 
41-45 year old was higher (odds ratio [OR] 1.53, 95% confidence interval [CI] 0.88–2.66, 
p < 0.16) but was not significantly different regarding the studied population. 
In a model containing age, body weight, presence of diabetes, excessive alcohol 
intake, educational achievement, fruit & vegetable intake, hypertension and smoking, non-
exposition related risk factors for seropositivity were gender (for women compared to men: 
OR 2.620, 95% CI 1.296-5.293; p< 0.007) and excessive alcohol intake (for excessive 
users versus non-excessive: OR 2.215 95% CI 1.084-4.522; p< 0.029). Similarly, non-
exposition related risk factors for PCR positivity were gender (for women compared to 
men: OR 1.942 95% CI 1.077-3.501; p< 0.026) and excessive alcohol intake (for 
excessive users versus non-excessive:  OR 1.705  95% CI 0.923-3.148; p< 0.088). 
  Chapter II  60 
We analyzed the effect of seropositivity and/or PCR positivity on inflammation 
(white blood cell count, high-sensitive CRP, fibrinogen). After adjustement for known 
confounders, we found no clear significant pattern suggesting an inceased inflammatory 
burden. In general, seropositivity trended to slightly higher levels of inflammatory 
variables (all non-significant), whilst PCR positivity trended to no-effect or even lower 
inflammatory levels. We tested wether the subgroup of subjects having at least weekly 
contact with psitacciformes had more inflammation (irrrespective of PCR or serostatus), 
but found no evidence of increased inflammatory burden. 
 
 
Table 2.2. Cp. psittaci zooonotic risk related to contact of humans with one certain bird species. 
Contact with: Number (%) of persons on 540 
examined individuals, in contact 
with only one bird species  
PCR  
positivesa (%)  
PCR and/or ELISAb 
positives *(%) 
OR (95% CI) C P value 
Psittacine birds 31 (5.7) 7 (22.5) 8 (25.8) 6.3 (2.6-15.2) 0.00001 
 Parakeet  23 (4.2) 6 (26.0) 6 (26) 5.9 (2.2-15.8) 0.00001 
 Parrot  8 (1.5) 1 (12.5) 2 (25) 4.9 (1-24.3) 0.050 
Canary  69 (12.8) 9 (13.0) 12 (17.4) 4.8 (2.2-10.5) 0.00001 
Pigeon  32 (5.9) 7 (22) 8 (25) 6.0 (2.5-14.7) 0.00001 
Duck  2 (0.3) 0 (0) 0 (0) - - 
Goose  5 ( 0.9) 0 (0) 0 (0) - - 
Turkey  5 (0.9) 1 (20) 1 (20) 3.8 (0.43-33.8) 0.23 
Total      144 24 29 - -
aEach individual had only contact with one bird species; brMOMP ELISA; cOdd ratio for PCR and/or ELISA positives with  
95% confidence intervals 
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Table 2.3. Cp. psittaci zoonotic risk related to daily contact with one single bird species. 
Total number of persons daily in contact with 
Parakeet Parrot Canary Pigeon Duck Goose Turkey 
16 5 55 17 1 3 4 
              
Number of persons (%) positive by PCR and/or rMOMP ELISA 
5 1 10 7 0 0 1 
(31.2%) (20%) (18.2%) (41.2%) 0 0 (20%) 
 
 
 
 
 
 
Table 2.4. Cp. psittaci zoonotic risk related to weekly contact with one single bird species. 
Total number of persons weekly in contact with 
Parakeet Parrot Canary Pigeon Duck Goose Turkey 
3 2 8 9 0 1 1 
              
Number of persons (%) positive by PCR and/or rMOMP ELISA  
1 1 2 1 0 0 0 
(33.3%) (50%) (25%) (11%) 0 0 0 
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4. Discussion  
We strongly believe that the annually reported psittacosis cases do not reflect the real 
Cp. psittaci infection status in Belgium. Moreover, scientific reports of the COST855 on 
animal chlamydiosis and zoonotic implications indicate the underestimation of psittacosis 
in Europe (www.vetpathology.uzh.ch/forschung/CostAction855/). We therefore examined 
the prevalence of Cp. psittaci infections in a randomly selected apparently healthy human 
population sample of East-Flanders, in contact with domestic and/or companion birds.  
Canaries and Psittaciformes, especially parakeets and parrots were the most popular 
pet birds, followed by racing pigeons, ducks, geese and turkeys. Individuals in contact 
with Psittaciformes and racing pigeons are more frequently infected. However, daily 
contact with Psittaciformes is as dangerous as weekly contact, while daily contact with 
racing pigeons is significantly more dangerous than weekly contact. This is in accordance 
with the literature, ascribing most psittacosis cases to contact with Psittaciformes (Smith et 
al., 2005; Kaibu et al., 2006; Heddema et al., 2006c). One single contact can be result in 
zoonotic transfer (Harkinezhad et al., 2007; Matsui et al., 2007). Psittacosis cases 
described in literature are on severe disease with pneumonia and in some cases even 
cardiac and neurological complications. However, in this study (which was primarily 
focused on cardiovascular disease and ageing, the main interest of the researchers was 
chronic inflammation. Those with recent or active infection/inflammation were asked to 
return for blood sampling after their symptoms had subsided for at least 10 days.  Thus, no 
correlation between the presence of chlamydial DNA and clinical respiratory disease can 
be drawn.    
Surprisingly, also canaries seemed to present a substantial zoonotic risk, as 45 of 69 
(65.2%) PCR positives had contact with canaries. However, only 9 (20%) of them had 
exclusively contact with canaries. Thirty of them (66.6%) also had contact with 
Psittaciformes, while 21 (46.6%), 16 (35.5%), 16 (35.5%) and 8 (17.7%) also had contact 
with pigeons, ducks, geese or turkeys, respectively. Thus, Psittaciformes, rather then 
canaries, were more likely responsible for the high number of positives claiming to have 
contact with canaries. The disease occurs more often in Psittaciformes and the course of 
infection is also more severe, often leading to mortality as illustrated by Vanrompay et al., 
(1993a), isolating 45 Cp. psittaci strains from 264 dead birds, among them only four 
(8.8%) isolates of canaries and 25 (55.5%) isolates from Psittaciformes. Additionally, over 
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a period of 11 years (1991-2001), Dovc et al. (2005), found 14 of 1677 (0.8%) canaries to 
be sero-positive, compared to 238 of 3869 (6.2%) parrots.  
Racing pigeons and especially daily contact with racing pigeons means a serious 
zoonotic risk. Although not examined, feral pigeons must also present a substantial 
zoonotic risk as several studies showed feral pigeons to be highly infected (Salinas et al., 
1993a; Travnicek et al., 2002; Dovc et al., 2004; Tanaka et al., 2005; Heddema et al., 
2006b). At present, there was one Cp. psittaci PCR positive person, claiming no contact 
with domestic or companion birds. Maybe, zoonotic transfer occurred through contact 
with infected feral pigeons or other wild birds such as waterfowl. On the other hand, the 
person could also became infected by human to human transmission although this is 
thought to be extremely rare (Hughes et al., 1997; Ito et al., 2002). 
The rMOMP ELISA is routinely used in our department for epidemiology in birds as 
the test is highly sensitive and specific as compared to LPS- or whole organisms-based 
serological assays (Verminnen et al., 2006). However, birds only become infected with Cp. 
psittaci, while humans can become infected with other chlamydial species with Cp. 
trachomatis and Cp. pneumoniae being most prevalent. As MOMP carries family-specific 
epitopes, the presence of cross-reactive antibodies against Cp. pneumoniae and Cp. 
trachomatis must be ruled out. The presence of cross-reactive Cp. trachomatis antibodies 
can be examined by the Cp. trachomatis specific MOMP-peptide-based ELISA of Medac. 
However, there is no Cp. pneumoniae or Cp. psittaci-specific serological assay for humans. 
We used the Medac ELISA to check for cross-reactive antibodies (data not shown) and 
only 1 of 28 rMOMP ELISA positive sera was also positive for Cp. trachomatis IgA, none 
was positive for Cp. trachomatis IgG. However, we still cannot rule out cross-reactive 
antibodies to Cp. pneumoniae MOMP, but MOMP of Cp. pneumoniae is not 
immunodominant and all 28 rMOMP ELISA positives were negative by the Cp. 
pneumoniae nested PCR.  
The MIF test, for long regarded as the serological ‘gold standard’, is poorly sensitive 
as only 3 out of 69 (4.3%) sera reacted positive, and moreover, positive control sera 
remained negative. The MIF test cannot be regarded as chlamydial specific, due to cross 
reaction of chlamydial LPS or heat shock protein with antibodies to other bacteria 
(Haralambieva et al., 2001) and like the rMOMP ELISA is not chlamydial species-specific 
(Bourke et al., 1989; Ozanne and Lefebvre, 1992). The latter was nicely demonstrated by 
Ceglie et al (2007), who found 24 of 34 (70.6%) pigeon sera positive for both Cp. psittaci 
and Cp. pneumoniae, with titers up to 1:256, although birds are not infected by Cp. 
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pneumoniae and molecular characterization of isolates clearly demonstrated the presence 
of Cp. psittaci. Additionally, the MIF test is subjective and tiring, only semi-quantitative 
and has poor reproducibility (Peeling et al., 2000).  
The Serion ELISA is believed to be more sensitive than MIF. However, this was not 
true in our study as none of the 69 Cp. psittaci PCR positives reacted positive. Maybe, 
because the Serion ELISA uses genotype D antigen, while genotype A is being used in 
both MIF and rMOMP ELISA. The majority of PCR positives had contact with 
Psittaciformes, mostly being infected with genotype A. The Serion ELISA uses whole 
chlamydial organisms and is therefore not chlamydial species-specific.  
In conclusion, Cp. psittaci infected racing pigeons and Psittaciformes present a main 
risk for psittacosis as compared to other domestic and companion birds. Zoonotic transfer 
can result in severe disease. However, as demonstrated in the present study, severe cases 
are probably only the tip of the iceberg. What lies underneath are asymptomatic infections 
or less severe, clinically unnoticed infections, which are misdiagnosed due to symptoms 
similar to those caused by other respiratory pathogens. The impact of these ‘unnoticed’ 
infections on human health is difficult to determine. 
We demonstrated the usefulness of a highly sensitive and specific nested PCR/EIA for 
detecting Cp. psittaci DNA in human clinical specimens. In general, clinicians should be 
strongly recommended to use nucleic acid amplification tests for diagnosing psittacosis 
rather than serology as molecular tests are extremely sensitive and specific and present 
direct evidence of a Cp. psittaci infection.  
Additionally, we also demonstrated the usefulness of serology for epidemiological 
research, as 18 of 96 PCR negatives were serologically positive. However, a Cp. psittaci- 
specific recombinant or peptide-based ELISA must be designed as present cross-reactive 
tests cannot be used for a human population, as Cp. pneumoniae is highly prevalent in 
humans.  
Finally, psittacosis occurs more often than reported in Belgium. Psittacosis is most 
likely also underestimated in other European countries, stressing the need for more 
accurate diagnostic monitoring and reporting, a veterinary vaccine, and information 
campaigns with recommendations for psittacosis risk reduction strategies. 
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Summary 
Thirty-six birds from a parrot relief and breeding centre as well as the manager were 
examined for the presence of Chlamydophila psittaci. In the relief unit, 5 on 20 Grey 
amazon parrots showed depression, ruffled feathers, loss of weight and mild dyspnoea. 
The birds received no antibiotic treatment. Birds of the breeding unit, 14 Blue and gold 
macaws and 2 Green-winged macaws were healthy. They received doxycyclin at the start 
of each breeding season. The manager complained of shortness of breath but took no 
medication. Using a nested polymerase chain reaction enzyme immunoassay (nested 
PCR/EIA), Cp. psittaci was detected in the faeces of all five sick birds as well as in a nasal 
and pharyngeal swab of the manager. The veterinarian and her assistant became infected 
while sampling the parrots as pharyngeal and nasal swabs of both were positive in the 
nested PCR/EIA after visiting the parrot relief and breeding centre. Bacteria were isolated 
from 3 on 5 nested PCR/EIA positive birds, from the manager and the veterinarian, but not 
from the veterinary assistant. Using an ompA genotype-specific real-time PCR, Cp. 
psittaci genotype E/B was identified as the transmitted strain. All breeder birds tested Cp. 
psittaci negative. This is the first report on C. psittaci genotype E/B transmission from 
parrots to humans. In contradiction to genotype A strains which are thought to be highly 
virulent to both birds and men, the currently described genotype E/B strain apparently 
caused no severe clinical symptoms in both parrots and humans. 
 
 
1. Introduction 
Chlamydophila psittaci, an obligate intracellular bacterium has 7 known avian 
serovars, all considered transmissible to humans (Andersen, 1991b; Vanrompay et al., 
1993a; Andersen, 1997). The serovars are identified by monoclonal antibodies recognizing 
serovar-specific epitopes on the major outer membrane protein (MOMP). These serovars 
correspond to 7 genotypes that are readily distinguished using outer membrane protein A 
(ompA) gene sequencing, restriction fragment length polymorphism (RFLP) analysis of 
the ompA gene (Vanrompay et al., 1997) or a recently developed genotype-specific real-
time PCR (Geens et al., 2005b).  
Genotype A is endemic among cockatoos, parrots, parakeets and lories 
(Psittaciformes) and is well known as a zoonotic agent. Genotype B is endemic among 
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pigeons. Genotypes C and D are mostly detected in non-Psittaciformes. They are highly 
pathogenic to domestic poultry and are admitted occupational hazards for slaughterhouse 
workers and generally for all people in contact with poultry, especially turkeys and ducks. 
Genotype E isolates were first isolated during an outbreak of pneumonitis in humans in the 
late 1920s and early 1930s. Subsequently, genotype E isolates have been obtained from a 
variety of avian hosts worldwide, including turkeys, ducks, pigeons, ostriches and rheas. 
Genotype F was first obtained from an American parakeet (Andersen, 1997) and eight 
years later also from a Belgian fattening turkey (Van Loock et al., 2005a).  
Recently, a new genotype E/B was described (Geens et al., 2005a), being isolated 
from Italian urban pigeons, German commercial fattening Pekin ducks and Belgian 
fattening turkeys. Genotype E/B reacts with both the serovar E and B-specific monoclonal 
antibodies and generates the ompA RFLP pattern characteristic for genotype E. However, 
it differs from genotype E and B by a unique combination of a guanosine at positions 
1,006 and 1,021 and a cytidine at position 1,022 resulting in an A instead of S at position 
341 in the variable segment 4 of the MOMP. Genotype E/B can only be distinguished 
from genotypes E and B by ompA sequencing or by the recently developed genotype-
specific real-time PCR (Geens et al., 2005b). Presently, the genotype-specific real-time 
PCR was used to examine the transmission of a Cp. psittaci genotype E/B strain from 
African grey parrots to humans.  
 
2. Material and methods 
2.1. Background 
 In November 2004, a parrot relief and breeding centre nearby Antwerp was visited in 
order to investigate the presence of Cp. psittaci infections in birds and their owners. The 
parrot relief unit housed twenty Grey Amazon parrots (Psittacus erithacus), received from 
people moving houses or elderly people unable to nurse their birds any longer. The parrots 
were kept in separate cages. Additionally, 7 couples of Blue and gold macaws (Ara 
ararauna) and one couple of Green-winged macaws (Ara chloroptera) were kept for 
breeding. Relief and breeder birds were housed in clean, heated, separate, but adjacent 
rooms. Every day, the 56 year-old manager was handling the parrots of the relief unit, 
cleaning their cages, hand feeding and even nuzzling the birds. The man felt healthy 
although he complained of continued shortness of breath. He took no medication and was 
a non-smoker. The breeder birds were treated with doxycyclin (Soludox, Eurovet) in the 
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drinking water during 14 days before each breeding period and they were healthy. 
However, 5 out of 20 (25%) birds of the relief unit showed depression, ruffled feathers, 
loss of weight and mild dyspnoea. One of them was blind. They received no antibiotic 
treatment.  
 
2.2. Samples 
 All birds as well as the manager were sampled using dacron-tipped aluminium 
shafted swabs (Fiers) filled with 2ml Cp. psittaci transport medium (Vanrompay et al., 
1992) or DNA stabilization buffer (Roche) for chlamydial isolation or detection of the 
ompA gene, respectively. As bird catching was to be avoided due to stress, fresh droppings 
were collected from each cage floor sampling five different spots per cage. The manager 
was sampled by taking both pharyngeal and nasal swabs. The veterinarian and her 
assistant, were identically examined ‘by chance’ 7 weeks later, at the start of a psittacosis 
occupational risk study in which they voluntarily participated. Humans were sampled with 
informed consent. All swabs were kept on ice during transport and stored at –80°C until 
use.  
 
2.3. Cp. psittaci identification and molecular characterization 
 The presence of the Cp. psittaci ompA gene was examined using a nested PCR/EIA 
as described by Van Loock et al., (2005b). The nested PCR/EIA allows an ELISA-based 
detection of the amplified gene, which becomes biotin and fluorescein labelled during the 
amplification reaction. The presence of viable Cp. psittaci was examined by isolation in 
Buffalo Green Monkey (BGM) cells identifying the organisms by a direct 
immunofluorescence staining (IMAGEN™, Dakocytomation, Denmark), as previously 
described (Vanrompay et al., 1992). Cp. psittaci was characterized directly from the 
clinical specimens using a genotype-specific real-time PCR as described by Geens et al., 
(2005b). The latter, is a TaqMan probe-based real-time PCR able to distinguish the ompA 
gene of all 6 currently described avian Cp. psittaci genotypes A to F, plus the recently 
described genotype E/B.  
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3. Results and discussion 
Notwithstanding possible air contact with infected birds of the relief unit, all breeders 
were Cp. psittaci negative in both nested PCR/EIA and culture. Regular doxycyclin 
treatment might have prevented spreading of the infection to the adjacent breeder unit. 
With the risk of developing tetracycline resistant strains, as described for the Cp. psittaci 
related species Cp. suis (Dugan et al., 2004; Dugan et al., 2007), this is surely not to be 
recommended as a preventive strategy. However, there is no avian Cp. psittaci vaccine 
and therefore owners of Psittaciformes frequently use tetracyclines in any case of 
respiratory disease or even prophylactically. One of the problems is that you can buy these 
drugs through the internet even without a prescription as a prescription is not needed in 
every country. Most people are unaware of the dangerous situation they might create by 
using these drugs frequently. They are ignorant on tetracylines being the drugs of choice 
when treating human psittacosis and the fact that mortality rate prior to the advent of 
antimicrobial treatment was approximately 15-20%. Vaccination as well as information 
campaigns on antibiotic use in birds with respect to zoonotic agents might prevent the 
development of tetracycline resistant Cp. psittaci strains.  
For the relief unit, nested PCR/EIA revealed 5 out of 20 (25%) Cp. psittaci positive 
parrots and Cp. psittaci could be isolated from the faeces of three of them. The chlamydial 
ompA gene was detected in the nasal and pharyngeal swab of the manager. Nasal and 
pharyngeal swabs of the veterinarian and her assistant, examined 7 weeks after visiting the 
parrot and relief centre, also contained Cp. psittaci DNA. As in birds, the infection of the 
manager and the veterinarian were confirmed by isolating viable bacteria. Cp. psittaci 
isolates from the parrots, the manager and the veterinarian were all characterized as ompA 
genotype E/B. However, at that time, we could not isolate live chlamydial organisms from 
the veterinary assistant nor could we type the strain directly from the clinical specimens, 
as the genotype-specific real-time PCR remained negative. Of the three persons involved, 
the veterinary assistant was the one with least close contact to the parrots as she was only 
handing over the swabs to the veterinarian. In contradiction to the other two persons, she 
never went into the cages. This could explain why she was negative by culture and only 
positive by our nested PCR/EIA, which is able to detect 1 organism, while our genotype-
specific real-time PCR has a detection limit of 10 chlamydial organisms.  
During a subsequent medical consult, the manager was advised not to take antibiotics 
because he apparently showed no severe clinical symptoms. However, the manager 
 
Transmission of Cp.psittaci genotype E/B….  75
decided to close the parrot relief unit, not only due to our findings but also for economical 
reasons as heating costs became too high. All birds of the relief unit were treated with 
doxycycline and subsequently given to intimate Psittaciformes bird breeders. So far, there 
were no reports on sickness or abnormal mortality in these birds (personal communication, 
2006). However, as already mentioned by Heddema et al. (2006c), the maintenance of 
accurate records of bird-related transactions for at least 1 year should be recommended 
and every new bird brought into a colony should be tested for Cp. psittaci. Track records 
should include the species of bird, bird identification, source of bird and any identified 
illness. Upon closure of the relief unit, the manager tested negative in the nested PCR/EIA 
and by culture.  
As in the birds and the manager, the infection caused no severe clinical symptoms in 
the veterinarian and here assistant. In fact, the latter two persons were unaware of being 
infected. Therefore, they received no antibiotic treatment. Both persons tested negative in 
the nested PCR/EIA and in culture 10 weeks after visiting the parrot relief and breeding 
centre.   
Worldwide, Cp. psittaci has been proven to infect at least 465 different avian species 
from 30 avian orders that include 153 Psittaciformes species (Kaleta and Taday, 2003). 
From 1988-2003, 935 human cases of psittacosis were reported to the US centers for 
disease control and prevention (CDC) (Smith et al., 2005). At present, approximately 100 
cases of human psittacosis are reported annually in the United States, and one person may 
die from it each year. Many more cases may occur that are not correctly diagnosed or 
reported. However, the incidence of psittacosis in men seems to be increasing in 
developed countries, which is correlated to the import of exotic birds.  
Birds of the order Psittaciformes seem to be highly susceptible as most veterinary 
case reports are on Cp. psittaci infections in Cacatuidae (Cockatoos) and Psittacidae 
(parrots, parakeets, lories), dealing with severe clinical signs such as eye discharge or 
swelling, laboured breathing, diarrhoea, poor appetite, lethargy, "fluffed up" appearance, 
or weakness and even mortality (Bracewell and Bevan, 1986; Kaleta and Taday, 2003; 
Chahota et al., 2006). Many of the birds become chronically infected but show no clinical 
signs until stressed. These birds often shed Cp. psittaci intermittently and serve as a source 
of infection for humans and other birds. Especially, Amazon parrots (88%), macaws 
(87%), budgerigars (81%), Cockatoos (80%), Conures and Senegal parrots (78%), African 
greys and Eclectus (75%), Grey cheek parrots (70%), lovebirds (68%) and Cockatiels 
(65%) are highly infected as serologically demonstrated (Fudge, 1997). 
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 However, we do not really know if Psittaciformes are more susceptible to Cp. psittaci 
than other bird species. It might be that the disease is simply noticed and therefore 
diagnosed more often due to the severe clinical signs in these birds. For instance, when 
comparing epidemiological data of chlamydiosis in Psittaciformes and pigeons, the 
prevalence seems to be comparable ranging from 16 to 81% and 23 to 85%, repectively 
(Fudge, 1997; Travnicek et al., 2002). However, chlamydiosis in pigeons is less severe. 
Signs of uncomplicated chlamydiosis in pigeons are variable and often the disease is 
unnoticed. Those that develop acute disease are anorexic, unthrifty, and diarrhetic. Some 
develop conjunctivitis, swollen eyelids, and rhinitis. Respiratory difficulty is accompanied 
by rattling sounds. As disease progresses, birds become weak and emaciated. Recovered 
birds become carriers without signs of disease. Some birds progress through an infection 
showing no signs or, at the most, transient diarrhea before becoming carriers. Mortality is 
more due to secondary infections such as Salmonellosis and Trichomoniasis.  
In fact, the overall clinical picture in a given species is the result of strain virulence 
and host immunogenetics. We do know less about bird immunogenetics but we do know 
that Cp. psittaci genotypes A, B, and F have been isolated from Psittaciformes. However, 
Psittaciformes are most frequently infected with genotype A strains which are highly 
virulent, are intensively excreted and are often causing mortality (Andersen, 1991b; 
Vanrompay et al., 1997). Pigeons on the other hand, mostly become infected by genotype 
B and sometimes genotype E strains. However, the term genotype only refers to the 
sequence of the outer membrane (ompA) gene encoding for the Cp. psittaci 
immunodominant major outer membrane protein (MOMP). We do know that the MOMP 
is a porine and also a possible bacterial adhesine, but the direct contributions of this 
protein to the virulence of the bacterium are not clear. Actually, we do not know why 
Psittaciformes are most frequently infected with genoytype A strains which apparently 
cause severe disease and mortaltity in these birds and why pigeons are most frequently 
infected by other genotypes which apparently are less virulent. The question could 
probably be solved if we would know more about host immunogenetics and bacterial 
virulence factors such as the Type Three Secretion System (TTSS), which was recently 
discovered in Cp. psittaci (Beeckman et al., 2006).  
However, given the fact that Psittaciformes are almost always infected with genotype 
A strains and the proven zoonotic transmission of genotype A strains (Heddema et al., 
2006c), we were surprised to find genotype E/B in both parrots and men. So far, genotype 
E/B has only been discovered in pigeons, ducks and turkeys. All birds appeared clinically 
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healthy except for the turkeys, which showed mild respiratory symptoms. Apparently, an 
asymptomatic psittacosis infection occurred in all three persons involved. Maybe, the E/B 
strain was indeed less virulent, although zoonotic transmission occurred. On the other 
hand, frequent exposure to Cp. psittaci could also explain the asymptomatic course of 
infection in these persons. However, we don’t know anything about natural protection 
following a Cp. psittaci infection in humans. We do know that fattening turkeys can 
become infected with two different genotypes during one production period of 15 weeks.  
We do know that Cp. psittaci can go into a carrier status, characterized by dormant 
aberrant bodies, i.e., enlarged pleomorphic RBs, and reduced inclusion size inside the host 
cell with the absence of elementary bodies capable of infecting new cells (Goellner et al., 
2006). In turkeys, a Cp. psittaci infection aggravated the outcome of a viral avian 
pneumovirus infection (Van Loock et al., 2006a) and an Escherichia coli infection in Cp. 
psittaci latently infected turkeys, aggravated the E. coli infection and reactivated 
chlamydial replication and excretion (Van Loock et al., 2006b). However, we can only 
speculate on similar pathogenic interactions between Cp. psittaci and human respiratory 
pathogens.  
The number of psittacosis cases is surely underestimated in humans. For accurate 
diagnosis in both birds and humans we recommend the nested PCR/EIA, which detects 
Cp. psittaci specifically at high sensitivity. The genotype-specific real-time PCR is very 
convenient for tracking down the avian source and allows the identification of new ompA 
genotypes. Above all, a Cp. psittaci vaccine for Psittaciformes is urgently required, as it 
will definitely diminish the number of symptomatic and asymptomatic zoonotic infections 
in humans.  
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Abstract 
We studied Chlamydophila psittaci zoonotic transmissions in 39 breeding facilities 
for Psittaciformes (cockatoos, parrots, parakeets, lories). Antibiotics were frequently used. 
Nevertheless, genotype A or E/B transmissions occurred in 14.9% of the humans involved. 
Information campaigns on sensible antibiotic use in Psittaciformes and a Cp. psittaci 
vaccine are urgently required.  
 
1. Introduction 
Chlamydophila psittaci, an obligate intracellular gram-negative bacterium has 7 
known genotypes A to F and E/B (Geens et al., 2005a), all considered transmissible to 
humans causing psittacosis or parrot fever (Vanrompay et al., 1997; Andersen and 
Vanrompay, 2003). Genotypes are distinguished using outer membrane protein A (ompA) 
gene sequencing or by a recently developed ompA genotype-specific real-time PCR 
(Geens et al., 2005b). C. psittaci has been proven to infect 465 different avian species 
from 30 avian orders with at least 153 species from the order Psittaciformes (Kaleta and 
Taday, 2003). From 1988-2003, 935 human cases of psittacosis were reported to the US 
centers for disease control and prevention (Smith et al., 2005), most of them related to 
contact with Psittaciformes. Presently, approximately 100 psittacosis cases are reported 
annually in the United States, and one person may die from it each year. The incidence of 
psittacosis in men seems to be increasing in developed countries, which is related to the 
import of exotic birds. Many more cases occur that are not correctly diagnosed or 
reported. 
 
2. The study 
We investigated the occurrence of C. psittaci zoonotic transmissions in Belgian 
breeding facilities for Psittaciformes (cockatoos, parrots, parakeets, lories). Participants 
were recruited through the Belgian Society for Parakeet and parrot breeders. Fifty 
breeding facilities received a sampling package, delivered by regular mail. The package 
contained a questionnaire designed to asses information on: a) the pet bird owners 
professional and non-professional activities, smoking habits, general health status, use of 
medication, allergy, clinical signs specifically related to psittacosis and on b) the birds 
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origin, housing, feeding, breeding, health status, medication and presence of other bird 
species. We also included dacron-tipped swabs and instructions for faecal (cage floor) or 
pharyngeal sampling in birds or humans, respectively (Fig 3.1). Additionally, we provided 
transport medium (Vanrompay et al., 1992) for isolation and DNA stabilization buffer 
(Roche) for PCR, to be added to the swabs after sampling. Packages returned by express 
mail one day after sampling were stored at –80°C until use. Sampling packages are 
convenient and above all safe for the investigator. Forty-one on 50 (82%) breeders 
returned the packages. Two packages were incomplete and therefore excluded, resulting in 
308 birds and 46 humans from 39 Psittaciformes breeding facilities to be tested. We also 
got the opportunity to take pharyngeal samples from a veterinary student, involved in 
another study in those breeding facilities. The student was examined before starting his 
study and thereafter monthly during 4 months. All humans were examined with informed 
consent.  
The presence of the ompA gene in birds and men was examined using a C. psittaci-
specific nested PCR/EIA (Van Loock et al., 2005b). The presence of viable C. psittaci was 
examined by isolation in Buffalo Green Monkey cells identifying the organisms by a 
direct immunofluorescence staining (IMAGEN™, Dakocytomation), (Fig. 3.2), 
(Vanrompay et al., 1992). In case of zoonotic transmissions, the infection source was 
traced using a genotype-specific real-time PCR (Geens et al., 2005b) on specimens of both 
the birds and their owner. 
 
 
 
 
 
Fig. 3.1. Package sent to the breeders to sample their birds and themselves. 
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Fig. 3.2. Direct immunofluorescence (FITC) staining (IMAGEN®) of BGM cells 6 days 
A B
after inoculation (bar 20  
characteristic chlamydial inclusions inside the cytoplasm of the host cell. 
 
 
 µm). Negative control (A), a positive parrot sample (B) with 
ifty-nine out of 308 (19.2%) Psittaciformes were positive in the nested PCR/EIA and 
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A in 6 out of 46 (13%) pet bird owners, all 
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eria were isolated from 25 (42.3%) PCR-positive birds. Thus, on a total of 39 tested 
breeding facilities, 8 (20.5%) were positive in both nested PCR/EIA and culture, and 
respiratory disease was present in all. Five additional breeding facilities were only nested 
PCR/EIA positive. Interestingly, one of them was currently treating the birds with 
doxycycline and the remaining 4 had recently used doxycycline, oxytetracycline or 
enrofloxacine. Treatment was successful as live C. psittaci were no longer present in these 
5 breeding facilities and all birds appeared healthy. Thus, in total we had 13 on 39 (33.3%) 
positive breeding facilities with a significant correlation between faecal excretion of live 
chlamydial organisms and respiratory disease (OR 14.5, 95% CI 1.6-130.5, p < 0.05). The 
remaining 26 breeding facilities with healthy birds were negative in both PCR and culture. 
Table 3.1 shows the bird species that have been tested in this study. We are aware that we 
might have missed early infections as faecal excretion occurs following primary bacterial 
replication in the respiratory tract and septicaemia. Moreover, faecal shedding occurs 
intermittently and healthy carrier birds might not excrete for more than one year.  
Pharyngeal swabs would have been a better choice but psittacine owners are reluctant to 
catch their birds, as stress induces respiratory disease. Reactivation of a C. psittaci carrier 
status might be involved in this phenomenon.  
Nested PCR/EIA revealed Cp. psittaci DN
 different breeding facilities and all with birds diagnosed positive in both PCR and 
culture. Most of the infected persons (age 22, 24, 31, 38, 49 and 56) were relatively young 
as the mean age of the pet bird owners was 46. Live organisms were present in 4 out of 6 
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PCR positive humans and all 4 (non-smokers, non-allergic) showed mild respiratory 
illness (shortness of breath or rhinitis and coughing). However, although the study was 
performed in the summer period, 8 (20%) of the remaining 40 negative breeders 
complained of rhinitis and/or coughing during the last two weeks, sometimes (7.5%) 
together with a sore throat. Thus, it was impossible to draw statistical conclusions on the 
relationship between the presence of viable chlamydial organisms in humans and 
respiratory disease. Remarkably, the veterinary student (age 23) tested negative before 
starting his study but his first pharyngeal specimen after start visiting the breeders was 
positive in both PCR and culture. He remained infected until one month after ending his 
study but showed only mild respiratory illness. Thus, protective clothing, including air 
filter face masks are recommended for preventing occupational disease, as the infection 
risk may not be underestimated. The transmitted C. psittaci strains in 5 pet bird owners 
and in the veterinarian were all genotype A and those persons showed rhinitis and 
coughing while genotype E/B was present in one pet bird owner complaining of continued 
shortness of breath. Thus, in contradiction to the recently published reports on human 
psittacosis related to pet birds (Telfer et al., 2005; Kaibu et al., 2006; Heddema et al., 
2006c), severe clinical signs with pneumonia did not occur in these humans and therefore 
none of them was treated. Interestingly, 10 on 39 (25.6%) humans had pneumonia since 
keeping Psittaciformes, while normally 8/1000 pneumonia cases occur each year in 
Belgium. Most likely, pet bird owners and veterinarians are regularly infected and maybe 
they become protected against severe disease. But, we don’t know if they become carriers 
and what might be the consequences of this.  
It was alarming that 18 on 39 (46.2%) breeders treated their birds with tetracycline, 
doxycycline or enrofloxacine over the past year. Four on 39 (10.2%) were even using 
tetracyclines prophylactically. Nevertheless, of those 18 breeding facilities, 8 (44%) still 
tested positive in the nested PCR/EIA while culture was positive in 3 (16.6%). With the 
risk of developing antibiotic resistant strains, as being described for C. suis (Dugan et al., 
2004; Dugan et al., 2007), the regular use of antibiotics must be avoided.  However, there 
is no vaccine and therefore pet bird owners frequently use tetracyclines in case of 
respiratory disease and sometimes even prophylactically. These drugs are sold on the 
internet even without a prescription as a prescription is not needed in every country. 
People are ignorant on tetracylines being the drugs of choice when treating human 
psittacosis and the fact that mortality rate prior to the advent of antimicrobial treatment 
was 15-20%.  
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n, vaccination and information campaigns on sensible antibiotic use in 
Psitta
In conclusio
ciformes are urgently needed to prevent psittacosis in men as well as the 
development of antibiotic resistant strains.  
 
 
 
 
 
 
 
 
 
    
Table 3.1. Bird species tested from 39 breeding facilities. 
No Family  Genus and species  Common names 
Number 
tested  
Number 
Positives 
Percentage 
positives/species 
       
1  Psittacidae Agapornis personata Masked Lovebird 5 0 0 
2  Agapornis roseicollis Rosy-faced Lovebird 3 0 0 
3  Agapornis taranta Black-winged Lovebird 4 1 25 
4  Amazona aestiva aestiva Blue-fronted Amazon 2 1 50 
5  
Amazona aestiva 
xanthopteryx 
Blue-fronted Yellow-
shouldered Amazon 2 1 50 
6  
Amazona amazonica 
amazonica Orange-winged Amazon 1 0 0 
7  Amazona auropalliata Yellow-naped Amazon 3 0 0 
8  
Amazona autumnalis 
autumnalis Red-lored Amazon 6 3 50 
9  Amazona festiva bodini Bodinus' Amazon 1 0 0 
10  Amazona oratrix Yellow-headed Amazon 2 0 0 
11  Amazona viridigenalis Green-cheeked Amazon 1 0 0 
12  
Aprosmictus erythropterus 
erythropterus Red-winged Parrot 2 0 0 
13  Ara ararauna Blue and Yellow Macaw 1 0 0 
14  Ara auricollis Yellow-collared Macaw 6 1 16 
15  Ara chloropterus Green-winged Macaw 1 0 0 
16  Aratinga jandaya Jandaya Conure 2 1 50 
17  Aratinga solstitialis Sun Conure 5 1 20 
18  
Bolborhynchus aurifrons 
aurifrons Mountain Parakeet 6 1 16 
19  Bolborhynchus aymara Aymara Parakeet 5 2 40 
20  
Bolborhynchus lineola 
lineola Barred Parakeet 6 2 33 
 
 Table 3.1. Bird species tested from 39 breeding facilities (continued). 
No Family  Genus and species  Common names 
Number 
tested  
Number 
Positives 
Percentage 
positives/species 
21  Eclectus roratus roratus Grand Eclectus Parrot 11 1 9 
22  Forpus coelestis Pacific Parrotlet 13 3 23 
23    
Loriculus philippensis 
regulus 
Central Island Hanging 
Parrot 6 0 0
24     Melopsittacus undulatus Budgerigar 5 0 0
25  Nannopsittaca dachilleae Amazonian Parrotlet 3 0 0 
26  Neophema pulchella Turquoise parrot 6 2 33.3 
27  Neophema splendida Scarlet-chested Parrot 6 2 33.3 
28  Neopsephotus bourkii Bourke's Parrot 5 3 60 
29     
Northiella haematogaster 
haemetogaster Blue-bonnet 1 0 0
30  
Pionites melanocephala 
melanocephala Black-headed Caique 6 1 16.7 
31  
Pionopsitta barrabandi 
barrabandi Barraband's Parrot 2 0 0 
32  Pionus menstruus Blue-headed Parrot 1 0 0 
33  Pionus menstruus menstruus Blue-headed Parrot 2 0 0 
34  Pionus senilis White-capped Parrot 1 0 0 
35  Platycercus Crimson rosella 10 0 0 
36  
Platycercus adelaidae 
adelaidae Adelaide Parakeet(Rosella) 1 0 0 
37  
Platycercus adscitus 
palliceps Pale-headed Rosella 1 0 0 
38  
Platycercus barnardi 
barnardi Barnard's Parakeet 2 0 0 
39  Platycercus caledonicus Green Rosella 2 0 0 
40  Platycercus elegans elegans Crimson Rosella 4 0 0 
 
    
Table 3.1. Bird species tested from 39 breeding facilities (continued). 
No Family  Genus and species  Common names 
Number 
tested  
Number 
Positives 
Percentage 
positives/species 
41  Platycercus icterotis icterotis Western Rosella 1 0 0 
42  
Platycercus zonarius 
semitorquatus Twenty-eight Parrot 1 0 0 
43  
Platycercus zonarius 
semitorquatus Twenty-eight Parrot 1 0 0 
44  
Platycercus zonarius 
zonarius Port Lincoln Parrot 2 0 0 
45  
Poicephalus senegalus 
senegalus Senegal Parrot 6 0 0 
46  Poicephalus gulielmi gulielmi Jardine's Parrot 2 0 0 
47  Poicephalus meyeri meyeri Meyer's Parrot 1 0 0 
48  Polytelis alexandrae Princess Parrot 1 0 0 
49  Psephotus chrysopterygius Golden-shouldered Parrot 2 0 0 
50  
Psephotus haematonotus 
haematonotus Red-rumped Parrot 6 3 50 
51  Psittacula cyanocephala Plum-headed Parakeet 1 0 0 
52  Psittacula derbyana Derbyan Parakeet 2 0 0 
53  Psittacula eupatria eupatria Alexandrine Parakeet 3 0 0 
54  Psittacula krameri Rose-ringed Parakeet 20 3 15 
55  Psittacus erithacus African Grey Parrot 22 2 9 
56  Psitteuteles goldiei Goldie's Lorikeet 2 1 50 
57  Psitteuteles iris iris Iris Lorikeet 2 1 50 
58  Psitteuteles versicolor Varied Lorikeet 2 0 0 
59  Pyrrhura rhodocephala Rose-crowned Conure 9 2 22.2 
 Cacatuidae      
60  Cacatua alba White Cockatoo 1 0 0 
       
 
Table 3.1. Bird species tested from 39 breeding facilities (continued). 
No Family  Genus and species  Common names 
Number 
tested  
Number 
Positives 
Percentage 
positives/species 
61  
Cacatua leadbeateri 
leadbeateri Major Mitchell's Cockatoo 2 0 0 
62  Cacatua sulphurea sulphurea Sulpher-crested Cockatoo 1 0 0 
63  
Eolophus roseicapillus 
roseicapillus Roseate Cockatoo 12 2 16.6 
64     Nymphicus hollandicus Cockatiel 21 8 38
 Loriidae      
 
65   
Charmosyna placentis 
subplacens 
Sclater's Red-flanked 
Lorikeet 2 1 50
66  Lathamus discolor Swift Parrot 4 2 50 
67  
Trichoglossus haematodus 
moluccanus Blue Mountain Lorikeet 6 3 50 
68  Trichoglossus rubritorquis Red-collared Lorikeet 2 1 50 
 Platyceridae      
69  
Eunymphicus cornutus 
cornutus Hooded parrot 1 0 0 
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Abstract 
Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein 
(MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its 
ability to induce protective immunity against Cp. psittaci challenge in budgerigars. Eight 
pairs of male and female budgerigars were housed in eight separate bird cages placed in 
two negative pressure isolators, four cages per group. All budgerigars were immunized 
twice intramuscularly with 100 µg plasmid DNA. Both groups received a primary DNA 
inoculation at day 0 followed by a booster inoculation 3 weeks later. Group 1 received 
pcDNA::MOMP A while group 2 received the placebo vaccine pcDNA1. Budgerigars 
were challenged by aerosol two weeks following the booster vaccination. The challenge 
consisted of 108 TCID50 of the homologous Cp. psittaci genotype A strain. Cloacal and 
pharyngeal swabs of all budgerigars, taken prior to the experimental infection were 
negative in both PCR and culture. However, all budgerigars showed low pre-existing 
serum antibody titers, indicative of a previous infection. Nevertheless, DNA immunization 
could significantly reduce clinical symptoms, macroscopic lesions, pharyngeal and cloacal 
excretion as well as chlamydial replication, even in the presence of pre-existing serum 
antibodies, as compared to the placebo-vaccinated controls. 
 
1. Introduction 
Chlamydophila psittaci, a Gram-negative obligate intracellular pathogen, causes 
chlamydiosis in Psittaciformes (cockatoos, parrots, parakeets, lories) and psittacosis or 
parrot fever in humans. The infection is highly prevalent in Psittaciformes as studies in 
wild and captive Psittaciformes in North and South America, Australia, Europe and Japan 
showed 16 to 81% of examined birds to be positive for Cp. psittaci (Yamashita and Hirai, 
1981; Schwartz and Fraser, 1982; Hirai et al., 1984; Bracewell and Bevan, 1986; 
Dorrestein and Wiegman, 1989; Raso et al., 2002; Dovc et al., 2005). The outer membrane 
protein A (ompA) genotype A is found most often in these birds. The infection is also 
highly prevalent among captive Belgian Psittaciformes as we recently demonstrated by 
examining 39 Belgian Psittaciformes breeding facilities. Fifty-nine (19.2%) of 308 
Psittaciformes were positive for Cp. psittaci by nested PCR/EIA, and bacteria were 
isolated from 25 (42.3%) birds with PCR-positive results. Eight on 39 (20.5%) breeding 
facilities were positive in both nested PCR/EIA and culture, and respiratory disease was 
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present at all these facilities (Vanrompay et al., 2007). Interestingly, we not only 
discovered ‘the expected’ genotype A, but for the first time also detected genotype E/B 
strains in Psittaciformes (Harkinezhad et al., 2007). Moreover, we also demonstrated the 
transmission of this genotype E/B from African grey parrots to humans. Thus, as in other 
countries, infected Belgian Psittaciformes present a zoonotic risk, which is clearly 
underestimated as shown in Chapters II and III.  
In birds, the course of infection can be rather mild but on the other hand a mortality 
rate of 50% or even higher is not unusual (Dovc et al., 2007). Faecal and nasal excretions 
of diseased birds are the primary source of human infections (Smith et al., 2005; Heddema 
et al., 2006c; Harkinezhad et al., 2007; Vanrompay et al., 2007). However, apparent 
clinically healthy Psittaciformes also present a threat to human health, as many cockatoos, 
parrots, parakeets and lories never get rid of the bacterium once being infected and most of 
them actually become Cp. psittaci carriers, shedding the bacteria again after being stressed 
(Schachter et al., 1978; Andersen and Vanrompay, 2003). 
Thus, a considerable number of people are at risk of becoming infected with this 
bacterium such as people working in pet shops, garden centres, quarantine stations and 
zoos. But, also visitors of these facilities and people keeping Psittaciformes as pets can 
become infected. Vaccinating Psittaciformes could significantly reduce the zoonotic risk. 
However, there is no commercial vaccine available against avian chlamydiosis. Maybe, 
DNA vaccination might be used for future vaccination of Psittaciformes, as the 
significance of DNA immunization as a means of preventing severe clinical signs, lesions 
and bacterial excretion, has been demonstrated in a specific pathogen free turkey and 
chicken experimental model of Cp. psittaci infection (Vanrompay et al., 1999a; 
Vanrompay et al., 1999b; Vanrompay et al., 2001a; Van Loock et al., 2004; Verminnen et 
al., 2005; Zhou et al., 2007). DNA vaccination induces humoral (B cell) and cellular 
(CD4/CD8) immune responses, only low doses are needed (µg), DNA vaccination is 
effective in the presence of maternal antibodies, reversion to virulence as compared to live 
bacteria is not possible, as compared to killed vaccines no toxic treatment is needed, DNA 
vaccines are easy to design and lyophilization is possible, transport and storage does not 
require a cold chain and DNA vaccines are more stable at room temperature.Therefore, we 
evaluated the ability of plasmid DNA expressing the major outer membrane protein 
(MOMP) of a Cp. psittaci genotype A strain to raise protective immunity in budgerigars 
(Melopsittacus undulatus) experimentally infected with the homologous Cp. psittaci strain. 
The ompA gene encoding the MOMP was used because it is the only chlamydial antigen 
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which has been unambiguously identified as protective antigen. MOMP also caries 
serovar- neutralising epitopes.  Taking into account our previous DNA vaccination results 
in SPF turkeys, we tried to increase the immunogenicity of the vaccine further by 
optimizing the codon-usage. 
 
2. Material and methods 
2.1. Cp. psittaci strain 
Cp. psittaci strain 89/1051, isolated from the liver of blue-fronted Amazon parrot 
(Amazona aestiva aestiva) (Vanrompay et al., 1993a), was used. The strain was previously 
characterised using both serovar-specific monoclonal antibodies, outer membrane protein 
A (ompA) restriction fragment length polymorphism (RFLP) analysis and sequencing of 
the ompA gene and was classified as an avian serovar/genotype A strain (Vanrompay et al., 
1993a; Vanrompay et al., 1997; Geens et al., 2005a). The bacteria were grown in Buffalo 
Green Monkey (BGM) cells as previously described (Vanrompay et al., 1992) and the 
50% tissue culture infective dose (TCID50) was determined on BGM cells by the method 
of Spearman and Kaerber (Mayer et al., 1974).  
 
2.2. DNA vaccine 
Plasmid pcDNA1::MOMP A was constructed by sticky-end ligation of the outer 
membrane protein A (omp A) gene of Cp. psittaci genotype A strain 89/1051 into the 
EcoRI and  BamHI site of pcDNA1 (Vanrompay et al., 1998). The ompA gene was codon 
optimized for expression in avian cells (GenScript Corporation, USA). E. coli MC1061/P3 
cells were transfected by electroporation (Gene Pulser; Bio-Rad, Nazareth, Belgium), and 
clones were selected on medium containing ampicillin plus tetracycline and grown in 
microtiter plates. The presence of inserts was confirmed by EcoRI and BamHI restriction 
enzyme analysis of plasmid mini preparations (QIAGEN) and by PCR clone analysis 
using Sp6 and T7 primers, which flanked the cloning site. PCR clone analysis was 
performed in microtiter plates with the BioMek Thermal Cycler (Perkin-Elmer Cetus 
Zaventem, Belgium). First, 5 µl of each clone was subjected to PCR in a 50 µl final 
reaction mixture containing 50 mM KCl, 20 mM Tris-HCl (pH 8.3), 2 mM MgCl2, 0.1% 
Tween 20, 200 mM each deoxynucleoside triphosphate, 20 mM each primer, and 0.1 U of 
SuperTaq (15 U/ml) polymerase. Samples were subjected to 25 cycles of amplification. 
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Cycling conditions were as follows: denaturation for 30 s at 95°C, primer annealing for 1 
min at 55°C, and primer extension for 2 min at 72°C. The sequence of the codon 
optimized ompA insert was confirmed by the VIB Genetic Service Facility (University of 
Antwerp, Antwerp, Belgium) using vector associated T7 and SP6 priming sites. 
Finally, pcDNA1 control (placebo) and pcDNA1::MOMP A were grown in 
MC1061/P3 and purified using the Endo Free Giga plasmid preparation method 
(QIAGEN). DNA concentration was determined by measuring the optical density at 260 
nm and was confirmed by comparing intensities of ethidium bromide-stained 
EcoRI/BamHI restriction endonuclease fragments with standards of known concentrations. 
DNA was stored at -20°C in 1mM Tris (pH 7.8)-0.1 mM EDTA. 
Expression of the ompA gene was confirmed by indirect imunofluorescence staining 
of DEAE dextran transfected COS-7 cells, transfected either with pcDNA1::MOMP A or 
pcDNA1 control plasmid, as described previously (Vanrompay et al., 1998). For each 
immunization 100 µg pcDNA1::MOMP A diluted in sterile saline (0.9% NaCl) was used. 
 
2.3. Vaccination trial 
The experimental design was evaluated and approved by the Ethical Commission for 
Animal Experiments of Ghent University. Sixteen one-year-old budgerigars were 
purchased from a private breeding facility in East-Flanders. We used conventional 
budgerigars, as SPF Psittaciformes are unavailable. Pharyngeal swabs of all birds of this 
breeding facility were negative in a Cp. psittaci species-specific nested PCR/EIA and in 
culture on BGM cells (Vanrompay et al., 2007). Eight pairs of male and female 
budgerigars were housed in eight separate bird cages placed in two negative pressure 
isolator units (IM 1500, Montair, Sevenum, The Netherlands) (Fig. 4.1), four cages per 
unit. In this way, two groups of four bird pairs each were created. Food (seed mixture for 
budgerigars, food sticks, sepia shells) and water were provided ad libitum.  
All budgerigars were immunized intramuscularly (m. quadriceps) with 100 µg 
plasmid DNA in 100 µl sterile saline (0.9% NaCl). Both groups received a primary DNA 
inoculation at day one and one booster inoculation 3 weeks later. Group 1 received 
pcDNA::MOMP A while group 2 received the placebo vaccine pcDNA1. Budgerigars 
were challenged by aerosol (Cirrus Nebulizer, Intersurgical, UK) two weeks following the 
booster vaccination. The challenge consisted of 108 TCID50 of the Cp. psittaci genotype 
A strain 89/1051. See Table 4.1 for experimental set-up of the vaccination trial. 
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Fig. 4.1. Negative pressure isolators were used for housing the birds. 
 
 
2.4. Samples 
All budgerigars were observed daily for clinical signs. Pharyngeal swabs were 
collected at the beginning of the experiment, at day 1 and at euthanasia, 21 days post 
challenge infection. Faecal excretion was evaluated at the day of challenge and 
subsequently every day until 20 days post challenge by taking swabs from fresh faecal 
droppings on the cage floor. All swabs were stored at -80°C in Cp. psittaci transport 
medium until tested. Blood samples for the quantification of MOMP- specific serum 
antibody titres were collected immediately prior to each DNA inoculation, immediately 
prior to the experimental infection and at the day of euthanasia. Blood samples were stored 
overnight at room temperature, centrifuged (325 x g, 10 minutes, 4°C) and afterwards 
serum was collected and frozen at -20°C until tested. At the time of euthanasia, 21 days 
post challenge, proliferative responses in spleen cells were determined. All budgerigars 
were examined for macroscopic lesions. Macroscopic lesions were scored (Table 4.2) as 
previously described (Vanrompay et al., 1994). Cryostat tissue sections of the lungs, 
conchae, abdominal and thoracic airsacs, pericardium, kidney, liver and gut (caecum) were 
examined for the presence of chlamydial antigen.  
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    Table 4.1. Experimental set-up of the vaccination experiment 
Time  Manipulation Samples 
Day 0 Primary 
vaccination 
Pharyngeal swabs Cloacal swabs 
 
Blood  
 
 
Day 14 Booster 
vaccination 
Pharyngeal swabs Cage floor swabs 
 
Blood  
 
 
Day 35  Challenge - Cage floor swabs 
 
Blood  
 
 
Cage floor swabs were taken every day until euthanasia 
Day 56 Euthanasia  Pharyngeal swabs Cloacal  swabs 
 
Blood  
 
 
 
 
2.5. Cp. psittaci excretion 
Pharyngeal and cloacal swabs were examined for the presence of viable Cp. psittaci 
by culture in BGM cells, as previously described (Vanrompay et al., 1994). The number of 
BGM cells with chlamydial inclusions was counted in five ad random selected 
microscopic fields (Radiance 2000MP, Bio-Rad; 600 x). For each cage or bird pair, the 
excretion was scored from 0 to 5. Score 0 indicated no chlamydophilae present; score 1 
was given when a mean of 1-5 elementary bodies was present in the absence of replicating 
reticulate bodies; score 2, 3, 4 and 5 were given when a mean of 1-5, 6-10,11-20 and more 
than 20 inclusion positive cells was present. Pharyngeal and cloacal shedding is presented 
as a mean score per bird pair ± standard deviation (S.D.).  
 
2.6. Cp. psittaci detection in the tissue organs 
Cryostat tissue sections of different organs were examined by the IMAGENTM direct 
immunofluorescence staining (Novo Nordisk Diagnostics, Cambridge, UK), as previously 
described (Vanrompay et al., 1994). The presence of chlamydophila antigen in tissues of 
the placebo-vaccinated control group and of the pcDNA1::MOMP A vaccinated group 
was scored as mentioned above for swab cultures.  
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Table 4.2. Score system for macroscopic lesions 
Tissue Score 
 + ++ +++ 
Conchae congestion necrosis necrosis and granulomata 
Lungs congestion bilateral grey foci unilateral grey foci bilateral 
Airsacs opacity focal fibrinous airsacculitis diffuse fibrinous airsacculitis 
Pericard serous pericarditis fibrinous pericarditis fibrinous adhesive pericarditis 
Liver congestion pale pale and soft 
Spleen slightly enlarged moderately enlarged severely enlarged 
Kidney  slightly enlarged moderately enlarged severely enlarged 
Gut slightly congested severely congested enteritis 
 
 
 
2.7. Antibody responses  
Enzyme-linked immunosorbent assays (ELISAs) were performed on sera being pre-
treated with kaolin to remove background activity (Novak et al., 1993). MOMP-specific 
antibody titres were determined using standard protocols with rMOMP as antigen directly 
coated on the plates. Recombinant MOMP was produced in COS-7 cells, transiently 
transfected with pcDNA1::MOMP A, as described previously (Vanrompay et al., 1998). 
 For the determination of antibody titres in serum, 1/1000 and 1/2000 dilutions of 
cross-reactive biotinylated anti-chicken/turkey IgG (H+L) antibody (Invitrogen) and 
peroxidase-conjugated streptavidin (Invitrogen) were used, respectively. Anti-MOMP 
immunoglobulin titres were presented as the reciprocal of the highest serum dilution that 
gave an optical density (OD405) above the cut-off value.  The cut-off value was the mean 
OD of a negative African grey parrot serum ± twice the standard deviation (S.D.).  
 
2.8. Lymphocyte proliferative responses 
Leukocytes were isolated from the spleen of each budgerigar, at 21 days post 
challenge. Lymphocyte proliferative tests were performed as previously described 
(Vanrompay et al., 1999b). Briefly, non-adherent cells were grown in duplicate in 96-well 
tissue culture plates at 6 x 105 cells in 150 µl of Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20% heat-inactivated foetal calf serum (FCS; Integro, 
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Zaandam, The Netherlands), 1% non-essential amino acids (Life Technologies), 1% 
sodium pyruvate (Life Technologies), 1% L-glutamine (Life Technologies), 1% 
gentamycine (Life Technologies) and 5 x 10-5 M ß-mercaptoethanol (ß-ME; Life 
Technologies). For antigen proliferation, 20 µg of rMOMP was added to individual wells. 
Negative and positive controls included cells stimulated with either plain medium or with 
10 µg concanavalin A (Con A), respectively. Cells were incubated at 39.5°C in a 
humidified incubator with 5% CO2. Con A or antigen-induced proliferation was measured 
by incorporation of 3H-thymidine (1 µCi/well) during at last 16 hours of culture, at days 2 
(ConA) and 6 (DNA primed groups), respectively. Cultures were harvested onto glass 
fibre filter strips with a cell harvester (Skatron, Liers, Norway). The radioactivity 
incorporated into the DNA was measured with a β-scintillation counter (Perkin-
Elmer, Life Science, Brussels, Belgium) and was expressed as a stimulation index 
(SI: mean counts per minute in the presence of antigen divided by the mean 
counts per minute in the absence of antigen). 
 
2.9. Statistics 
The two-tailed Student t test, Mann-Whitney test and one tailed Spearman’s rank 
correlation was employed for statistical analyses. Results were considered significantly 
different at the level of P < 0.05.   
 
3. Results 
3. 1.  Clinical symptoms 
Clinical signs were first observed at five days post challenge. At that time, two non-
vaccinated birds showed mild dyspnoea. Another non-vaccinated bird had diarrhoea 
(green watery droppings) and was shaking his head as a sign of rhinitis. Vaccinated birds 
appeared healthy. From day 6 onwards till the end of the experiment, all non-vaccinated 
birds showed severe dyspnoea and diarrhoea, all but one (87.5%) had fluffy feathers. 
Three out of eight birds (37.5%) showed lethargy and two out of eight birds (25%) were 
shaking their heads regularly (Figure 4.2).  Symptoms in the non-vaccinated group were 
most severe from post inoculation day 6 till day 15. In the vaccinated group, two out of 
eight birds (25%) had diarrhoea at post inoculation day 11, four out of eight birds (50%) 
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showed dyspnoea from post inoculation day 10 till day 13 and at the same time five out of 
eight (62.5%) birds had fluffy feathers and one out of eight birds (12.5%) were lethargic. 
At euthanasia, at 21 days post challenge, only one out eight (12.5%) vaccinated birds 
showed fluffy feathers and was less active. All other vaccinated birds were more active as 
compared to the non-vaccinated control group as three out of four male birds were 
flaunting and some birds even played with the toys (mirror, bell) inside the cage. During 
the experiment, two out of eight (25%) vaccinated birds lost 7.0 and 7.7% of their body 
weight, respectively. In the non-vaccinated group, six out of eight (75%) birds lost 2.5, 2.6, 
3.0, 5, 8.1 and 15.0% of their body weight, respectively.   
 
3. 2. Cp. psittaci excretion 
Faecal excretion was examined by bacterial culture in BGM cells. Faecal Cp. psittaci 
excretion was not observed before challenge and during the first four days post challenge. 
At five days post challenge, fresh faecal droppings present on the cage floor of three out of 
four (75%) non-vaccinated  bird  pairs  were  culture positive. Mean culture scores per bird  
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Fig. 4.2. Percentage of budgerigars with clinical signs observed in vaccinated and non-     
vaccinated groups from 6 till 20 days post challenge. 
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pair are presented in Figure 4.2. One day later, all four (100%) non-vaccinated bird pairs 
excreted live bacteria and the faeces of all pairs remained positive until 20 days post 
challenge. In the four pcDNA1::MOMP A vaccinated bird pairs, bacterial excretion was 
first observed at 6 days post challenge. At that time, two out of four (50%) vaccinated bird 
pairs were shedding Cp. psittaci and one day later, the faeces of all vaccinated bird pairs 
became culture positive. All four vaccinated bird pairs remained culture positive until 14 
days post challenge. On day 15, two out of 4 (50%) vaccinated bird pairs were culture 
positive and from day 17 to 20, one out of four (25%) bird pairs was positive. Overall, 
non-vaccinated bird pairs showed significantly (p<0.01) higher mean culture scores as 
compared to the non-vaccinated control group (Figure 4.3). At 21 days post challenge, 
only one out of eight (12.5%) cloacal swabs of the vaccinated birds was positive with a 
mean immunofluorescence score of 0.37. On the other hand, all (100%) cloacal swabs of 
the non-vaccinated budgerigars were culture positive with a mean immunofluorescence 
score of 3.25.  
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Fig. 4.3. Presence of Cp. psittaci in fresh faecal droppings of vaccinated and non-
vaccinated bird pairs following challenge. The results of vaccinated and non-vaccinated 
birds were singnificantly different from day 5 until day 20. 
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3.3. Macroscopic lesions  
At euthanasia, budgerigars were examined for the presence of macroscopic lesions. 
Lesion scores in individual birds of vaccinated and non-vaccinated groups are presented in 
Table 4.3. Macroscopic lesions were clearly more severe in the non-vaccinated group, 
with prominent lesions in especially the respiratory tract and the spleen as all budgerigars 
showed focal to diffuse fibrinous airsacculitis, bilateral congestion to bilateral pneumonia 
and a slightly to severely enlarged spleen. Additionally, all birds showed congestion of the 
gut, all but one (87.5%) had a congested liver, 5 out of 8 (62.5%) showed serous to 
fibrinous adhesive pericarditis, 3 out of 8 (37.5%) showed slightly to moderately enlarged 
kidneys and 2 out of 8 (25%) showed necrosis of the conchae. Macroscopic lesions in the 
vaccinated group were less severe and as in the non-vaccinated group mainly located in 
the respiratory tract and the spleen. Actually, all vaccinated budgerigars showed mild 
lesions in the lower respiratory tract, 6 out of 8 (75%) had a slightly enlarged spleen and 5 
out of 8 (62.5%) showed mild lesions in the upper respiratory tract. No further lesions 
were observed in this group.  
 
 
3. 4. Cp. psittaci presence in different tissues  
 Immunofluorescence staining of frozen tissue sections revealed strong chlamydial 
replication in the upper (conchae and trachea) and lower (lungs and airsacs) respiratory 
tract of all non-vaccinated budgerigars (Table 4.4). With the exception of the pericard of 
one bird, replication was less prominent in the pericard, liver, kidney and gut of non-
vaccinated budgerigars. However, all non-vaccinated birds experienced a systemic 
infection as bacterial replication was clearly observed outside the respiratory tract 
resulting in faecal shedding in all birds until the end of the experiment at 21 days post 
challenge. The infection probably also spreads throughout the body of immunized birds as 
faecal shedding occurred in all four vaccinated bird pairs from 7 until 14 days post 
challenge. However, the infection seems to be eliminated more efficiently as demonstrated 
by diminished faecal shedding during subsequent days and by the absence of bacteria in 6 
out of 8 (75%) cloacal swabs, at 21 days post challenge. Notwithstanding this, replicating 
Cp. psittaci organisms were still present in the upper and especially lower respiratory tract 
of all but one (87.5%) vaccinated budgerigars at 21 days post challenge.  
    
Table 4.3. Macroscopic lesion scores in tissues of budgerigars, 3 weeks post Cp. psittaci challenge. 
 
 Macroscopic lesion scores in tissues of budgerigars 
Tissue   Vaccinated bird number  Non-vaccinated bird number 
 
 
                   
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Conchae                  + - + + - + + - - - - - ++ - - ++
Lungs                  
                  
                 
                  
                  
                   
                  
+ - + + + + + + + ++ ++ ++ +++ + +++ +
Airsacs + + + + + + + + +++ ++ ++ ++ +++ ++ ++ +++
Pericard - - - - - - - - +++ - - - +++ + + +++ 
Spleen + + + + + + - - +++ + + + ++ + ++ +
Liver - - - - - - - - + + + + + - + +
Kidney - - - - - - - - - + - - + - - ++
Gut - - - - - - - - + + + + + + + +
 
 
 
 
 
 
 
 
 
 
 
Table 4.4. Immunofluorescence scores for the presence of Cp. psittaci antigen in tissues of vaccinated and non-vaccinated budgerigars. 
aTh. airsacs: thoracal airsacs; bAbd. airsacs: abdominal airsacs. 
 
 
 
 
 
 
 Immunofluorescence scores for the presence of Cp. psittaci antigen  
 Vaccinated bird number  Non-vaccinated bird number 
Tissue                  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Conchae                  ++ - + + ++ + ++ - + + ++ + ++ ++ ++ ++
Trachea                  
                  
                
                 
                  
                  
                   
                  
+ - + + - - + ++ +++ ++ ++ ++ ++ + +
Lungs + - - - + - + - ++ ++ +++ ++ ++ ++ + +++
Th. airsacsa ++ - ++ ++ + ++ +++ - +++ ++++ ++++ ++ ++++ +++ ++ ++++
Abd. airsacsb ++ - ++ ++ +++ +++ + + +++ ++++ ++++ +++++ +++ +++++ ++ +++
Pericard - - - - - - - - + - + + ++ +++ + +
Liver - - - - - - - - + ++ + + + - + +
Kidney - - - - - - - - ++ + ++ ++ + + + ++
Gut - - - - - - - - + ++ + - + + + +
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3. 5. MOMP antibody responses 
All budgerigars had anti-MOMP antibody titers (titer of 60 to 120) before being 
vaccinated with the Cp. psittaci genotype A vaccine pcDNA1::MOMP A or the placebo 
vaccine pcDNA1 (Fig. 4.4).  MOMP antibody titers raised at least four-fold in all 
pcDNA1::MOMP A vaccinated birds, except for bird number 8, in which the MOMP 
antibody titer raised only two-fold. The effect of the booster vaccination was apparently 
less spectacular as antibody titers following pcDNA1::MOMP A booster vaccination 
raised only further in 3 out of 8 (37.5%) immunized budgerigars. Following challenge, 
antibody titers stayed identical in 4 out of 8 (50%), declined in 3 out of 8 (37.5%) and 
raised in 1 of 8 (12.5%) immunized budgerigars. Strangely, antibody titers raised four-fold 
in 2 out of 8 (25%) pcDNA1-vaccinated controls at 3 weeks post primary-vaccination. 
However, at the day of the experimental infection, MOMP-antibodies were absent in  2 
out of 8 (25%) non-vaccinated control birds, and MOMP-antibody titers were  60 and 120 
in 2 out of  8 (25%) and 4 out of 8 (50%) pcDNA1 immunized birds, respectively. 
Antibody titers in non-vaccinated controls did not augment following challenge, except for 
bird numbers 10, 12 and 16. There was a significant (P<0.05) difference in mean antibody 
titers between the vaccinated and non-vaccinated groups at 3 weeks post primary-
vaccination and at all subsequent time points during the experiment. 
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Fig. 4.4. MOMP specific antibody titers. The vaccinated group was intramuscular 
immunized with pcDNA1::MOMP. Budgerigars in the non-vaccinated group received an 
empty pcDNA1 plasmid (placebo). Sampling time-points: day of the primary vaccination 
(Prevaccination);  post primary vaccination (PPV); post booster vaccination (PBV);  post 
challenge (PC). 
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3.6. MOMP-specific lymphocyte proliferation test 
Proliferative responses to rMOMP (genotype A strain 89/1051) of spleen lymphocytes 
of pcDNA1::MOMP A or pcDNA1 immunized control budgerigars were determined 21 
days following challenge with the Cp. psittaci genotype A strain 89/1051. The spleen 
lymphocytes of pcDNA1::MOMP A immunized birds displayed significantly higher 
proliferative responses than the spleen lymphocytes of the placebo-vaccinated budgerigars 
(Table 4.5).  
 
Table 4.5. Proliferative responses of spleen lymphocytes of immunized and non-
immunized budgerigars to recombinant major outer membrane protein (rMOMP) at day 21 
post challenge. 
 Mean stimulation index ± S.D. 
Group (n)*   
Non-vaccinated (8) 11.0 ± 2.25  
Vaccinated (8) 25.45 ± 4.25 
*Number of budgerigars per group. 
 
 
4. Discussion 
Reported human psittacosis cases are most often related to contact with Cp. psittaci 
infected poultry (ducks and turkeys) or Psittaciformes. Psittaciformes are kept in 
specialized breeding facilities, zoos and quarantine stations, but with respect to public 
health the increasing habit of keeping cockatoos, parrots, parakeets and lories as pets in 
many households, needs even more attention. In 2001, 750.000 budgerigars were kept as 
pet in the U.K. and households owning budgerigars comprised 2.8% of U.K. pet owners 
(http://www.defra.gov.uk/animalh/ and http://www.pfma.org.uk/). We have no recent data, 
nor do we have information from other countries. However, the current situation in Europe 
is most likely more or less the same as the one described for the U.K. in 2001, as 
Psittaciformes are still extremely popular pets. 
Vaccination of Psittaciformes against Cp. psittaci infections might diminish the 
zoonotic risk, but successful vaccination could also improve the breeding performances of 
captive Psittaciformes and their general health status. Commercial Cp. psittaci vaccines 
are not existent in birds. Previously, we demonstrated the use of major outer membrane 
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protein (MOMP)-based DNA vaccination as a mean of preventing severe clinical signs 
and lesions in a specific pathogen free (SPF) turkey model of Cp. psittaci infection. The 
major outer membrane protein is an immunodominant protein representing the majority of 
the surface exposed proteins of Cp. psittaci and the MOMP contains serovar-specific 
neutralizing epitopes (Zhang et al., 1987; Kikuta et al., 1991; Sandbulte et al., 1996). 
In the present study, pcDNA1::MOMP A immunized budgerigars were significantly 
protected against severe clinical signs and lesions following challenge with a very high 
dose (108 TCID50) of the highly virulent homologous Cp. psittaci genotype A strain, 
89/1051. Non-vaccinated budgerigars showed severe clinical signs and lesions and in 
contradiction to the vaccinated birds, excreted high amounts of Cp. psittaci during 3 weeks 
post challenge. However, notwithstanding the severity of the disease, none of the placebo-
vaccinated control budgerigars died, as observed in specific pathogen free (SPF) turkeys 
infected with this highly virulent strain (Vanrompay et al., 1995b). This might be due to 
the pre-existing anti-MOMP serum antibody titers detected in all budgerigars prior to the 
experimental infection. Indeed, pharyngeal and cloacal swabs taken prior to the 
experimental infection were negative in both nested PCR and culture, but nevertheless, all 
budgerigars must at least once have been infected, during their stay in the breeding facility 
as they all had pre-existing MOMP serum antibody titers. Indeed, the prevalence of Cp. 
psittaci infections is high among Psittaciformes (Vanrompay et al., 2007) and therefore 
previous exposure to the organism is hardly surprising. Moreover, Cp. psittaci serum 
antibody titers in Psittaciformes can remain for months.  
Interestingly, DNA vaccination could significantly reduce clinical symptoms, 
macroscopic lesions, bacterial excretion as well as chlamydial replication, even in the 
presence of serum antibodies originating from a previous infection. Maybe not 
surprisingly, as MOMP-antibody titers in pre-sera were rather low (maximum 120) and 
experimental DNA immunization is known to be effective in turkeys having high maternal 
antibody titers (Van Loock et al., 2004). Nevertheless, this could be an essential 
observation regarding future vaccination, as Cp. psittaci genotype A strains are endemic in 
Psittaciformes and most birds, if not all, will have antibodies against the organism.  
As demonstrated before, serum antibodies did not protect against a respiratory Cp. 
psittaci infection, as all non-vaccinated controls got sick, even when having (low) pre-
existing MOMP-serum antibody titers. We have no information on protective mucosal 
antibody titres in these birds prior to immunization, but the experimental infective dose 
was extremely high, thus clinical disease in non-vaccinated budgerigars was actually 
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inevitable, even in the presence of higher serum antibody levels and/or protective mucosal 
antibodies The experimental infective dose most likely did not reflect the natural infective 
dose. Actually, the latter is unknown and might vary depending on the virulence of the 
strain. Thus, it might be interesting to determine the protective capacity of the DNA 
vaccine using lower infective doses.  
Budgerigars 2 and 8, responding best to both primary and booster vaccinations and 
showing no secondary antibody responses upon challenge were best protected. Similar 
observations have been made following MOMP-based DNA immunization in SPF turkeys. 
In turkeys, best protection occurred in immunized turkeys that upon challenge did not 
demonstrate secondary antibody responses, as the bacteria were probably unable to 
replicate to boosting levels (Vanrompay et al., 1999a; Vanrompay et al., 1999b; 
Vanrompay et al., 2001a; Van Loock et al., 2004).  
During former DNA vaccination studies in turkeys, non-vaccinated birds showed a 
primary antibody response upon challenge. At present, bird number 13 and 16 showed a 
MOMP-specific immune response following immunization with the placebo vaccine, 
which could only mean that they experienced a Cp. psittaci infection during the first 3 
weeks of the experiment. However, pharyngeal and faecal swabs of these two birds were 
PCR and culture negative at the day of the experimental infection, and at that time, 2 
weeks post booster (placebo) vaccination, antibody titers were lower than after the 
primary-vaccination. Placebo-vaccinated birds 13 and 16 were most severely infected 
regarding clinical signs, macroscopic lesions and presence of bacteria in cloacal swabs at 
the end of the experiment. Maybe, these 2 birds were Cp. psittaci ‘carriers’ and handling 
them reactivated the persistent infection leading to a four-fold raise in antibody titer during 
the first 3 weeks of the experiment. However, bacterial shedding by these two birds prior 
to the experimental infection must have been low, as their cage mates (birds number 12 
and 15) did not became infected. However, we could not proof the ‘carrier hypothesis’ as 
swabs prior to challenge were negative and the ones collected following the experimental 
infection only contained genotype A.  
Currently, we have no real explanation for the absence of a significant antibody 
response in all but one (bird number 16) non-vaccinated controls. Maybe, circulating  
antibodies remained longer in vaccinated birds and serum antibodies in non-vaccinated 
birds were more difficult to detect as most antibodies were ‘captured’ by the extreme high 
amount of bacteria presenting in these heavily infected birds.  
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Evidence for the mobilization of T cell memory in response to challenge was shown 
by the significantly increased spleen lymphocyte proliferative response upon challenge 
when compared to the placebo-vaccinated control group. However, 10-fold increases in SI 
between vaccinated and non-vaccinated budgerigars as observed in previously performed 
DNA vaccination experiments in SPF turkeys, could not be demonstrated.  
The essential observation of this report is that a codon-optimized, MOMP-based DNA 
vaccine is capable of circumventing the influence of circulating antibody inhibition. 
Budgerigars in the present study showed relatively moderate levels of pre-existing 
circulating antibodies and a totally inhibited antibody response to the vaccine construct in 
the presence of higher circulating antibody titers cannot be excluded. However, circulating 
antibody titers affected neither the induction of vaccine-specific T cell response nor 
significant protection in budgerigars. Therefore, prime-boost DNA vaccination may be 
useful for preventing Cp. psittaci infections in Psittaciformes, a bird population in which 
Cp. psittaci infections are nearly endemic. In addition, research on DNA vaccination in 
persistently infected birds would be useful in order to study possible clearance of the 
infection by DNA immunization.  
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General discussion and perspectives 
In humans, Cp. psittaci causes psittacosis or parrot fever usually characterized by 
fever chills, headache, dyspnoea and cough. The chest X-ray often shows an infiltrate 
(Yung and Grayson, 1988; Schlossberg et al., 1993; Smith et al., 2005). However, the 
disease seems to vary considerably in severity as the clinical features of the infection can 
range from none to sepsis with multi-organ failure requiring intensive-care-unit admission 
(Heddema et al., 2006c). People usually contract the infection by inhaling an aerosol of 
droppings of infected birds.  
Psittacosis is found worldwide and the incidence seems to be increasing in developed 
countries, which is correlated to the import of exotic birds. However, the actual number of 
human infections is probably still underestimated because psittacosis is difficult to 
diagnose, is covered by antimicrobials, which may be employed empirically for therapy of 
community-acquired pneumonia, and often is not reported. Annually reported psittacosis 
cases in Belgium were 7 in 2005, 2 in 2006 and 3 in 2007 (www.iph.fgov.be). Thus, 
specific data need to be collected to assess the current epidemiological situation 
concerning zoonotic transmission of Cp. psittaci in Belgium. Additionally, molecular 
analysis of the strains isolated from humans and birds would improve our knowledge of 
risk factors for bird-to-human transmission. Recent advances in molecular diagnosis of Cp. 
psittaci infections such as nested PCR/EIA (Van Loock et al., 2005b) and Real-time PCR 
(Geens et al., 2005b; Heddema et al., 2006a) have been recognized as powerful techniques 
for rapid, specific and sensitive diagnosis of chlamydial infections and were therefore used 
in the present study to obtain current epidemiological data.  
Thus, it was our first purpose to examine the prevalence of Cp. psittaci infections in a 
generally healthy human population in contact with domestic and/or companion birds to 
gain insight on the real occurrence of psittacosis, as we strongly believe that the annually 
reported psittacosis cases do not reflect the real Cp. psittaci infection status of our general 
Belgian population. The prevalence study would also allow us to define the general human 
population being most at risk of getting psittacosis. Results obtained would allow 
subsequent examination of the prevalence and the clinical consequences of Cp. psittaci 
infections in a human population being highly at risk of getting psittacosis. Finally, it was 
our purpose to use the obtained knowledge on bird species and Cp. psittaci genotypes, 
most often involved in psittacosis, to design a recombinant vaccine and to evaluate the 
protective capacity of the vaccine in a well-defined avian experimental infection model.  
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In the first part of our research, we indeed confirmed the underestimation of human 
Cp. psittaci infections in Belgium as 69 (12.7%) pharyngeal swabs of 540 examined 
generally healthy Flemish persons contained Cp. psittaci DNA as demonstrated by the Cp. 
psittaci-specific nested PCR/EIA. Cp. psittaci PCR positives included 57 of 254 (22.4%), 
11 of 58 (19%), 0 of 108 (0%) and 1 on 120 (0.8%) persons who, according the 
questionnaire, claimed to have daily, weekly, sporadic, or no contact with domestic or 
companion birds, respectively. Thus, contact frequency with birds seems to be an 
important risk factor. Interestingly, individuals in contact with parakeets, parrots 
(Psittaciformes) and racing pigeons are more at risk of becoming infected with Cp. psittaci 
than those in contact with other bird species. Additionally, daily contact with racing 
pigeons is significantly more dangerous than weekly contact. However, this is not the case 
for Psittaciformes, as the infection risk for humans is the same whether they are daily or 
only weekly in contact with parakeets or parrots. Thus, infected Psittaciformes are strictly 
seen more dangerous to public health. This could be due to the presence of predominantly 
Cp. psittaci genotype A strains in Psittaciformes against genotype B and sometimes E 
strains in pigeons. The latter genotypes are regarded less virulent for birds as they replicate 
slower and produce smaller inclusions with lower percentages of infectious elementary 
bodies (Vanrompay et al., 1993b). Thus, maybe bacterial excretion levels are not that high 
in pigeons, presenting a lower risk for bird to human transmission of Cp. psittaci.  But 
how can we than explain the high percentage of positive individuals (44.6%) having daily 
contact with racing pigeons. Perhaps, because racing pigeons were kept as a group, all 
together creating high infection pressure, whereas parakeets and parrots were mostly 
housed individually and in case of parakeets sometimes as pairs.  
Cp. psittaci zoonotic transmission from Psittaciformes can cause severe disease in 
humans (Samra et al., 1991; Newton et al., 1996; Kay, 1997; Soni et al., 1999; Henrion et 
al., 2002; Bourne et al., 2003; Saito et al., 2005; Kaibu et al., 2006; Heddema et al., 
2006c). However, as demonstrated in our prevalence study, these severe cases are 
probably only the tip of the iceberg. What lies underneath are less severe, clinically 
unnoticed infections, which are misdiagnosed due to symptoms similar to those caused by 
other respiratory pathogens, or even asymptomatic infections. The impact of these types of 
Cp. psittaci infections on human health still needs to be determined. Nothing is known of 
natural protection, the consequences of recurrent infections, and the possible pathogenic 
interactions between Cp. psittaci and other human respiratory pathogens. We can try to 
extrapolate our knowledge on avian infections to human psittacosis. Cp. psittaci can go 
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into a carrier status in birds and although not proven it is also thought to be possible in 
men. Dormant aberrant bodies, i.e., enlarged pleomorphic reticulate bodies, and reduced 
inclusion size inside the host cell with the absence of elementary bodies capable of 
infecting new cells, characterize a carrier status (Goellner et al., 2006). In turkeys, an 
Escherichia coli superinfection in Cp. psittaci carriers aggravated the E. coli infection and 
reactivated chlamydial replication and excretion (Van Loock et al., 2006b). Additionally, a 
Cp. psittaci infection aggravated the outcome of a viral avian pneumovirus infection in 
turkeys (Van Loock et al., 2006a). However, we can only speculate on similar pathogenic 
interactions between Cp. psittaci and other human respiratory pathogens, but we do know 
that co-occurrence of Cp. psittaci with other human respiratory pathogens has been 
reported (Yano et al., 1990; Nakajima et al., 1996).  
Interestingly, the prevalence study also demonstrated the usefulness of a nested 
PCR/EIA for detecting psittacosis in humans. The PCR/EIA was originally designed for 
demonstrating chlamydiosis in birds and is highly specific as primers were specifically 
designed for amplifying Cp. psittaci DNA and no other chlamydial DNA. The latter is 
extremely important when examining human specimens as humans can become infected 
with several chlamydial species. Clinicians should be strongly recommended to use 
nucleic acid amplification tests for diagnosing psittacosis in humans rather than serology 
as these molecular tests are extremely sensitive and specific, and present direct evidence 
of a Cp. psittaci infection. However, the U.S. Centers for Disease Control and Prevention 
(CDC), the U.S. National Association of State Public Health Veterinarians (NASPHV) 
and the U.S. Council of State and Territorial Epidemiologists (CSTE), world-wide all 
recognized as established ‘advisory organizations’, still promote the use of culture and 
serology for establishing clinical diagnosis of psittacosis (www.nasph.org; 
www.avma.org). This is incomprehensible as, the main serological tests commonly used 
for screening, the complement fixation test (CFT) and the so-called ‘gold standard’ MIF 
test (more sensitive than CFT), both do not distinguish Cp. psittaci from Cp. pneumoniae 
and C. trachomatis. Moreover, several researchers (Wong et al., 1994; Smith et al., 1997; 
Telfer et al., 2005; Fenga et al., 2007; Matsui et al., 2007) and also our present study 
showed that the MIF test is actually not a good test because of its lack of specificity, 
sensitivity, reproducibility, objectivity and agreed protocol. In addition, obligatory 
examination of paired sera removes serology from immediate clinical relevance. 
Treatment with antibiotics may also delay and/or diminish the antibody response, so a 
third serum sample might even be needed. Thus, to our opinion, these serological tests 
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might be helpful for comparative epidemiology, but it is quite a different matter to be 
confident about the meaning of their result in an individual human patient. Culture is also 
recommended by the CDC, the NASPHV and CSTE to confirm human psittacosis. 
However, culture can only be performed in specialized biosafety level 3 (BSL3) 
laboratories, it takes at least 3 days, sampling, transport and storage of specimens requires 
special attention, culture is technically difficult and some strains simply don’t grow in cell 
cultures or embryonated eggs. Thus, nucleic acid amplification tests should be used to 
confirm psittacosis in humans and this should be made clear to the authorities, a currently 
task undertaken by the European COST action 855 on Animal chlamydiosis and its 
zoonotic implications. Nucleic acid amplification tests present important benefits as they 
allow rapid outbreak management and subsequent genotyping of the strains involved using 
for instance, a genotype-specific real-time PCR (Geens et al., 2005b), as demonstrated in 
Chapter III or a genotyping micro array (Sachse et al., 2005), allowing to trace the avian 
infection source.  
In the second part of the research, we studied zoonotic transmissions of 
Chlamydophila psittaci in 39 Belgian breeding facilities for Psittaciformes (cockatoos, 
parrots, parakeets, lories) that frequently used antimicrobial drugs. Genotypes A (6 
persons) and E/B (one person) were detected in 14.9% of humans at these facilities. 
Additionally, we illustrated the occupational risk for veterinarians and their assistants in a 
case report on Cp.psittaci genotype E/B transmission from African grey parrots to humans. 
We showed the need for information on sensible antimicrobial drug use in Psittaciformes 
as tetracycline resistant zoonotic Cp. psittaci strains could develop by frequent 
prophylactic use of these drugs. These drugs are sold on the internet, even without a 
prescription as a prescription is not needed in every country. Legal authorities should 
urgently deal with this problem, which presents a serious threat to public health.  
Our findings contributed to raising the awareness of chlamydial infections, as well as 
their zoonotic dimensions. Ultimately, this should allow the introduction of improved 
prevention and control measures such as: 1) protection of persons at risk, advising them to 
wear protective clothing, gloves and a fitted respirator with appropriate P3 filter when 
cleaning cages or handling infected birds. Necropsies should be performed in a biological 
safety cabinet, preferably wetting the carcass with detergent and water to prevent 
aerosolization of the infectious particles, 2) Maintain accurate records of all bird-related 
transactions for at least one year to aid in identifying sources of infected birds and 
potentially exposed persons as currently trace-backs of infected birds to distributors 
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and breeders is often not possible because of limited regulation of the pet bird 
industry, 3) avoid to purchase or sell birds that have signs consistent with avian 
chlamydiosis, 4) isolate newly acquired birds, ill, or exposed birds, 5) test birds before 
they are to be boarded or sold on consignment, 6) screen groups of birds with frequent 
public contact routinely by nucleic acid amplification tests, 7) practice preventive 
husbandry (avoid contact with wild birds), 8) control the spread of an infection, 9) 
quarantine of all infected and exposed birds, 10) use disinfection measures, 11) bird 
importation regulations.  
Zoonotic risk reduction strategies are urgently needed, but an avian vaccine would 
significantly reduce the risk of Cp. psittaci bird to human transfer. At present, only 
vaccines for chlamydioses in cats and sheep are commercially available, and some of 
those in use are known to have considerable limitations (Longbottom and Livingstone, 
2006). Vaccination studies based on DNA vaccines and recombinant MOMP have 
recently been performed in turkeys. Cp. psittaci DNA vaccination significantly protected 
SPF turkeys against severe clinical disease and significantly reduced chlamydial excretion, 
as well as the lesions caused by this pathogen, whereas recombinant MOMP vaccination 
induced less protective immune responses (Van Loock et al., 2004; Verminnen et al., 
2005). A DNA vaccination protein-boost study in SPF turkeys has been completed and 
shown to generate both cellular and humoral immune responses (Verminnen et al., 2005), 
although these responses were less protective than DNA prime-boost strategies. Therefore, 
we evaluated the ability of plasmid DNA (pcDNA1::MOMP A) expressing the major 
outer membrane protein (MOMP) of the Cp. psittaci genotype A strain 89/1051 to induce 
protective immunity against Cp. psittaci challenge in budgerigars. DNA immunization 
could significantly reduce clinical symptoms, macroscopic lesions, pharyngeal and cloacal 
excretion as well as chlamydial replication, even in the presence of pre-existing serum 
antibodies, as compared to the placebo-vaccinated controls. However, full protection was 
not achieved, if albeit possible.  
We are convinced that the protection ability of the candidate vaccine can be further 
improved. There are several approaches to enhance the efficacy of DNA vaccines such as; 
improving uptake of plasmid into the cell and nucleus including gene gun delivery 
(Vanrompay et al., 1999a; Babiuk et al., 2003), phage delivery (Clark and March, 2004; 
March et al., 2004), liposome mediated transfection (Gregoriadis et al., 2002) and 
generating complexes of plasmid DNA with cationic polymers to improve transfection 
efficiencies (Verminnen et al., 2008b). In vivo electroporation has been shown to improve 
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the efficacy of DNA vaccination in large animals (Babiuk et al., 2002; Scheerlinck et al., 
2004), but is rather difficult to use in smaller, stress-sensitive animals such as pet birds. 
Enhancing the immune response to the antigen is another strategy that can improve the 
efficacy of DNA vaccines. This can be achieved by incorporating genes encoding 
cytokines (IFN-γ, IL-1β, IL-2, IL-8, IL-15, IL18, GM-CSF, TNF-4β and lymphotactine) 
or cytidine phosphate guanosine (CpG) motifs into the plasmid (Gurunathan et al., 2000; 
Krieg and Davis, 2001; Babiuk et al., 2003; Garmory et al., 2003; Loots et al., 2006). 
Moreover, identification of suitable adjuvants is as critical as the choice of antigen for 
improvement of the protective efficacy of the vaccine.  
In the future, we would like to enhance the protective capacity of our Cp. psittaci 
genotype A DNA vaccine further by using a complex of a cationic polymer with codon-
optimized pcDNA1::MOMP A, as constructed by Verminnen et al.,(2008b) for Cp. 
psittaci genotype D vaccination of turkeys. Additionally, we would like to repeat the 
vaccination experiment in budgerigars using lower infective doses, as 108 TCID50 of the 
highly virulent Cp. psittaci strain 89/1051 most certainly does not reflect the natural 
infective dose.  
An important issue that needs to be addressed in order to prevent zoonotic 
transmission to humans is legislation. A new EU commission regulation, EC no 318/2007 
applies from 1 July 2007 after being published in the Official Journal of the EU.  This 
regulation lays down the animal health conditions for imports of certain birds from third 
countries and parts thereof into the EU. It is not applicable to: a) fowl, turkeys, guinea 
fowl, ducks, geese, quails, pigeons, pheasants, partridges, ratites reared or kept in captivity 
for breeding, the production of meat or eggs for consumption, or for restocking supplies fo 
games (poultry),  b) racing pigeons which are introduced to the territory of the Community 
from a neighbouring third country where they are normally resident and then immediately 
released with the expectation that they will fly back to that third country, c) birds imported 
from Andorra, Liechtenstein, Monaco, Norway, San Marino, Switzerland and the Vatican 
City State, d)birds intended for zoos, circuses , amusement parks or experiments, e) pet 
animals referred to in the third paragraph of Article 1 of Directive 92/65/EEC, 
accompanying their owner, f) birds imported for conservation programmes approved by 
the competent authority  of the Member State of destination. The regulation also lays 
down the quarantine conditions. For instance: 1) approved quarantine facilities and centres, 
2) direct transport of birds to quarantine stations, 3) attestation by the importers or their 
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agents, 4) quarantine for at least 30 days, 5) examination, sampling and testing to be 
carried out by an official veterinarian, 6) actions in case of disease suspicion which are in 
case of chlamydiosis treatment of all birds and prolonged quarantine for at least two 
months following the date of the last recorded case.  Importantly the regulation only 
allows imports of birds from approved breeding establishments, thus for birds other than 
poultry, only birds bred in captivity carrying an individual identification number and 
accompanied by an animal health certificate are allowed.  
Thus, current EU psittacosis legislation is strictly on import of birds. There is no 
legislation/regulation on risk reduction strategies in member states, or on outbreak 
management. Some years ago there was the Dutch foundation, “Bestrijdingsplan 
papegaaienziekte – B.P.P.”, but it no longer exists because the proposed risk reduction 
strategies were too expensive. The foundation tried to: a) improve the birds’ health, b) 
reduce contact of humans with psittacosis, c) improve the awareness of bird sellers and 
their customers. Bird breeders could voluntarily participate. Ten percent of their birds 
were examined twice a year and when Cp. psittaci was present, all birds had to be treated 
with antibiotics. If negative, breeders received a “psittacosis-negative” certificate. Maybe, 
we should reconsider the implementation of such a psittacosis risk reduction strategy, but 
this time on EU level. 
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Summary 
Psittacosis, also known as parrot fever is a bacterial infection in humans that can 
cause asymptomatic infections but also severe pneumonia with serious health problems. It 
is caused by Chlamydophila psittaci, an obligate intracellular Gram-negative bacterium, 
formerly known as Chlamydia psittaci. Cp. psittaci includes 9 known outer membrane 
gene A (ompA) genotypes designated A to F, E/B, M56, and WC (Everett et al., 1999; 
Geens et al., 2005a). The 7 first genotypes are known to naturally infect birds. All Cp. 
psittaci genotypes should be considered to be readily transmissible to humans. Infected 
birds shed the bacteria through faeces and nasal discharges, and humans become infected 
by inhaling an aerosol of these materials. Psittacosis is a notifiable disease in most 
countries. Psittacosis is found worldwide and the incidence is increasing in developing 
countries, which is correlated to the import of exotic birds. However, the actual number of 
psittacosis cases is probably still underestimated because psittacosis is difficult to 
diagnose, is covered by antimicrobials which may be employed empirically for therapy of 
respiratory disease and/or community-acquired pneumonia, and often is not reported.  
The aim of the present thesis was to collect specific data to assess the current 
epidemiological situation concerning zoonotic transmission of Cp. psittaci in a Flemish 
population having contact with domestic and/or companion birds. We tried to define the 
human population being most at risk of getting psittacosis and subsequently tried to gather 
information on the prevalence and the clinical consequences of psittacosis in this human 
population. Finally, the obtained information on bird species and Cp. psittaci genotypes 
being most often involved in bird to human transmission, was going to be used for 
designing a recombinant Cp. psittaci vaccine and evaluating its protective capacity in a 
well-defined avian experimental infection model.  
Chapter I gives and overview on the history, taxonomy, and infection biology of 
chlamydial infections in general. Moreover, different aspects of avian chlamydiosis such 
as epidemiology, transmission between birds, clinical disease, diagnosis, treatment, public 
health significance, prevention, control measurements and current legislation, are 
reviewed.  
In Chapter II we investigated the occurrence of Cp. psittaci infections in a 
representative Flemish population of 540 individuals claiming to have daily, weekly, 
sporadically or no contact with domesticated and/or companion birds. Participants, 264 
males and 276 females, at the age of 36 to 57 years (median 46) were sampled 
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pharyngeally and at the same moment a blood sample was obtained. Each individual 
completed a questionnaire allowing insight into professional and nonprofessional activities, 
smoking habits, medical history and contact frequency with different bird species and 
other animals. Pharyngeal swabs were analyzed using a Cp. psittaci-specific nested 
PCR/enzyme immunoassay (EIA), and a Cp. pneumoniae- specific nested PCR. Sera were 
tested for IgG/IgM by a recombinant Cp. psittaci MOMP-based ELISA, by MIF and by 
the Serion Chlamydia IgG/IgA ELISA. Canaries and Psittaciformes, (especially parakeets 
and parrots) were the most popular pet birds, followed by racing pigeons, ducks, geese and 
finally turkeys. Individuals in contact with Psittaciformes and racing pigeons are more at 
risk of becoming infected with Cp. psittaci. Daily contact with racing pigeons is 
significantly more dangerous than weekly contact. However, this is not the case for 
Psittaciformes, as the infection risk for humans is the same whether they are daily or only 
weekly in contact with parakeets or parrots. Racing pigeons were kept as a group, all 
together creating a high infection pressure, whereas parakeets and parrots were mostly 
housed individually and in case of parakeets sometimes as pairs. Thus, infected 
Psittaciformes are strictly seen more dangerous to public health.  
Additionally, we showed the usefulness of a highly sensitive and specific nested 
PCR/EIA for detecting Cp. psittaci DNA in human clinical specimens and the urgent need 
for the development of a sensitive but especially Cp. psittaci specific recombinant or 
peptide-based antibody detection test for testing human sera. Results stress the need for 
more accurate diagnostic monitoring and reporting, a veterinary vaccine, and information 
campaigns with recommendations for psittacosis risk reduction strategies. 
In chapter III, we describe the transmission of a Cp. psittaci genotype E/B strain 
from African green parrots to humans hereby demonstrating for the first time the zoonotic 
potential of Cp. psittaci genotype E/B strains. Results of this study also underline the 
occupational risk for veterinarians. In Chapter III, we additionally describe the 
transmission of Cp. psittaci from Psittaciformes (cockatiels, parakeets, parrots, lories) to 
humans in a zoonotic risk study in a human population proven (chapter II) to be highly at 
risk of getting psittacosis. A population of 308 Psittaciformes from 39 breeding facilities 
as well as 46 of the pet bird owners were tested for Cp. psittaci infections. Fifty-nine 
(19.2%) birds were positive for Cp. psittaci by nested PCR/EIA detecting the chlamydial 
outer membrane protein A (ompA) gene in faecal samples. Cp. psittaci were cultured from 
25 (42.3%) PCR- positive samples inoculating them onto BGM cells and subsequently 
identifying the bacteria by immunofluorescence staining. Eight of 39 (20.5%) tested 
 
Summary   127
breeding facilities were positive in both nested PCR/EIA and culture and respiratory 
disease was present at all eight. Five breeding facilities gave only positive results in the 
nested PCR/EIA and birds showed no clinical signs. Birds in one of these facilities were 
currently being treated with doxycycline, and the remaining four breeding facilities 
recently used doxycycline, oxytetracycline, or enrofloxacin. In 13 of 39 (33.3%) Cp. 
psittaci – positive breeding facilities a significant correlation between faecal excretion of 
viable chlamydophila and respiratory disease was shown (odds ratio 14.5, 95% confidence 
interval 1.6-130.5, p<0.05). The remaining 26 breeding facilities with healthy birds had 
negative results for PCR and culture. Nested PCR/EIA showed the presence of Cp. psttaci 
DNA in pharyngeal samples of 6 on 46 (13%) pet bird owners. Interestingly, birds of those 
pet bird owners were positive in both PCR and culture. Viable organisms could be isolated 
from 4 out of 6 PCR positive human samples. Subsequent ompA genotyping by use of a 
genotype-specific real-time PCR revealed the presence of genotypes A (5 of 6) and E/B (1 
of 6). Only mild clinical signs appeared in these persons and none were treated. In our 
study, 18 (46.2%) of 39 breeding facilities had treated their birds with tetracycline, 
doxyclycline, or enrofloxacin in the past year. Four (10.2%) of 39 also used tetracyclines 
prophylactically. Thus, a Cp. psittaci vaccine for Psittaciformes and information on 
sensible use of antibiotics are needed to prevent psittacosis in humans and birds as well as 
possible development of drug-resistant zoonotic Cp. psittaci strains. 
In chapter IV, we describe the development of a Cp. psittaci genotype A DNA 
vaccine for budgerigars (Melopsittacus undulatus). Codon-optimized plasmid DNA 
(pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of 
Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce 
protective immunity against Cp. psittaci challenge in budgerigars. Eight pairs of male and 
female budgerigars were housed in eight separate bird cages placed in two negative 
pressure isolators, four cages per group. All budgerigars were immunized twice 
intramuscularly with 100 µg plasmid DNA. Both groups received a primary DNA 
inoculation at day 1, followed by a booster inoculation 3 weeks later. Group 1 received 
pcDNA::MOMP A while group 2 received the placebo vaccine pcDNA1. Budgerigars 
were challenged by aerosol two weeks following the booster vaccination. The challenge 
consisted of 108 TCID50 of the homologous Cp. psittaci genotype A strain. Cloacal and 
pharyngeal swabs of all budgerigars, taken at the beginning of the experiment and prior to 
the experimental infection were negative in both PCR and culture. However, all 
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budgerigars showed low pre-existing serum antibody titers, indicative for a previous 
infection. Nevertheless, DNA immunization could significantly reduce clinical symptoms, 
macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, 
even in the presence of pre-existing serum antibodies, as compared to the placebo-
vaccinated controls.  
In conclusion, we clearly demonstrated the underestimation of human Cp. psittaci 
infections in Belgium and identified racing pigeons, but especially Psittaciformes as the 
main infection source for humans having contact with domestic and/or companion birds. 
We also demonstrated the occupational risk for veterinarians and their assistants of getting 
psittacosis from Psittaciformes. We stressed the need for 1) zoonotic risk reduction 
strategies, 2) information campaigns on sensible antibiotic use in Psittaciformes, 3) control 
on antibiotic availability through the internet, 4) a Cp. psittaci-specific antibody detection 
assay for testing human sera, as well as the need for 5) a Cp. psittaci vaccine, as it will 
definitely diminish the number of symptomatic and asymptomatic Cp. psittaci infections 
in humans and the risk of creating antibiotic resistant zoonotic C. psittaci strains. Future 
research will be directed towards improvement of protective immunity obtained by our 
DNA vaccine by generating complexes of plasmids with cationic polymers in order to 
increase plasmid delivery and towards the development of a recombinant or peptide-based 
Cp. psittaci-specific antibody enzyme-linked immunosorbent assay for testing human sera.  
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Samenvatting 
Psittacosis, ook gekend als de papegaaienziekte, is een humane bacteriële infectie 
veroorzaakt door Chlamydophila psittaci, een Gram-negatieve obligaat intracellulaire 
bacterie. De infectie kan asymptomatisch verlopen doch kan eveneens een erge 
longontsteking veroorzaken met eventueel ernstige complicaties en in een enkel geval kan 
de infectie zelfs dodelijk zijn. Cp. psittaci wordt onderverdeeld in 9 gekende ‘outer 
membrane protein’ A (ompA) genotypen, namelijk de genotypen A tot F, E/B, M56 en 
WC. De zeven eerste genotypen veroorzaken een infectie bij vogels. Al deze genotypen 
zijn potentieel gevaarlijk voor de mens daar zij kunnen overgedragen worden van vogels 
naar mensen. Geïnfecteerde vogels scheiden de bacterie uit via hun faeces maar ook via 
neussecreet en de mens wordt geïnfecteerd door het inademen van aërosolen van deze 
excreties. Psittacosis is een aangifteplichtige ziekte in de meeste Europese landen, De 
Verenigde Staten van Amerika, Australië en Japan.   
Psittacosis komt bijgevolg wereldwijd voor en de incidentie neemt de laatste jaren 
toe. De reden voor deze toename is nog onbekend. Mogelijk zijn artsen veel alerter 
geworden, maar het kan ook zijn dat de ziekte besmettelijker aan het worden is. Ook is de 
stijging mogelijk te wijten aan onzorgvuldig gedrag van vogelhandelaren die de vogels 
onnodig vaak behandelen met antibiotica waardoor de infectie gemaskeerd wordt, 
waardoor de vogels zelf niet ziek lijken, maar de infectie wel verder kunnen verspreiden. 
Er is de laatste jaren een toename van het aantal psittacosis gevallen in de ons omringende 
landen (Nederland, Duitsland en Frankrijk). Doch wij zijn, samen met andere 
onderzoekers, van mening dat het werkelijke aantal psittacosis gevallen in deze landen en 
ook in België, nog steeds sterk onderschat wordt. De milde vorm van de ziekte doet 
immers denken aan griep, waardoor de infectie niet herkend wordt. Vaak wordt een 
antibioticumtherapie gestart bij een respiratoire infectie, zonder dat het oorzakelijke agens 
daadwerkelijk geïdentificeerd werd. Tevens wordt de infectie niet altijd gerapporteerd. Het 
werkelijke aantal psittacosis gevallen zal vermoedelijk veel hoger zijn dan de officiële 
cijfers laten zien. In België werden respectievelijk 7, 2 en 3 psittacosis gevallen gemeld in 
2005, 2006 en 2007.  
Aan de hand van deze thesis wilden wij de actuele epidemiologische situatie 
aangaande zoönotische Cp. psittaci transmissies in Vlaanderen verduidelijken en dit in 
eerste instantie bij mensen met vogels (gedomesticeerd/gezelschap) als huisdier. Het was 
onze bedoeling om een humane risicopopulatie binnen deze groep van mensen te 
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identificeren. Vervolgens werd de prevalentie van psittacosis en de klinische gevolgen 
hiervan onderzocht binnen deze geïdentificeerde humane risicopopulatie. Op deze wijze 
wilden we wetenschappelijke informatie bekomen over het vogelspecies en de Cp. psittaci 
stammen die het meest betrokken waren bij de overdracht van Cp. psittaci van vogels naar 
de mens. Deze informatie zou tenslotte gebruikt worden voor de doelgerichte aanmaak van 
een recombinant Cp. psittaci vaccin voor vogels. De beschermende capaciteiten van het 
vaccin zouden onderzocht worden in een experimenteel infectiemodel bij vogels.  
In hoofdstuk I geven we eerst een algemeen literatuuroverzicht over de geschiedenis, 
de taxonomie en de biologie van chlamydiale infecties bij mens en dier. Vervolgens wordt 
een overzicht gegeven over Cp. psittaci infecties bij vogels waarbij de epidemiologie, de 
klinische aspecten van de infectie, de diagnose, de behandeling van de infectie, het belang 
voor de volksgezondheid alsmede preventieve maatregelen en de huidige wetgeving 
hieromtrent beschreven worden.  
In  hoofdstuk II onderzoeken we het voorkomen van Cp. psittaci infecties in een 
Vlaamse populatie van 540 mensen (264 mannen en 276 vrouwen), 36 tot 57 jaar oud 
(mediaan 46), die verklaarden dagelijks, wekelijks, sporadisch of nooit in contact te 
komen met gedomesticeerde en/of gezelschapsvogels. Bij al de deelnemers werd een 
faryngeale swab genomen alsmede een bloedstaal. Elke persoon vulde tevens een 
anamnese in met vragen over professionele en niet-professionele bezigheden, 
rookgewoonte, medische achtergrond en contactfrequentie met verschillende vogelspecies 
en andere dieren. De faryngeale swabs werden onderzocht met een Cp. psittaci-specifieke 
‘nested PCR enzyme immunoassay’ (nested PCR/EIA) en Cp. psittaci-positive swabs 
werden tevens onderzocht met een Cp.pneumoniae-specifieke nested PCR. De sera 
werden onderzocht aan de hand van een recombinante enzyme-linked immunosorbend 
assay (ELISA) gebaseerd op de detectie van antistoffen tegenover het recombinant ‘major 
outer membrane protein’ (MOMP) van Cp. psittaci. De humane sera werden tevens 
onderzocht met de IgG/IgA micro-immunofluorescentie test en de Serion Chlamydia 
ELISA.  De resultaten toonden aan dat kanaries en Psittaciformes (vnl. parkieten en 
papegaaien) de meest populaire aviaire huisdieren waren gevolgd door sportduiven, 
eenden, ganzen en kalkoenen. Personen die in contact kwamen met Psittaciformes en 
sportduiven liepen een significant hoger risico om geïnfecteerd te worden met Cp. psittaci 
dan mensen die in contact kwamen met andere vogelspecies. Dagelijks contact met 
sportduiven resulteerde in een significant hoger risico dan wekelijks contact. Dagelijks of 
wekelijks contact met Psittaciformes resulteerde in een even hoog aanzienlijk risico op 
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een Cp. psittaci infectie. Sportduiven werden steeds in groep gehouden, waardoor de 
contactpersonen waarschijnlijk werden blootgesteld aan een vrij hoge infectiedruk. 
Papegaaien en parkieten daarentegen werden door de onderzochte populatie particulieren 
meestal individueel gehouden, of in het geval van parkieten soms als koppel, maar zelden 
als groep. Geïnfecteerde Psittaciformes zijn bijgevolg, strikt gezien meer risicovol voor de 
volksgezondheid.  
In hoofdstuk II tonen we ook het nut aan van een zeer gevoelige en specifieke nested 
PCR/EIA voor de detectie van Cp. psittaci DNA in humane klinische stalen. Tevens wordt 
duidelijke aangetoond dat de MIF test, een serologische test die momenteel nog steeds 
aangewend wordt voor de diagnose van psittacosis onvoldoende gevoelig en specifiek is. 
Het gebruikt van deze test wordt nog steeds geadviseerd door wereldwijd erkende 
instanties zoals de U.S. ‘Centers for Disease Control and Prevention’ (CDC), de U.S. 
National Association of State Public Health Veterinarians (NASPHV) en de U.S. Council 
of State and Territorial Epidemiologists (CSTE). Er is bijgevolg een dringende nood aan 
de ontwikkeling van een recombinante of peptide-gebaseerde ELISA voor de detectie van 
Cp. psittaci- specifieke antistoffen. Deze test zou dan naar onze mening gebruikt moeten 
worden voor epidemiologisch onderzoek, eerder dan voor de klinische diagnose van 
psittacosis bij de individuele patiënt. Hiervoor adviseren wij het gebruik van recent 
ontwikkelde gevoelige en specifieke moleculaire diagnostische testen.  
In hoofdstuk III, richten we ons onderzoek op de kwekers van Psittaciformes 
(kaketoes, papegaaien, parkieten en lori’s). Aan de hand van de resultaten van hoofdstuk II 
hebben we immers kunnen vaststellen dat er een hoog risico is voor deze personen om 
geïnfecteerd te worden met Cp. psittaci. We beschrijven de transmissie van een Cp. 
psittaci genotype E/B stam van Afrikaanse grijze roodstaart papegaaien naar de mens en 
tonen hierbij voor het eerst aan dat genotype E/B stammen kunnen overgedragen worden 
van vogels naar de mens. De resultaten van deze studie demonstreren ook het 
beroepsrisico voor dierenartsen om besmet te worden met Cp. psittaci door contact met 
geïnfecteerde vogels. In hoofdstuk III onderzochten we tevens een populatie van 308 
Psittaciformes van 39 verschillende kweekfaciliteiten, alsmede 46 van de kwekers. 
Negenenvijftig (19.2%) vogels excreteerden Cp. psittaci in hun faeces zoals vastgesteld 
kon worden aan de hand van de nested PCR/EIA. Cp. psittaci kon bovendien geïsoleerd 
worden uit 25 (42.3%) PCR positieve stalen. Acht van de 39 (20.5%) kweekfaciliteiten 
werden positief bevonden a.d.h.v. de nested PCR/EIA en kiemisolatie in Buffalo Green 
Monkey (BGM) cellen. In alle 8 kweekfacilteiten waren er klachten van respiratoire 
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symptomen bij de vogels. Vijf kweekfaciliteiten waren enkel positief a.d.h.v. PCR en de 
vogels aldaar vertoonden geen klinische symptomen. In één van deze 5 kweekfaciliteiten 
werden de vogels op het moment van  staalnamen behandeld met doxycycline en in de 
andere 4 kweekfaciliteiten waren de vogels recent behandeld geweest met doxycycline, 
oxytetracycline of enrofloxacine. In 13 van de 39 (33.3%) van de kweekfaciliteiten werd 
een significante correlatie waargenomen tussen fecale excretie van levende Cp. psittaci 
kiemen en de aanwezigheid van respiratoir symptomen bij de vogels. De overige 26 
kweekfaciliteiten met gezonde vogels waren negatief a.d.h.v. PCR en kiemisolatie. Met 
behulp van de nested PCR/EIA konden we Cp. psittaci DNA aantonen in de faryngeale 
swabs van 6 van de 46 (13%) onderzochte kwekers. De vogels van deze geïnfecteerde 
kwekers waren positief a.d.h.v. PCR en kiemisolatie. We konden levende Cp. psittaci 
kiemen isoleren bij 4 van de 6 positieve kwekers. Met behulp van een genotype-specifieke 
real-time PCR werden ‘outer membrane protein A’ (ompA) genotype A (n=5) of E/B 
(n=1) stammen teruggevonden bij deze 6 kwekers. Opmerkelijk was dat 18 van de 39 
(46.2%) kwekers verklaarden dat ze hun vogels het afgelopen jaar behandeld hadden met 
tetracycline, doxycycline of enrofloxacine. Vier van de 39 (10.2%) kwekers verklaarden 
dat ze tetracyclines profylactisch gebruikten. Uit deze studie blijkt de nood aan een Cp. 
psittaci vaccin voor Psittaciformes. Een dergelijk vaccin zou het aantal zoönotische 
transmissies naar de mens aanzienlijk kunnen reduceren. Bovendien blijkt uit deze studie 
dat we dringend informatie moeten verschaffen aangaande een verantwoord gebruik van 
antibiotica bij vogelkwekers om het ontstaan van antibioticum resistente zoönotische Cp. 
psittaci te voorkomen.  
In hoofdstuk IV beschrijven we de ontwikkeling van een Cp. psittaci genotype A 
DNA vaccin voor grasparkieten (Melopsittacus undulatus). Er werd een plasmide 
(pcDNA1::MOMP A) aangemaakt dat het ‘major outer membrane protein’ (MOMP) van 
de Cp. psittaci genotype A stam 89/1051 tot expressie bracht. Hierbij werd een codon-
geoptimaliseerd construct aangemaakt. Dit DNA vaccin werd vervolgens uitgetest op zijn 
vermogen om een beschermende immuunrespons te induceren bij grasparkieten, 
experimenteel geïnfecteerd met de homologe Cp. psittaci stam. Acht koppels (man + 
vrouw) grasparkieten werden gehuisvest in 8 afzonderlijke kooien en geplaatst in 2 
negatieve druk isolatoren, 4 kooien per isolator. Al de grasparkieten werden twee maal 
intramusculair geïmmuniseerd met 100 µg plasmide DNA. Beide groepen kregen een 
primary-vaccinatie op dag één, 3 weken later gevolgd door een boostervaccinatie. Groep 1 
werd gevaccineerd met pcDNA1::MOMP A terwijl groep 2 geïmmuniseerd werd met het 
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placebo vaccin pcDNA1. Twee weken na de boostervaccinatie werden de beide groepen 
aërogeen geïnfecteerd met 108 Tissue Culture Infective Dose 50 (TCID50) van de 
homologe Cp. psittaci genotype A stam. Cloacale en faryngeale swabs genomen bij het 
begin van het experiment en vóór de experimentele infectie waren negatief a.d.h.v. PCR 
en kiemisolatie. Niet tegenstaande deze bevinding,  hadden al de grasparkieten lage 
antistoftiters tegenover het MOMP van Cp. psittaci, zoals bleek uit het onderzoek van 
presera a.d.h.v. de MOMP-gebaseerde recombinante antistof ELISA. Dit wees uiteraard 
op een voorgaande infectie bij deze één jaar oude dieren. Ondanks de aanwezigheid van 
deze antistoffen in de beide groepen, werd in de pcDNA1::MOMP A gevaccineerde groep, 
in vergelijking met de placebo gevaccineerde groep, een significante reductie 
waargenomen van: 1) de klinische symptomen, 2) de pathologie vastgesteld bij 
lijkschouwing, 3) de faryngeale en cloacale kiemexcretie en 4) de vermeerdering van Cp. 
psittaci in het lichaam van deze vogels.  
Als besluit kunnen we stellen dat we duidelijk aangetoond hebben dat het aantal 
psittacosis gevallen in België sterk onderschat wordt. Sportduiven, maar vooral 
Psittaciformes vormen een reëel Cp. psittaci infectie-risico voor mensen die in contact 
komen met gedomesticeerde en/of gezelschapsvogels. We hebben in hoofdstuk III ook 
duidelijk kunnen aantonen dat er een reëel beroepsgebonden risico is voor dierenartsen om 
geïnfecteerd te worden met Cp. psittaci wanneer zij in contact komen met Psittaciformes. 
Een éénmalig contact met geïnfecteerde Afrikaanse grijze roodstaartpapegaaien was 
voldoende om besmet te worden. We hebben aangetoond dat er een dringende nood is aan: 
1) voorlichtingscampagnes om het risico op Cp. psittaci overdracht van vogels naar de 
mens te reduceren, 2) informatiecampagnes aangaande een doordacht en verantwoord 
gebruik van antibiotica door kwekers van Psittaciformes, maar misschien ook meer in het 
algemeen, door alle vogelkwekers en ook door vogelhandelaren, 3) maatregelen om de 
aankoop van antibiotica via het internet in te dijken en/of beter te controleren, 4) een Cp. 
psittaci -specifieke antistofdetectie test voor onderzoek van humane sera, 5) een Cp. 
psittaci vaccin voor vogels, in het bijzonder Psittaciformes, om het risico op zoönotische 
transmissies naar de mens de reduceren maar ook om het risico op het ontstaan van 
antibiotica resistente Cp. psittaci stammen te voorkomen. Verder onderzoek zal bijgevolg 
gericht zijn op de ontwikkeling van een recombinante of peptide-gebaseerde Cp. psittaci 
antistofdetectie test voor onderzoek van humane sera en op de verdere optimalisatie van 
het DNA vaccin door o.a. koppeling van het plasmide aan kationische polymeren om de 
transfectie efficiëntie te verhogen.                                                                                         
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